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Abstract 
 
AUTO-DELINEATION OF OROPHARYNGEAL CLINICAL TARGET 
VOLUMES USING DEEP LEARNING TECHNIQUES  
Carlos Eduardo Cardenas, M.S. 
Advisory Professor: Laurence E. Court, Ph.D.  
Head and neck intensity modulate radiation therapy allows for the delivery of 
high-precision radiotherapy by conforming radiation dose to the defined treatment 
targets achieving more accurate target dose distribution and better sparing of normal 
tissues. However, producing very precise treatment plans may be ineffective if the 
target volumes are not defined accurately. Furthermore, there are several reports of 
significant inter-observer variability when delineating these target volumes for head 
and neck cancers making this variability one of the largest sources of uncertainty in 
head and neck radiation therapy.  
The purpose of this study was to develop algorithms to automate target 
delineation for oropharyngeal cancer patients. Automating this delineation process 
could aid in reducing inter-observer variability and provide a venue for head and neck 
target delineation standardization in radiation therapy. These algorithms would be 
especially valuable for head and neck cancers where the observed variability is 
highest amongst radiation oncologists.  
v 
 
An assessment of our head and neck section’s inter-observer clinical target 
volume delineation variability was conducted to quantify the variability in our 
algorithm’s inputs. We then developed two novel deep learning algorithms to auto -
delineate high-risk and low-risk clinical target volumes. The predicted delineations for 
high-risk and low-risk clinical target volumes performed well in comparison to their 
respective ground-truth delineations. The quantitative analysis showed that the 
predicted volumes provided, on average, improved delineations when compared to 
the assessed inter-observer variability. Lastly, we investigated dosimetric differences 
on target coverage and normal tissues based on the physician delineated and deep 
learning auto-delineated low-risk target volumes. The percent volume receiving 95% 
of the prescribed dose on the original physician PTVs was found acceptable, per 
RTOG 1016 guidelines, on over 70% of auto-delineated plans. In addition, we found 
no significant difference in normal tissue doses between the physician and auto-
delineated target plans.  
This study resulted in strong evidence that auto-delineated clinical target 
volumes could aid in the standardization of target delineation in radiation therapy. The 
target volume auto-delineation algorithms showed an improvement in overlap and 
dosimetric agreement with respect to the reported variability in the literature. Future 
studies may validate the clinical use of these algorithms. 
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Chapter 1: Introduction 
Radiation therapy prevails as the principal non-surgical treatment option for 
head and neck cancer and it is estimated that almost 75% of head and neck tumors 
will receive some form of radiation treatment [5, 11]. While cancer of the head and 
neck can originate within the nasal cavity, oral cavity, pharynx, larynx, or sinuses, 
larger incidence and mortality rates are observed for disease of the oropharynx (oral 
cavity and pharynx) [52], mainly due to the prevalence in tumors of the base of tongue 
and palatine tonsils. Tumors in the oropharynx are predominantly squamous cell 
carcinoma arising from the epidermis of the upper aerodigestive tract.  
 In the U.S. alone, there were 49,670 new oropharyngeal cancer cases along 
with 9,700 deaths estimated for 2017 [47]. Five-year overall survival for oropharyngeal 
cancer patients is 64.5%; the respective 5-year overall survival for localized, regional, 
and distant oropharyngeal disease is 83.7%, 64.2%, and 38.5%, respectively. 
Oropharyngeal cancers have been on the rise over the last 10 years (average: +0.7% 
per year). The percent of oropharynx cancer diagnosis and deaths is highest amongst 
people aged 55-64 with median age of diagnosis of 63 years and median age at death 
of 67 years. The primary risk factors associated with squamous cell carcinoma of the 
oropharynx include alcohol and tobacco use, which are associated with mutation and 
overexpression of the p53 gene, as well as human papillomavirus (HPV) infection [89], 
which is believed to responsible for the rise in squamous cell carcinoma of the 
oropharynx.  
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Oropharyngeal cancer radiation therapy is normally delivered using external 
high-energy (megavoltage) x-ray beams. It is common to use 200 cGy (± 20 cGy) 
fractionated doses which are delivered over the course of several weeks. Total dose 
prescriptions are patient- and target-specific but can typically range from 54 to 70 Gy. 
Intensity modulated radiation therapy and volumetric arc radiation therapy are 
generally the top choices for external beam treatment delivery due to their superiority 
in sparing doses to the head and neck normal tissues [45]. Treatment plans are usually 
generated based on patient anatomy from a pre-treatment computed tomography 
scan. During this treatment simulation scan, the patient is positioned and typically 
secured to the treatment couch to reduce inter-fraction setup uncertainties. A 
thermoplastic mask (and sometimes tongue suppressors or bite blocks) are normally 
used as immobilization devices in head and neck patients to effectively reproduce 
patient positioning between treatment fractions [10, 87, 93]; however, other cost-
effective solutions have been shown to provide comparable motion restrictions [83].  
Due to the large number of organs at risk located near head and neck tumors, 
the complexity of radiation therapy treatment planning is greatly increased in 
comparison to other treatment sites such as the prostate. The treatment plan is 
typically developed by the radiation oncology team (radiation oncology, medical 
physicist, and dosimetrist) using a treatment planning system (TPS). The TPS allows 
for the contouring of tumors, treatment targets, and normal tissues on top of the 
simulation CT scan. The radiation oncologist is tasked with contouring the gross tumor 
volume (GTV) and the clinical target volumes (CTVs) with the latter being required for 
radiation dose calculation. The GTV is defined as the position and extent of gross 
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tumor (what can be seen, palpated, or imaged); whereas, the CTV consists of the GTV 
plus a margin extension which aims to cover any microscopic disease present that 
cannot be imaged [14]. Delineating the CTV is considered a more difficult task since 
it requires detailed knowledge of the surrounding anatomy and pathways of tumor 
spread. Additionally, several CTV levels are often used to deliver reduced doses to 
intermediate- and low-risk disease spreading regions, such as lymph node levels of 
the head and neck. There are several recommendations in regards to how many CTV 
levels to use. Lee et al [59] recommends using two to three target volumes, a high- 
and intermediate- to low-risk target volume, with prescriptions of 70 and 59.4 Gy, 
respectively, while sometimes treating the contralateral neck to a dose of 56 Gy. 
Similar recommendations are made by Garden et al [1].  
The task of contouring normal tissues is also generally performed by the 
radiation oncologist. Then, a uniform margin expansion is typically used to convert the 
physician manually contoured CTVs to planning target volumes. The addition of a 
margin provides some tolerance to account for various uncertainties throughout the 
course of the radiation therapy treatment including anatomical and positioning 
variations [48]. The planning target volumes, in conjunction with normal tissue volume 
contours (which may also have margins), are then used as objective volumes to 
optimize doses using the TPS’s optimization algorithm and to assess the resulting 
dose distributions. The radiation oncologist then reviews the final plan prior to start of 
treatment.  
Accurate and reproducible clinical target volume delineation is very important 
in radiation oncology. As physicians rely on training and experience to manually 
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delineate CTVs, this process can become subjective, and contours have the potential 
to greatly differ between physicians. The inability to accurately and consistently define 
CTVs could translate to under-treating a tumor which could lead to higher rates of 
loco-regional recurrence; on the other hand, over-treating surrounding tissues could 
lead to higher rates in normal of tissue toxicities and could have a significant impact 
on quality of life after treatment. Several guidelines have emerged to provide guidance 
and to try to standardize the delineation process for head and neck cancers clinical 
target volumes [34, 35, 37, 43, 57].  
 Unfortunately, these guidelines have not gained global acceptance and thus 
the challenges and inter-observer variabilities in clinical target volume delineation 
continue to be widely documented [2, 12, 46, 81]. Hong et al [46] conducted a target 
delineation study where 20 institutions with head and neck intensity modulated 
radiation therapy expertise were asked to delineate targets on an identical case. Their 
study showed large heterogeneity in both clinical practice (dose prescription, use of 
chemotherapy, etc.) and target delineation. In particular, there was large variability in 
target coverage (unilateral vs bilateral) as well as significant differences in margin 
expansions and anatomical boundaries used to define the targets. Volume ratio 
(Vmax/Vmin) for the contoured CTVs (irradiated volume) was 18.3 with a mean volume 
of 136 cm3 (range: 37-676 cm3). The mean volumes were 82 ± 43 and 205 ± 123 cm3 
for the high-risk and elective CTVs, respectively. A similar study by Rasch et al [81] 
investigated this inter-observer variability in 10 head and neck patients when using 
CT-based delineations alone and CT/magnetic resonance imaging (MRI) based 
delineations in a two-phase study. Mean volumes and variability, as measured by the 
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standard deviation of the volumes, were reduced when using a combination of CT/MRI 
scans for CTV delineations (25 ± 9 cm3 to 20 ± 5 cm3 and 103 ± 33 cm3 to 91 ± 21 
cm3 for high-risk and elective CTVs, respectively). Both Awan et al [2] and Blinde et 
al [12] also showed, in abstract form, significant variability in high-risk CTV 
delineations. In their study, Awan et al evaluated inter-discipline differences in the 
delineation of post-operative high-risk CTVs between radiation oncologists, surgeons, 
radiologists, with the three physician specialties subspecialized in head and neck 
cancers. They found mean overlap, based on the Dice similarity coefficient (DSC), 
was higher for delineations between physicians of the same specialty (mean DSC: 
0.55 ± 0.18) than those between physicians with different specialties (mean DSC: 0.38 
± 0.18). More recently, Blinde et al [12] showed large variability in a delineation study 
where twenty-four radiation oncologists from 7 institutions associated with the MR-
linac Consortium were asked to contour GTVs and high-risk CTVs on four 
oropharyngeal cancer patients. In their abstract, the volume ratio for high-risk CTVs 
was as high as 8 for one of the cases.  
These studies showed that, even though published guidelines are available to 
standardize head and neck target volume delineation, significant variations between 
physician contours still exist and that there is an urgent need to standardize this 
process. Standardizing CTV delineation would not only accurately and consistently 
define target volumes, but has the potential of improving patient outcomes by 
decreasing the risk of missing microscopic disease and reducing radiation therapy 
toxicity by sparing normal tissues that are being unnecessarily treated with 
overcompensating margins. Furthermore, reduced variation in the definition of the 
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clinical target volumes can make for a more robust evaluation of new radiation therapy 
techniques particularly when multiple institutions are involved. Lastly, using standard 
target volumes could result in better quality radiotherapy clinical trial data.  
Developing an effective way to automatically delineate clinical target volumes 
would provide a solution to the current radiation therapy standardization problem [6]. 
Very few approaches have been proposed to tackle this problem for head and neck 
tumors [8, 20, 21, 33, 88, 97]. Uniform margin expansions continues to be the clinical 
standard for some tumor sites [32]; yet, when treating head and neck tumors, margin 
expansions vary widely depending on surrounding anatomy and on GTV shape [101].  
Belshi et al [8] proposed automating high-risk CTVs using a 3D uniform margin 
expansion from manually contoured GTVs for conformal radiation therapy. However, 
the introduction of intensity modulated radiation therapy allowed for more complex, 
conformal, and patient-specific radiation plans, which required more accurate target 
definition to ensure the tumor is not undertreated and to limit the dose to the 
surrounding normal tissues. Chao et al [19] showed that using a 1-cm uniform margin 
expansion from the GTV reduced observer variability when auto-delineating high-risk 
CTVs for 2 head and neck patients. However, their study did not provide an overlap 
comparison of these volumes to the ground-truth volume (volume used for treatment); 
thus, the ability of a 1-cm uniform margin to reproduce the physicians’ goal was 
unclear. More recently, the Danish Head and Neck Cancer Group (DAHANCA) 
implemented the use of uniform margin expansions, allowing edits for anatomical 
boundaries, for high-risk (CTV1 = GTV + 5 mm) and intermediate-risk (CTV2 = CTV1 
+ 5 mm) clinical target volumes. While their study [43] noticed a significant reduction 
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in delineation variability between centers, they did not provide patient outcomes since 
the implementation of this technique and the appropriateness of this approach 
warrants for further patient outcome studies.  
Heterogeneity in head and neck CTV contours becomes more evident when 
delineating low-risk target volumes which typically provide coverage to the neck node 
levels to prevent the spread of disease. A few atlas-based segmentation approaches 
have been proposed for head and neck lymph node automatic delineation [21, 33, 40, 
88, 97]; however, the low contrast of the nodal region and the high variability in 
different patients’ anatomies present significant challenges for low-risk target volume 
atlas-based auto-segmentation. Taking into consideration these anatomical variations 
in the head-and-neck region, Han et al [40] proposed the use of shape information to 
improve the registration between test and atlas subjects. Similarly, Yang et al [97] 
used a two-step registration approach (rigid, then deformable) to auto-segment low-
risk CTVs for tonsil cancer patients. Both of these studies reported large variability in 
overlap between the predicted segmentation and the physician manually-contoured 
ground-truth volumes, but it could be argued that this variability is just the product of 
largely variable physician input contours.  
 This work focuses on the development of a tool to automatically delineate 
oropharyngeal cancer clinical target volumes. We begin by assessing the clinical 
target volume contouring and peer-review process in our clinic (Chapter 3) in order to 
identify any clinical factors that may suggest changes in presented target contours. In 
Chapter 4 we quantify the delineation variability for high-risk clinical target volumes 
between the sub-specialized head and neck radiation oncologists at our institution. 
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We then propose two independent deep learning architectures to auto-delineate high-
risk (Chapter 5) and low-risk (Chapter 6) clinical target volumes. Lastly, we 
dosimetrically evaluate treatment plans based on our auto-delineated low-risk clinical 
target volumes and quantify the average coverage on the original physician contours 
(Chapter 7). Chapter 8 presents a discussion and the conclusions of this work.   
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Chapter 2: Purpose and Central Hypothesis 
Central Hypothesis 
The central hypothesis of this work is that we can identify and reproduce physician 
patterns in target delineation by retrospectively analyzing contours from treatment 
planning computed tomography images to automatically define oropharyngeal target 
volumes with high average overlap (Dice Similarity Coefficient >= 0.70) to the 
physician ground truth.  
Specific Aim 1: Assess Delineation Variability 
Aim: Determine clinical target volume delineation variability in our clinic  
Hypothesis: Changes made to clinical target volumes during MD Anderson’s Head 
and Neck Planning and Development Clinic are driven by clinical factors and that inter-
observer contouring variability for high-risk clinical target volumes is lower than 
variability observed in the literature. 
Study 1.1: Identify clinical factors that lead to clinical target volumes delineation 
changes in Head and Neck Planning and Development Clinic. 
Study 1.2: Determine inter- and intra-observer delineation variability in high-risk 
clinical target volumes. 
The results from these studies will provide quantitative measures to aid in assessing 
the results from Specific Aim 2 and Specific Aim 3.  
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Specific Aim 2: Auto-Delineating High-risk Clinical Target Volumes 
Aim: Develop an auto-delineation algorithm for high-risk clinical target volumes  
Hypothesis: We postulate that we can identify the relationship between adjacent 
normal tissues and the gross tumor volume to produce patient-specific high-risk 
clinical target volume margin expansions.  
Study 2.1: Develop an auto-delineation algorithm for high-risk clinical target volumes 
Specific Aim 3: Auto-Delineating Low-Risk Clinical Target Volumes 
Aim: Develop a novel segmentation technique for low-risk clinical target volumes 
Hypothesis: Low-risk clinical target volumes can be auto-delineated accurately for a 
large patient dataset and that the predicted target volumes can be used to produce 
treatment plans with acceptable ground-truth target dose coverage. 
Study 3.1: Develop a patient-specific low-risk clinical target volume delineation 
algorithm. 
Study 3.2: Evaluate target and normal tissues dosimetric differences when 
developing radiation therapy plans based on auto-delineated target volumes. 
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Chapter 3: Clinical Target Volumes Delineation 
Changes Suggested at the Head and Neck Planning 
and Development Clinic 
This chapter is based on the following publication:  
Cardenas, CE, Mohamed, ASR, Tao, R, Wong, AJR, Awan, MJ, Kuruvila, S, Aristophanous, M, Gunn, 
GB, Phan, J, Beadle, BM, Frank, SJ, Garden, AS, Morrison, WH, Fuller, CD, and Rosenthal, DI.  
"Prospective qualitative and quantitative analysis of real-time peer review quality assurance rounds 
incorporating direct physical examination for head and neck cancer radiation therapy." International 
Journal of Radiation Oncology• Biology• Physics 98.3 (2017): 532-540. © 2016 Elsevier Inc.  
No permission is required for reuse of this material, which was published under the Creative Commons 
CC-BY-NC-ND license.  
Introduction 
Extensive guidelines are available on the approaches to the physical and 
technical aspects of quality assurance (QA) to ensure accurate and safe delivery of 
radiation therapy (RT), but there are fewer standardized approaches to clinical QA 
[53, 55, 95]. Traditionally, clinical QA is accomplished during chart rounds, in which 
the RT plan and perhaps diagnostic imaging are reviewed. With the evolution of RT 
toward more conformal treatment of physician-defined target volumes and organs at 
risk (OARs), clinical QA and physician experience [80, 96] have become recognized 
as increasingly important to patient care along with the critical QA processes 
established for treatment machines in radiation physics [63].  
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At The University of Texas MD Anderson Cancer Center’s radiation oncology 
department, there has been a head and neck planning and development clinic 
(HNPDC) since its establishment by Dr. Gilbert Fletcher in the 1960s. The main goals 
are comprehensive peer review of a patient’s RT plan before the start of RT and 
trainee teaching [82]. In addition to the comprehensive review of a patient’s history, 
pathologic characteristics, diagnostic imaging, and discussion of the planned 
treatment, all patients undergo physical examination, including video-camera naso-
pharyngo-laryngoscopy and bimanual palpation performed by the head and neck 
radiation oncology sub-specialists in our group. The proposed computed tomographic 
(CT) image is reviewed slice by slice for gross tumor volume (GTV), clinical target 
volume (CTV), OAR segmentation, and dose-volume specifications.  
Rosenthal et al previously examined [82] the value of this peer-review process 
to characterize the types of changes proposed during the QA process. Changes in the 
radiation plans were noted in the majority of patients included in that study. Of those, 
11% were considered major changes, defined as potentially affecting patient 
outcomes [82]. The majority of RT plans in that study were 3-dimensional (3D) 
conformal, and it was demonstrated that physical examination is critical in the process 
of target volume delineation in those cases. Currently, in the era of intensity modulated 
radiation therapy (IMRT) and proton therapy (IMPT) with their high level of treatment 
precision, accurate target volume definition is increasingly critical, particularly for head 
and neck cancer [30, 39]. As a continuation of efforts to characterize the impact of a 
real-time peer review QA process, we performed an update of that previous study to 
assess the changes made during peer review in the setting of exclusive IMRT 
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planning. A quantitative analysis of the volumetric changes made as a result of 
HNPDC and patterns of failure analysis are included in this study. 
Methods and Materials 
Patients and Data Collection 
Data were collected from January to May 2012 from 85 consecutive patients 
who presented at the HNPDC, using a standard data collection form by 2 residents in 
the head and neck group. The qualitative patient information recorded for each case 
included patient and tumor characteristics, treating-attending physician, attending 
physicians performing peer review, and new findings by the group. Group 
recommendations such as suggesting additional tests; changes in chemotherapy 
plan; and changes in the proposed radiation volume, dose, or fractionation were also 
recorded. 
The current HNPDC peer review process, which follows MD Anderson’s clearly 
defined treatment policies [1], has been summarized in detail by Rosenthal et al [82]. 
The process can be described as follows: patients undergo a CT-based simulation 
under the care of the treating-attending physician. Before the HNPDC, the treating-
attending physician and the resident trainee contour the CTVs and OARs using the 
treatment planning software, either Pinnacle (Philips Healthcare, Andover, MA) or 
Eclipse (Varian Medical Systems, Palo Alto, CA). The high-risk CTV (CTV1) is defined 
as the GTV plus margin in definitive cases or the tumor bed plus margin in 
postoperative cases. The intermediate-risk CTV (CTV2) is then defined as the 
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adjacent region to the high-risk CTV, and a third CTV3 includes an elective region 
such as elective nodal basins or contralateral neck. After the delineation of initial target 
volumes by the attending radiation oncologist, plans are subsequently presented at 
the HNPDC, usually 1 to 2 days after the date of simulation. Each patient scheduled 
to undergo curative-intent RT is present during the HNPDC. As each patient’s case is 
presented, the treating radiation oncologist summarizes details of the patient’s history 
and tumor characteristics along with a review of the patient’s diagnostic imaging. The 
peer group then performs a physical examination, which includes inspection, palpation 
(including bimanual examination to define the submucosal borders of a tongue cancer) 
and a video-camera naso-pharyngo-laryngoscopy viewed by the group on a video 
monitor. Finally, the non-treating physicians conduct a peer review of the contoured 
volumes of the target and the OARs. Suggested changes are discussed until a 
consensus is reached. Real-time changes are made to the target volume contours 
during the review process. Once all required changes are made and a consensus is 
reached, the plan is submitted for dosimetric planning. Physics QA is performed 
before the start of treatment. 
Eight sub-specialized board-certified/eligible head and neck radiation 
oncologists participated in this study. Two were junior faculty physicians who had less 
than 2 years of post-training experience and were defined as “less experienced” in our 
analysis. The remaining 6 were defined as “experienced.” 
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Qualitative Assessment 
 As in our institution’s previous study [82], changes in treatment plans were 
qualitatively classified as major if they were believed to clinically affect the likelihood 
of cure, adverse events, or locoregional control. Changes were classified as minor 
when the recommendations made were more elective or stylistic; they included 
modifications of field delineation for additional margins to accommodate penumbra or 
potential motion/position change, and changing the fractionation schedule. 
Quantitative Metrics 
The treating physician’s original (pre-HNPDC) target volumes (CTVpre) were 
saved in Pinnacle to facilitate a quantitative analysis of pre-HNPDC and post-HNPDC 
target volume contours. The final (post-HNPDC) contours (CTVQA) submitted after 
peer review were then compared with the initial contours by use of volume-based 
measures. Target volumes (cm3) were computed with the use of Pinnacle for pre-
HNPDC and post-HNPDC contours, and their normalized volumetric difference (VD) 
was calculated with Equation 3.1: 
QA
QApre
V
VV
VD

      (3.1) 
To characterize the spatial overlap between the CTVpre and CTVQA volumes, 
the Dice Similarity Coefficient (DSC) was calculated with the use of Equation 3.2: 
         
QApre
QApre
VV
VV
DSC



2
     (3.2) 
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In addition, the false-negative Dice (FND) and the false-positive Dice (FPD) 
were calculated to assess potential near misses and overtreatment, respectively.  
QApre
QApre
VV
VV
FND



2
             (3.3) 
            
QApre
QApre
VV
VV
FPD



2
       (3.4) 
FND (Equation 3.3) measures the volume added after peer review that was originally 
not included by the treating-attending physician, and FPD (Equation 3.4) measures 
the volume removed after peer review that the treating-attending physician originally 
included.  
The Dice Similarity Coefficient (DSC) is a volume overlap metric widely used in 
image segmentation to evaluate differences between two contours. DSC values range 
from 0 (no overlap) to 1 (perfect agreement). When comparing tumor and target 
volumes, the False Negative Dice (FND) and the False Positive Dice (FPD) can be 
used as surrogates to assess potential near misses and overtreatment in radiation 
oncology, respectively. For the FND and FPD, values range from 0 (perfect 
agreement) to 2 (complete miss). Figure 1 and Figure 2 illustrate these metrics in the 
context of our study. In Figure 1, the region of interest (ROI) in red represents the CTV 
contours prior to the HNPDC, whereas the ROI in blue represents the post-HNPDC 
CTV contours. In Figure 2, we see an example of two patients with post-HNPDC CTV 
changes and their effect on FND and FPD overlap metrics.  
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Figure 1. Over-treatment and under-treatment in HNPDC 
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Figure 2. Patient images showing differences in over-treatment and under-
treatment based on HNPDC CTV changes 
The top row shows a simulation CT images for a patient with T1N1 cancer of the right 
tonsil. Differences in contours before (red) and after (blue) quality assurance (QA) are 
visualized. For this patient, high FND and Dice similarity coefficient (overtreatment) 
values were recorded for CTV1 and CTV3, as can be visually assessed on the axial 
and coronal images. The bottom row shows a patient with T4N2c of the left tonsil who 
was treated with definitive radiation therapy. CTV volumes after QA (blue) show 
regions that were added and could be considered potential near misses. 
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Lastly, we quantified the differences in pre-HNPDC and post-HNPDC treatment 
volumes (union of all CTVs). 
Patterns of Failure Analysis 
Patients completing treatment received initial posttreatment evaluations after 8 
to 12 weeks. Subsequently, patients were followed up every 2 to 3 months for the first 
year, every 3 to 4 months for the second year, and at least twice a year up to 5 years. 
Ten patients with documented posttreatment recurrence were analyzed for the relation 
of volume recurrence relative to both pre-HNPDC and post-HNPDC volumes. The 
CT/PET-CT images documenting recurrence were manually delineated by a single 
observer and reviewed by 2 head and neck radiation oncologists. The recurrence 
images were subsequently registered to the planning CT with deformable image 
registration software Velocity AI 3.0.1 (Velocity Medical, Atlanta, GA). The recurrence 
contours were reviewed relative to the spatial location of the original and post-QA 
contours and to the dose grid according to our institutional patterns of failure 
classification scheme [74]. 
Statistical Analysis 
The Pearson χ2 test was used for comparing qualitative assessments according 
to different HNPDC-associated covariates. Statistical comparison of the volumetric 
changes in CTV levels was performed with the paired Wilcoxon rank-sum test. In 
addition, quantitative metrics were classified by threshold values, shown in Table 1.  
Although the literature recommends a DSC > 0.70 for good overlap [102, 103], we 
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took a more conservative approach in our analysis by slightly raising these threshold 
values.  
Table 1. Classification of HNPDC quantitative changes by metric 
Trivial Minor Major 
DSC ≥ 0.95 0.95 > DSC ≥ 0.80 DSC < 0.80 
FND ≤ 0.05 0.05 < FND ≤  0.20 FND > 0.20 
FPD ≤ 0.05 0.05 < FPD ≤  0.20 FPD > 0.20 
 
The overall DSC change was determined for each patient as follows: if any 
change in CTV level was classified as major, then the overall DSC change was labeled 
major; if no changes in CTV levels were classified as major but at least 1 change was 
classified as minor, then the overall DSC was labeled as minor; only when all changes 
in CTV levels were deemed trivial was the overall DSC labeled trivial. Data analysis 
was performed with the JMP version 12.1 statistical software (SAS Institute, Cary, 
NC). 
Results 
Qualitative Plan Changes and Physical Examination 
The patient and tumor characteristics are summarized in Table 2. Of the 85 patients, 
37 received definitive IMRT, and 48 received postoperative IMRT. All patients were 
examined by at least 1 non-treating attending radiation oncologist specializing in head 
and neck cancers, and 80 were examined by 3 physicians (94%). The median number 
of attending physicians present at the HNPDC (including the treating-attending) was 
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4. The CT images of the head and neck were reviewed for all patients; additional 
review of images included positron emission tomography (PET)/CT in 17 patients 
(20%), magnetic resonance imaging (MRI) in 3 patients (3.5%), and both PET/CT and 
MRI in 3 patients (3.5%). Group video-camera naso-pharyngo-laryngoscopy was 
performed on 37 patients (44%), including 70% of patients with larynx primaries, 100% 
of nasopharynx primaries, 5% of oral cavity patients, 92% of oropharynx patients, and 
67% of patients with unknown primaries. Endoscopy was not performed on patients 
with skin, salivary gland, and thyroid primaries. New findings as a result of group 
physical examination during HNPDC were documented for 12 patients (14%). These 
findings included evidence of tumor progression (n = 3); extension to surrounding 
anatomic structures such as soft palate, aryepiglottic fold, or piriform sinus (n = 3); 
further tumor shrinkage after chemotherapy (n = 3); impaired vocal cord mobility (n = 
2); and new neck adenopathy (n = 1). Of these, 7 of 12 findings (58%) were identified 
by group bimanual palpation and the remainder by endoscopic examination. In all 
cases, no changes were suggested to reject the use of RT or to change the treatment 
intent from curative to palliative. 
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Table 2. Patient and disease characteristics in HNDPC study 
Variables No. of patients (%) 
Age  
   Less than 40 4 (4.7%) 
   40 – 65 50 (58.8%) 
   Greater than 65 31 (36.5%) 
Gender  
   Female 23 (27.1%) 
   Male 62 (72.9%) 
Primary Site  
   Oropharynx 27 (31.8%) 
   Oral Cavity 20 (23.5%) 
   Larynx 10 (11.8%) 
   Skin 8 (9.4%) 
   Salivary 6 (7.1%) 
   Sinonasal 5 (5.9%) 
   Unknown Primary 5 (5.9%) 
   Thyroid 3 (4.0%) 
   Nasopharynx 2 (2.4%) 
T stage  
   Tx 2 (2.3%) 
   T0 4 (4.7) 
   T1 11 (13%) 
   T2 19 (22%) 
   T3 14 (16.5%) 
   T4 22 (26%) 
   Recurrent 14 (16.5) 
N stage  
   Nx 1 (1%) 
   N0 27 (32%) 
   N1 14 (16.5%) 
   N2 25 (29%) 
   N3 4 (5%) 
   Recurrent 14 (16.5) 
Overall Staging  
   Stage I 4 (4.7%) 
   Stage II 4 (4.7%) 
   Stage III 16 (18.8%) 
   Stage IV 47 (55.3%) 
   Recurrent 14 (16.5%) 
Treatment Intent  
   Adjuvant 48 (56.5%) 
   Definitive 37 (43.5%) 
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The IMRT plans featured qualitative changes in 65 cases (76%); 30 patients 
(35%) were classified as having major changes, and 35 patients (41%) were classified 
as having minor changes. There was no relationship between endoscopic examination 
and the frequency or type of qualitative changes (P = 0.74); furthermore, the site of 
the primary tumor was not associated with differences in the frequency or type of 
changes made (P = 0.22). No difference was seen in the frequency or type of 
qualitative changes between patients treated with definitive IMRT and those treated 
postoperatively (P = 0.77). Tumor stage did not have a relationship with frequency or 
type of qualitative change (P = 0.78). There was no relationship between the number 
of attending physicians present and the frequency or type of qualitative changes (P = 
0.12). Statistically significant higher rates of both major and minor changes were noted 
in the junior faculty plans compared with plans made by more experienced faculty (P 
< 0.0001), with a rate of 69% major changes in junior faculty plans compared with 
20% for more experienced faculty plans. However, there was not a significant 
difference between the individual members of each group (junior vs more experienced 
faculty) and the frequency or type of qualitative change (experienced, P = 0.30; junior, 
P = 0.12). A change in the total planned IMRT dose was suggested for 9 patients 
(11%); 8 of them were recommended to receive an increase in the prescribed dose to 
the primary and nodal regions, and 1 patient received a reduced dose. The addition 
or subtraction of a dose level was suggested for 12 patients (14%). The addition of 
electron fields was suggested for 3 patients. One patient’s plan changed from a whole -
field IMRT technique to a matched IMRT field with an anteroposterior supraclavicular 
24 
 
field, whereas the opposite was done for another patient. Last, the addition of 
contralateral lymph node coverage was suggested for a single patient. 
Quantitative Analysis of Clinical Target Volumes 
Differences in percentage for each type of qualitative and quantitative changes 
according to physician experience are illustrated in Figure 3.  
One patient was excluded from this analysis because of the addition of 2 dose 
levels to the post-HNPDC treatment plan. Quantitative results and analysis of metrics 
according to CTV level are summarized in Table 3. When the overall DSC 
classification was considered for all CTV levels, 23 patients (27%) had major 
modifications, and 36 (43%) had minor changes. The same metric showed that junior 
physicians had a lower rate of trivial changes (12%) than did more experienced 
physicians (37%, P = 0.02) and had a higher rate of major changes (44% junior vs 
20% experienced, P = 0.03). Major change rates were also found to be statistically 
significant when overall FPD was considered (48% junior vs 24% experienced, P = 
0.03). Figure 4 depicts the box plots of each individual overlap metric by experience 
and dose levels.  
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Figure 3. Percentage of qualitative and quantitative changes dichotomized based on physician experience 
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Table 3. Quantitative change evaluation metrics per CTV level 
    All Physicians (n = 84) Experienced (n = 59) Junior (n = 25) P Value 
CTV1 
 
 
        
 
VD -0.05 ± 0.13 -0.06 ± 0.10 -0.03 ± 0.18 0.155 
 
DSC 0.94 ± 0.09 0.95 ± 0.07 0.93 ± 0.13 0.825 
 
FND 0.09 ± 0.16 0.09 ± 0.12 0.10 ± 0.23 0.668 
 
FPD 0.03 ± 0.07 0.02 ± 0.05 0.05 ± 0.11 0.932 
CTV2 
 
 
        
 
VD 0.39 ± 2.91 0.05 ± 0.29 1.15 ± 5.21 0.613 
 
DSC 0.84 ± 0.23 0.87 ± 0.19 0.76 ± 0.29 0.041 
 
FND 0.14 ± 0.24 0.12 ± 0.20 0.21 ± 0.31 0.320 
 
FPD 0.18 ± 0.33 0.14 ± 0.23 0.27 ± 0.49 0.401 
CTV3 
 
 
        
 
VD -0.02 ± 0.32 0.01 ± 0.28 -0.07 ± 0.39 1.000 
 
DSC 0.87 ± 0.20 0.90 ± 0.18 0.80 ± 0.22 0.006 
 
FND 0.17 ± 0.34 0.11 ± 0.27 0.28 ± 0.43 0.029 
  FPD 0.10 ± 0.17 0.09 ± 0.18 0.12 ± 0.17 0.093 
Note - data represents means ± standard deviations. P values were calculated using Wilcoxon rank-sum test to assess difference between  
experienced and junior physician contours.  
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Figure 4. Boxplots of overlap metrics calculated for each target volume level and dichotomized by physician 
experience
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When DSC values for CTV1 were considered, no relationship was observed 
between DSC value and endoscopic examination (P = 0.82). Other covariates such 
as number of attending physicians (P = 0.30), tumor site (P = 0.22), and tumor stage 
(P = 0.79) were not found to have a significant impact on the frequency of overall DSC 
changes. A higher rate of major changes was noted in patients receiving definitive RT 
(36%) than in patients treated postoperatively (21%), but this difference was not 
statistically significant (P = 0.12). The resulting DSC values for CTV1 for all physicians 
were significantly higher than those for CTV2 and CTV3 (0.94 ± 0.12 vs 0.84 ± 0.23, 
and 0.87 ± 0.20; P = 0.0005 and P = 0.03, respectively) but no difference was 
observed in DSC values between CTV2 and CTV3 contours (P = 0.23). When 
physician experience was considered, the DSC values for CTV1 were higher than for 
CTV2 in both groups (experienced, 0.96 ± 0.05 vs 0.88 ± 0.19, P = 0.02; junior, 0.92 
± 0.17 vs 0.76 ± 0.26, P= 0.005). The DSC values from CTV1 and CTV3 showed 
higher agreement for the experienced physicians (0.96 ± 0.05 vs 0.90 ± 0.19, P = 
0.53), whereas for the junior physicians, the CTV3 values were significantly lower 
(0.92 ± 0.17 vs 0.80 ± 0.25, P = 0.009). The CTV2 and CTV3 DSC values showed no 
difference for the junior physicians (0.75 ± 0.26 vs 0.80 ± 0.25, P = 0.81), but for the 
experienced group, this difference was slightly increased (0.88 ± 0.18 vs 0.90 ± 0.19, 
P = 0.11), with the CTV3 DSC values being higher. Overall, physician experience was 
correlated with higher DSC values when all CTV levels were considered (0.91 ± 0.16 
vs 0.83 ± 0.23, P = 0.005). Table 4 shows a summary of quantitative changes 
classification. The rate of FND major changes in CTV1 was significantly higher than 
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FPD major changes (16% vs 2%, P = 0.003), suggesting that changes in CTV1 
contours were more likely to include additional coverage, possibly as a result of tumor 
progression or further extension findings noted during the real-time peer review QA 
clinic. Quantitative results are summarized on a per patient basis in Table 5. Only 
three patients’ (4%) CTV contours remained unchanged after peer-review. When 
considering the whole treatment volume (CTVall), the pre- and post-HNPDC mean 
DSC was 0.93 ± 0.08 (range: 0.56 – 1.00). The mean FND and FPD values were 0.08 
± 0.11 (range: 0.00 – 0.58) and 0.05 ± 0.11 (range: 0.00 – 0.85), respectively. On 
average post-HNPDC were larger with a mean VD of -0.01 ± 0.19 (range: -0.44 – 
1.41). The distribution of these metrics for the overall treated volumes are shown in 
Figure 5.  
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Table 4. Quantitative classification from changes in CTV contours 
  All Physicians (n = 84) 
    Trivial Major Minor 
CTV1    
 DSC 55 (65%) 4 (5%) 25 (30%) 
 FND 49 (58%) 13 (16%) 22 (26%) 
 FPD 67 (80%) 2 (2%) 15 (18%) 
CTV2    
 DSC 38 (47%) 18 (22%) 25 (31%) 
 FND 42 (52%) 18 (22%) 21 (26%) 
 FPD 37 (46%) 19 (23%) 25 (31%) 
CTV3    
 DSC 34 (51%) 13 (20%) 19 (29%) 
 FND 39 (59%) 15 (23%) 12 (18%) 
 FPD 39 (59%) 10 (15%) 17 (26%) 
Overall    
 DSC 25 (30%) 23 (27%) 36 (43%) 
 FND 25 (30%) 35 (42%) 24 (28%) 
  FPD 27 (32%) 30 (36%) 27 (32%) 
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Table 5. Quantitative results per patient 
Patient  
# 
Pre-HNPDC Contour  
Volumes (cm3) 
Post-HNPDC Contour  
Volumes (cm3) 
CTV1 CTV2 CTV3 CTVall Physician  
Experience 
CTV1 CTV2 CTV3 CTVall CTV1 CTV2 CTV3 CTVall DSC FND FPD DSC FND FPD DSC FND FPD DSC FND FPD 
1 65.2 90.6 50.8 206.6 65.2 114.0 50.8 230.0 1.000 0.000 0.000 0.917 0.166 0.000 1.000 0.000 0.000 0.945 0.111 0.000 Junior 
2 21.1 8.3  29.4 21.7 6.4  28.2 0.983 0.031 0.002 0.850 0.026 0.275    0.948 0.031 0.073 Experienced 
3 186.8   186.8 195.2   195.2 0.978 0.044 0.000       0.978 0.044 0.000 Experienced 
4 42.1 174.6 187.2 403.9 74.5 160.4 182.1 417.0 0.716 0.562 0.006 0.869 0.091 0.170 0.781 0.205 0.232 0.871 0.144 0.114 Experienced 
5 204.9 209.9 9.0 423.7 232.2 192.0 0.0 424.2 0.933 0.135 0.000 0.819 0.114 0.247    0.928 0.073 0.070 Experienced 
6 407.8 150.5 409.5 967.9 418.0 193.4 389.3 1000.7 0.886 0.126 0.102 0.693 0.432 0.183 0.803 0.172 0.223 0.898 0.118 0.086 Experienced 
7 113.4 56.9 69.9 240.2 102.0 2.3 125.1 229.3 0.934 0.013 0.118 0.010 0.061 1.918 0.611 0.672 0.106 0.878 0.109 0.136 Junior 
8 92.7 432.0  524.7 122.1 421.7  543.7 0.852 0.285 0.012 0.952 0.041 0.054    0.972 0.003 0.053 Experienced 
9 175.8 249.2  425.0 184.0 221.2  405.2 0.977 0.046 0.000 0.943 0.001 0.114    0.985 0.017 0.013 Junior 
10 280.9 199.1  480.0 278.3 203.7  481.9 0.986 0.010 0.019 0.982 0.029 0.006    0.965 0.046 0.024 Junior 
11 34.0 116.7 114.6 265.3 34.0 116.1 112.4 262.5 1.000 0.000 0.000 0.892 0.091 0.125 0.951 0.089 0.010 1.000 0.000 0.000 Experienced 
12 42.3 207.3  249.6 42.3 207.3  249.6 1.000 0.000 0.000 1.000 0.000 0.000    0.899 0.198 0.004 Junior 
13 153.4 3.7  157.1 162.2 5.2  167.4 0.970 0.058 0.002 0.836 0.327 0.000    0.967 0.065 0.002 Junior 
14 18.9 57.7 8.4 85.0 38.2 89.6 12.9 140.7 0.997 0.004 0.002 0.888 0.097 0.128 0.845 0.135 0.176 0.924 0.050 0.103 Experienced 
15 58.0 173.2 78.4 309.6 57.3 174.6 73.4 305.3 0.969 0.025 0.037 0.983 0.022 0.011 0.963 0.005 0.070 0.984 0.010 0.023 Junior 
16 143.1 193.2 26.6 363.0 178.0 239.7 21.7 439.5 0.883 0.226 0.009       0.864 0.256 0.017 Junior 
17 490.6 63.7 17.0 571.3 496.2 66.8 18.1 581.1 0.993 0.012 0.001 0.952 0.049 0.047 0.976 0.048 0.000 0.991 0.018 0.001 Experienced 
18 192.0 391.9 105.9 689.8 198.1 453.8 59.6 711.5 0.984 0.031 0.000 0.903 0.170 0.025 0.645 0.007 0.702 0.967 0.049 0.017 Junior 
19 228.2 127.9 12.6 368.6 228.2 135.1 12.6 375.8 1.000 0.000 0.000 0.973 0.040 0.014 1.000 0.000 0.000 0.988 0.025 0.000 Experienced 
20 76.0 200.8 83.6 360.4 76.0 200.8 107.6 384.5 1.000 0.000 0.000 1.000 0.000 0.000 0.850 0.277 0.023 0.963 0.072 0.002 Experienced 
21 172.2 81.7 169.4 423.3 74.1 95.3 80.9 250.3 0.602 0.000 0.797 0.235 0.605 0.926 0.716 0.566 0.002 0.990 0.005 0.014 Junior 
22 66.0 206.8 15.1 287.9 66.0 149.7 15.3 231.0 1.000 0.000 0.000 0.879 0.002 0.240 0.994 0.011 0.000 0.888 0.002 0.222 Junior 
23 363.2 133.9 28.1 525.2 320.6 213.9 168.6 703.1 0.927 0.010 0.135 0.024 0.393 1.559 0.136 1.727 0.002 0.813 0.360 0.014 Experienced 
24 308.1 92.7 17.3 418.1 306.6 95.9 17.0 419.4 0.980 0.017 0.022 0.921 0.114 0.044 0.934 0.054 0.077 0.974 0.031 0.020 Junior 
25 8.7 187.4 98.2 294.4 8.7 200.4 96.2 305.3 1.000 0.000 0.000 0.962 0.075 0.001 0.888 0.132 0.093 0.973 0.046 0.009 Junior 
26 150.2   150.2 121.9   121.9 0.895 0.000 0.209 0.854 0.226 0.067 0.972 0.051 0.004 0.986 0.011 0.016 Experienced 
27 631.2 151.9 23.5 806.6 623.2 289.2 113.7 1026.1 0.852 0.141 0.155 0.349 0.962 0.340 0.042 1.617 0.300 0.799 0.319 0.084 Junior 
28 40.0 67.1 73.7 180.8 40.0 67.1 73.7 180.8 1.000 0.000 0.000 1.000 0.000 0.000 0.992 0.000 0.017 0.997 0.000 0.006 Junior 
29 123.4 15.8 260.7 399.9 124.9 15.5 331.5 471.9 0.991 0.015 0.004 0.988 0.002 0.021 0.815 0.305 0.064 0.872 0.212 0.044 Junior 
30 44.9 223.1 86.6 354.7 152.0 108.6 160.0 420.7 0.453 1.094 0.000 0.587 0.062 0.764 0.541 0.741 0.177 0.819 0.266 0.096 Experienced 
31 281.8 286.5  568.3 284.0 318.2  602.2 0.994 0.009 0.002 0.944 0.099 0.012    0.961 0.070 0.007 Junior 
32 289.7 61.7 418.0 769.4 290.8 61.6 392.2 744.6 0.998 0.004 0.000 0.996 0.003 0.005 0.969 0.002 0.061 0.980 0.002 0.037 Junior 
33 112.1 320.3 60.4 492.8 112.1 319.8 55.1 486.9 1.000 0.000 0.000 0.969 0.000 0.062 0.849 0.093 0.209 0.965 0.011 0.059 Experienced 
34 552.6 323.2  875.8 516.3 391.3 68.7 976.3 0.964 0.001 0.070 0.881 0.221 0.016    0.920 0.138 0.023 Experienced 
35 138.5 90.6 61.5 290.6 156.8 80.0 58.7 295.5 0.936 0.126 0.002 0.831 0.131 0.207 0.907 0.069 0.116 0.941 0.071 0.047 Junior 
36 190.0 165.3 183.6 538.8 202.6 155.6 165.6 523.9 0.962 0.070 0.005 0.961 0.009 0.069 0.940 0.008 0.112 0.967 0.021 0.045 Experienced 
37 97.7 131.0 85.7 314.4 97.7 120.6 85.7 304.0 1.000 0.000 0.000 0.958 0.001 0.084 1.000 0.000 0.000 0.960 0.047 0.032 Experienced 
38 47.4 131.7 23.6 202.7 47.4 76.0 38.1 161.6 1.000 0.000 0.000 0.979 0.006 0.036 0.710 0.559 0.021 0.951 0.078 0.020 Experienced 
39 198.1 48.1 154.2 400.4 240.9 62.4 111.3 414.6 0.841 0.256 0.061 0.445 0.684 0.426 0.814 0.024 0.347 0.899 0.118 0.085 Experienced 
40 151.0 218.0 108.1 477.2 158.5 234.6 101.0 494.1 0.966 0.058 0.010 0.937 0.098 0.028 0.946 0.016 0.092 0.973 0.042 0.012 Junior 
41 95.9 312.8 10.3 419.0 108.4 299.6 10.3 418.2 0.939 0.122 0.000 0.971 0.000 0.059 1.000 0.000 0.000 0.988 0.007 0.016 Experienced 
42 27.6 184.1 50.6 262.2 37.4 182.8 53.6 273.9 0.846 0.305 0.003 0.943 0.054 0.061 0.971 0.058 0.000 0.968 0.052 0.012 Experienced 
43 369.7 507.3 152.0 1029.0 357.7 441.4 143.0 942.0 0.963 0.022 0.053 0.838 0.059 0.266 0.853 0.116 0.177 0.927 0.032 0.114 Experienced 
44 164.2 184.6 168.4 517.2 152.5 181.7 174.5 508.7 0.939 0.024 0.098 0.866 0.127 0.142 0.885 0.132 0.098 0.900 0.092 0.107 Experienced 
45 106.3 147.7 107.8 361.9 124.7 185.8 98.7 409.2 0.803 0.276 0.119 0.844 0.234 0.077 0.954 0.002 0.090 0.916 0.147 0.022 Experienced 
46 3.1 73.0 73.2 149.4 3.1 75.4 74.8 153.3 1.000 0.000 0.000 0.983 0.029 0.005 0.989 0.000 0.021 0.985 0.021 0.010 Experienced 
47 44.6 129.1 418.8 592.5 45.4 124.0 134.9 304.3 0.990 0.018 0.002 0.332 0.551 0.785 0.384 0.203 1.030 0.804 0.237 0.156 Experienced 
48 90.9 107.7 339.4 538.0 90.9 107.7 334.1 532.6 1.000 0.000 0.000 1.000 0.000 0.000 0.989 0.006 0.017 0.993 0.004 0.011 Experienced 
49 133.1 24.9 170.4 328.4 194.4 24.8 370.4 589.6 0.813 0.375 0.000 0.505 0.560 0.430 0.590 0.780 0.040 0.707 0.577 0.009 Junior 
50 70.1 77.0 205.3 352.3 70.1 77.0 195.6 342.7 1.000 0.000 0.000 1.000 0.000 0.000 0.976 0.000 0.048 0.986 0.000 0.028 Experienced 
51 121.4 309.1 5.8 436.3 88.6 115.0 302.5 506.1 0.643 0.202 0.513 0.274 0.257 1.195 0.036 1.928 0.000 0.871 0.089 0.168 Experienced 
52 180.6 212.8 80.4 473.8 174.3 235.5 59.5 469.3 0.955 0.027 0.064 0.815 0.221 0.148 0.813 0.038 0.336 0.873 0.214 0.041 Experienced 
32 
 
53 88.3 61.9 62.9 213.1 84.6 64.2 62.8 211.5 0.980 0.005 0.035 0.965 0.056 0.014 0.991 0.008 0.011 0.944 0.052 0.059 Experienced 
54 43.1 236.3  279.4 46.9 226.4  273.3 0.958 0.084 0.000 0.655 0.043 0.648    0.983 0.014 0.019 Junior 
55 158.5 15.4 56.7 230.6 164.1 22.8 55.9 242.8 0.925 0.093 0.058 0.279 0.524 0.918 0.983 0.010 0.024 0.917 0.070 0.096 Experienced 
56 35.4 90.2 113.7 239.4 40.2 88.5 115.0 243.7 0.936 0.128 0.000 0.966 0.029 0.038 0.995 0.011 0.000 0.956 0.062 0.027 Experienced 
57 187.8 48.2 208.3 444.3 209.4 52.4 45.1 306.9 0.945 0.110 0.001 0.530 0.021 0.920 0.663 0.643 0.031 0.761 0.061 0.417 Junior 
58 84.7 203.3 70.0 358.0 84.7 203.3 70.0 358.0 1.000 0.000 0.000 1.000 0.000 0.000 1.000 0.000 0.000 1.000 0.000 0.000 Experienced 
59 57.0 37.0 23.4 117.4 60.5 29.4 25.0 114.9 0.956 0.074 0.014 0.803 0.145 0.250 0.935 0.070 0.060 0.958 0.042 0.042 Experienced 
60 62.6 81.7 217.6 361.9 67.4 70.1 264.1 401.6 0.963 0.074 0.000 0.958 0.000 0.084 0.893 0.204 0.010 0.921 0.131 0.027 Junior 
61 254.1 10.0  264.1 288.5 35.6  324.0 0.923 0.141 0.014 0.225 1.338 0.212    0.881 0.218 0.019 Experienced 
62 111.3 46.5 55.6 213.4 131.6 105.8 53.4 290.8 0.915 0.169 0.000 0.791 0.300 0.117 0.944 0.036 0.076 0.931 0.113 0.025 Experienced 
63 230.0 9.7 254.9 494.6 233.6 9.7 245.6 488.9 0.992 0.016 0.000 0.000 0.955 1.045 0.958 0.042 0.041 0.993 0.009 0.005 Experienced 
64 78.6 335.5 38.1 452.2 113.6 277.1 38.1 428.8 0.814 0.369 0.002 0.919 0.023 0.138 0.997 0.000 0.006 0.947 0.024 0.081 Experienced 
65 36.6 47.9  84.4 40.3 43.9  84.2 0.953 0.094 0.000 0.971 0.000 0.059    0.987 0.010 0.016 Experienced 
66 193.1 55.6 65.2 313.9 193.6 57.6 65.2 316.3 0.996 0.005 0.002 0.979 0.038 0.004 1.000 0.000 0.000 0.994 0.010 0.002 Experienced 
67 188.7 86.0 100.5 375.2 187.5 87.1 100.5 375.1 0.997 0.000 0.007 0.989 0.023 0.000 1.000 0.000 0.000 0.998 0.001 0.002 Experienced 
68 57.6 0.0 72.5 130.2 25.2 51.8 61.6 138.6 0.305 0.318 1.073 0.640 0.661 0.058 0.330 0.035 1.304 0.563 0.024 0.851 Junior 
69 166.3 141.9 102.6 410.8 178.8 129.3 87.2 395.2 0.964 0.073 0.000 0.964 0.000 0.073 0.892 0.026 0.189 0.963 0.017 0.057 Experienced 
70 59.4 261.7 271.0 592.1 59.4 260.4 275.0 594.8 1.000 0.000 0.000 0.991 0.007 0.012 0.983 0.024 0.010 0.988 0.014 0.010 Junior 
71 173.5 358.7  532.3 217.5 323.5 34.3 575.2 0.887 0.226 0.000 0.932 0.022 0.113    0.950 0.086 0.014 Experienced 
72 112.1 75.3  187.3 139.9 86.4 29.4 255.6 0.814 0.297 0.076 0.609 0.458 0.324    0.796 0.355 0.053 Experienced 
73 138.0 135.4 23.2 296.6 138.0 135.4 23.2 296.6 1.000 0.000 0.000 1.000 0.000 0.000 1.000 0.000 0.000 1.000 0.000 0.000 Experienced 
74 271.4 34.8 28.4 334.5 269.6 35.0 30.0 334.6 0.929 0.067 0.074 0.990 0.012 0.007 0.938 0.091 0.034 0.937 0.064 0.062 Experienced 
75 79.8 27.3 328.6 435.7 79.8 27.3 329.2 436.3 1.000 0.000 0.000 1.000 0.000 0.000 1.000 0.000 0.000 1.000 0.000 0.000 Experienced 
76 278.1 104.6 44.8 427.5 273.5 111.1 35.7 420.3 1.000 0.000 0.000 0.953 0.077 0.016 0.661 0.226 0.452 0.961 0.033 0.044 Experienced 
77 125.0 10.5 406.2 541.7 135.9 6.0 423.0 564.9 0.958 0.083 0.000 0.713 0.000 0.575 0.973 0.043 0.011 0.975 0.043 0.006 Experienced 
78 79.6 375.7 379.3 834.6 79.5 373.1 386.2 838.8 0.999 0.000 0.002 0.967 0.003 0.064 0.976 0.029 0.019 0.980 0.027 0.014 Experienced 
79 76.4 90.6 121.7 288.7 69.2 43.7 148.6 261.5 0.839 0.111 0.210 0.373 0.297 0.956 0.653 0.446 0.248 0.807 0.144 0.241 Experienced 
80 130.8 47.2 34.7 212.7 128.3 46.6 34.6 209.6 0.982 0.008 0.027 0.972 0.022 0.033 0.999 0.000 0.002 0.990 0.003 0.018 Experienced 
81 165.5 13.0 629.1 807.6 158.6 25.1 631.5 815.2 0.959 0.020 0.063 0.679 0.638 0.004 0.992 0.010 0.006 0.992 0.012 0.003 Experienced 
82 110.1 72.6 67.2 249.9 111.9 72.1 67.2 251.2 0.991 0.017 0.001 0.985 0.005 0.025 1.000 0.000 0.000 0.997 0.002 0.003 Experienced 
83 93.0 79.7  172.7 92.8 86.2  179.0 0.999 0.000 0.002 0.897 0.064 0.141    0.965 0.046 0.025 Experienced 
84 164.8   164.8 245.9   245.9 0.800 0.398 0.003       0.800 0.398 0.003 Experienced 
85 87.9 47.3 144.4 279.6 87.9 47.3 145.3 280.6 1.000 0.000 0.000 1.000 0.000 0.000 0.996 0.008 0.001 0.998 0.004 0.000 Experienced 
  
33 
 
 
Figure 5. Volumetric comparison of treated volumes from pre- and post-HNDPC 
analysis 
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Patterns of Failure 
The median follow-up time was 38 months (range, 3-49 months). Two patients 
did not receive the planned RT after HNPDC, leaving 83 patients for patterns of failure 
analysis; 1 patient decided to postpone treatment because she was pregnant, and 
another patient’s disease metastasized to the lungs and the patient refused any further 
treatment. Nine patients had documented local recurrence, and 1 patient had regional 
recurrence. Seven patients had a central high-dose failure (i.e. the entire failure 
volume is encapsulated by the 95% isodose line and entirely within CTV1). Three 
patients had non-central high-dose recurrences. Of those, 1 patient had a central 
intermediate dose failure (i.e. entirely within CTV2). This recurrence was in the right 
buccal mucosa 2 years after treatment for T4N0 squamous cell carcinoma of the right 
floor of the mouth with surgical resection followed by flap reconstruction and adjuvant 
IMRT. The second patient with non-central high-dose recurrence had a peripheral 
high-dose failure (i.e. the failure centroid was marginal to CTV1, and the failure volume 
had less than the 95% dose). This patient was treated for left sinonasal recurrence 
(prior surgery but not prior radiation), and had progressive intracranial extension 
immediately after IMRT. Last, the third patient with non-central recurrence 
experienced extraneous failure in the contralateral right level II to IV neck 3 months 
after ipsilateral postoperative IMRT, after salvage surgical resection of right parotid 
recurrence in a patient with a history of T2 N0 squamous cell carcinoma of the left 
alveolar ridge. The target volumes before and after HNPDC did not affect the definition 
of patterns of failure for both central and non-central high-dose failures (i.e. the 
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recurrence volume carried a similar spatial relative location to both the pre-HNPDC 
and post-HNPDC target volume contours). 
Discussion 
 MD Anderson’s HNPDC peer review QA continues as a comprehensive and 
rigorous process, whose main goals are preventing tumor misses, preventing 
unnecessary normal structure treatment/dosing, and reducing operator error. The 
patient examination and case reviews in this study revealed that 35% of head and 
neck treatment plans required major qualitative changes, and 30% of patient CTV 
contours required major changes during the HNPDC. Without these changes the rates 
of cure could have been compromised and that the results presented in this study 
validate the need of a comprehensive weekly QA program.  
It was previously reported that in about 10% of cases, major qualitative 
changes were recommended under the same guidelines used in this study [82]. 
However, in the current study, the rate of qualitative major changes was 35%. The 
relatively higher rate of major qualitative changes in this study in comparison with the 
previous study reflects the requirement of more rigorous QA of IMRT plans compared 
with 3D conformal plans, which were the majority of plans in the previous study. 
Additionally, the contribution of more junior faculty in this study, which had significantly 
higher rates of major plan modifications, supported the increase in qualitative major 
changes. These results suggest that better solutions are needed in regards to the 
manual delineation of clinical target volumes for head and neck IMRT cases. 
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Automating this delineation process could reduce physician contouring time, but has 
the potential to aid in the delineation standardization of these volumes. 
Quantitatively, more experienced faculty had fewer post-HNPDC CTV changes 
as measured by all metrics than did less experienced faculty, concurring with the 
qualitative assessment and highlighting the crucial role of this peer review QA 
process, particularly for less experienced physicians. Additionally, the overall CTV 
volumes of the postoperative plans were shown to have fewer volumetric changes 
compared with the CTV volumes of the definitive plans. This is likely due to the already 
recognized larger volumes required for postoperative RT. This significantly higher 
magnitude of changes in definitive cases may also be due to the effect of the group 
clinical examination and review of the patient’s GTV compared with postoperative 
cases with no gross tumor left. However, the changes measured in high-dose CTVs 
for all cases were significantly lower than for intermediate and low-dose CTVs, 
denoting more agreement in the definition of high-dose target volumes compared with 
elective or lower-dose target volumes. Differences in the rates of major changes in 
FND and FPD for CTV1 contours suggested that the majority of changes in this CTV 
level were perhaps due to findings of tumor progression during physical examination.  
The importance of physician-led peer review chart rounds and the quality of RT 
has been the focus of several recent publications [4, 56, 80]. A recent survey revealed 
that the implementation of clinical QA programs varies greatly across American 
academic institutions and that the average time spent on each case during chart 
rounds was 2.7 minutes [56]. Overall, the majority of institutions surveyed reported 
that treatment changes were rare and occurred for < 10% of cases presented at chart 
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rounds. Only 11% of institutions reported that major changes were made to more than 
10% of cases, and 39% of institutions reported making minor changes. The evaluation 
of other clinical QA programs has illustrated their value in RT departments. Ballo et al 
[4] showed that since the inception of their weekly QA program the number of changes 
recommended for head and neck RT plans significantly decreased (P = 0.04) from 
44.8% to 26.1% from 2007 to 2010. Additionally, gastrointestinal, gynecologic, and 
breast cancer suggested delineation changes decreased significantly over the 4-year 
period in this same study. These findings suggest that the process of group QA can 
at least lead to greater uniformity in therapeutic approaches.  
Physician experience and sub-specialization are closely linked with improved 
patient outcomes. Recent publications have addressed the relationship between a 
center and a radiation oncologist’s patient throughput and quality of RT [13, 80, 96]. 
Peters et al [80] suggested that to achieve quality RT in a clinical trial, participation 
should be limited to clinics that can provide a large number of patients, which is closely 
related to radiation oncologist experience and sub-specialization. This was supported 
by Wuthrick et al [96], who reported that overall survival, progression-free survival, 
and loco-regional failure were significantly worse when patients were treated at 
historically low-accruing versus high-accruing cancer centers. Boero et al [13] 
conducted a retrospective study on the relationship between yearly patient volume per 
radiation oncologist (using Current Procedural Terminology codes) and patient 
outcomes. In that study, the authors reported that there was no significant relationship 
between provider volume and patient survival or any toxicity endpoint among patients 
treated with conventional radiation; by contrast, patients receiving IMRT by the higher -
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volume radiation oncologists had improved survival compared with those treated by 
low-volume providers.  
Even though the current study does not address patient survival outcomes, our 
patterns of loco-regional failure analysis showed that despite the rigor of our 
department’s clinical QA program, 12% of patients still experienced local and regional 
recurrences. These are largely attributed to radio-resistance or aberrant patterns of 
spread rather than to geographic misses, inasmuch as central high-dose failure 
represented 7 of 10 patients with loco-regional failure. These results demonstrate that 
even though the patients included in the current study had a wide variety of disease 
primary site, with the majority presenting with locally advanced (74%) or recurrent 
(16.5%) high-risk disease, only a very few patients (n = 3) experienced non-central 
high-dose failure after IMRT. The analysis of those 3 cases showed that the first 
patient with intermediate-dose failure likely had new primary disease in the ipsilateral 
buccal mucosa after 2 years of local control after treatment of primary disease in the 
floor of the mouth. The second patient had the only peripheral high-dose failure 
caused by progressive intracranial disease extension in a patient treated for recurrent 
disease after salvage surgery. The third patient had an aberrant pattern of spread in 
the contralateral neck. This patient initially underwent resection of early T2 alveolar 
cancer, with no indication for postoperative RT. That patient experienced a recurrence 
in the ipsilateral parotid and underwent salvage surgery and ipsilateral postoperative 
RT but later experienced recurrence in the contralateral neck. All patients with non-
central failure thus had recurrence outside of the standard anatomic patterns of 
spread. These represented anomalous disease progression that was not attributable 
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to errors in target delineation or to variations in delivery. This supports the utility of 
these QA efforts in precluding preventable operator-dependent delineation oversights, 
inasmuch as no geometric misses were observed with a median of more than 3 years 
of follow-up.  
This data suggest that even within a large group of sub-specialized head and 
neck radiation oncologists, physical examination and peer-reviewed QA clinic play a 
major role in pre-RT changes, both qualitatively and quantitatively. In addition, the 
experience of treating-attending physicians showed significant differences in 
frequency and type of the changes evaluated, which might suggest that chart rounds 
and clinical QA have pedagogic value for junior radiation oncologists.  
While our clinical QA process relies on the availability of a large group of 
experienced head and neck radiation oncologists, there might be some difficulties 
translating this approach to smaller clinics. The clinical QA process could be carried 
out by telemedicine or could be implemented by consulting the referring head and 
neck oncologists, surgeons, specialists, or a combination of them. The use of 
telemedicine would lack the critical step of patient examination, namely direct 
palpation, which would fail to provide a complete evaluation for addressing 3D tumor 
and target localization. Therefore, any technical efforts (e.g., high-quality endoscopic 
video transfer) that afford improved peer review will enhance the performance of 
remote assessment by a colleague. Our recommendation, then, is that in the absence 
of a qualified head and neck radiation oncologist, if at all feasible, the referring surgeon 
should formally affirm tumor localization, documenting carefully by notation in the 
electronic medical record, video-endoscopic recordings, or both.  
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Our study has a few limitations. Because this study was observational, data 
collection and treatment planning changes were performed in real time during chart 
rounds, and typical clinical practices remained unchanged. Although the junior 
physicians could have been less likely to criticize the experienced members’ treatment 
plans and contours, the more experienced physicians constituted a majority (6 of 8 
physicians) of the members in the clinical QA process. For those experienced 
members, approximately 24% of plans required major quantitative changes, showing 
that all members received a rigorous evaluation of treatment plans. Also, the 
classification of changes as major and minor were selected empirically according to 
what the authors deemed appropriate before the start of this study. In addition, it is 
difficult to assess the ultimate clinical impact of the changes made during the HNPDC 
because there was no other way to randomize patients to prove that patients benefited 
from this rigorous peer review process. In our clinic, this QA process is essential from 
a safety and practical standpoint, so it would be unethical to randomize patients to an 
“outside chart review” group versus a group receiving our comprehensive QA, 
including physical examination by HN sub-specialists, especially in the light of 
emerging data about the importance of operator experience. An inherent advantage 
of this QA process is the improvement in consistency in clinical practice and target 
delineations. 
The results from this chapter provide target volume metrics that will be useful 
for comparison in future chapters. While this data does not quantify inter-observer 
delineation variability (which will be quantified in Chapter 4), it illustrates that radiation 
oncologists agree more on other’s high-risk target volume delineations than they do 
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on intermediate- and low-risk volumes. The larger variability observed in intermediate- 
and low-risk target volume delineations could affect development and evaluation of 
predictions when auto-delineating these volumes. We propose a simple solution in 
Chapter 6 to address this limitation when developing an auto-delineation algorithm for 
low-risk target volumes using our institution’s clinical data. 
Conclusion 
In conclusion, practicing clinical QA chart rounds offers many benefits to 
radiation oncology departments. The current study demonstrated that the level of sub-
specialty experience played a major role in the frequency and type of changes made 
in patients’ IMRT plans. Additionally, thorough physical examination of patients and 
review of contours by sub-specialty peers are essential components of QA of plans, 
which led to major changes for approximately one-third of the study population. The 
data in this chapter shows the HNPDC QA process offers greater value than sole chart 
and patient imaging review for preventing errors, reducing adverse events, and 
improving safety related to target localization for patients undergoing IMRT for head 
and neck cancer, ultimately leading to favorable disease control and very few non-
central high-dose failures. Without adequate peer review of patient treatments, 
including comprehensive physical examination, there is an increased risk that target 
delineation errors could go unnoticed and directly affect the patient outcomes and 
quality of life after radiotherapy. 
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Chapter 4: Quantification of Inter- and Intra-
Observer Delineation Variability in High-Risk 
Clinical Target Volumes 
Introduction 
The widespread adoption of intensity modulated radiation therapy (IMRT), a 
conformal radiotherapy technique which allows for the use of high dose gradients even 
within complex patient anatomies, has resulted in improved sparing of organs at risk 
and has reduced the toxicity burdens typically associated with radiation therapy. The 
rapid shift from using conventional (2D) treatments to IMRT has greatly reduced acute 
toxicities, which are sometimes observed during the course of treatment, as well as 
the on-set of late side effects of radiation therapy. While the clinical benefits of IMRT 
are well documented [7, 38, 76], the use of highly conformal plans brought about new 
challenges to the clinic [22]. With the use of high precision treatments there has been 
a larger focus on accurate target delineation, patient set-up, and treatment delivery 
since small errors while performing these tasks may results in significant under-
dosage of at-risk regions and/or over-dosage of surrounding organs at risk.  
Clinical target volumes (CTVs) are one of the main inputs used for IMRT dose 
calculation and their delineation affects many subsequent steps in treatment planning 
and treatment delivery. Inadequate target delineations introduce systematic errors 
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that could potentially affect locoregional control and may increase toxicities for 
individual patients [84].  
Inter- and intra-observer variability when delineating targets has been widely 
studied for many treatment sites and the majority report significant variability amongst 
physicians. This large variability in target delineation is considered a major source of 
uncertainty [44, 84] and reduces our ability to systematically assess the quality of the 
radiation therapy plans. The inter-observer variability for delineation of the CTV for 
oropharyngeal cancer is one of the largest reported in the literature [84]. Hong et al 
[46] conducted a study to assess this variability on an oropharyngeal cancer patient 
and noticed significant variability in target delineation and clinical practices amongst 
head and neck radiation oncology experts. In a recently published commentary article, 
Beadle and Anderson describe the large variability observed in head and neck 
cancers target delineation by stating that “it is clear that 1 person’s target volume is 
not everyone’s target volume.” While several head and neck target delineation 
guidelines have been published in recent years [34–37, 57, 71], large variability 
continues to be documented in head and neck contouring studies [12, 46, 91].  
 In Chapter 3 we showed that high-risk CTV delineated volumes did not change 
significantly during group peer-review of the attending physician’s contours [17]. While 
these results may suggest that there was high agreement in high-risk CTV delineation 
between the radiation oncologists in our clinic, it lacks quantification of contouring 
variability for these volumes. By identifying the inter- and intra-observer variability for 
the radiation oncologists at our institution we can determine the necessary margins 
required to account for this variability when applying PTV margin expansions. In 
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addition, this information would allow us to better assess the development of auto-
delineation techniques that use and are modeled after contours routinely used in our 
clinic.   
The aim of this study is to quantify the inter- and intra-observer variability in 
oropharyngeal high-risk CTV delineation at our clinic in particular for a small subset of 
tonsil and base of tongue patients. We compare delineations on radiation therapy 
simulation computed tomography (CT) scans and provide rigidly-registered pre-
simulation diagnostic contrast-enhanced CT scans along with a brief overview of 
patient history and disease characteristics for each patient. We hypothesize that the 
inter-observer variability within our clinic is smaller in comparison to variability reported 
in the literature, and that intra-observer variability is less than the inter-observer 
variability.  
The resulting data from this chapter will provide valuable insight when 
evaluating clinical target volume auto-delineation models developed in Chapters 5 and 
6. Since these models will be developed based on patients treated by various 
physicians in our head and neck section they will be subject to inter-observer 
variability and quantifying this will allow us to better interpret these model’s 
predictions.  
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Methods and Materials 
Patients and Data Collection 
Seven oropharyngeal cancer patients previously treated with radiation therapy 
at our institution between January 2012 and January 2017 were selected for this study 
under an institutional review board approved protocol. Each case selected was treated 
by a different sub-specialized head and neck radiation oncologist and had available 
gross tumor volume (GTV) and high-risk CTV contours which were previously 
delineated on a simulation CT scan at the time of each patient’s treatment. Available 
patient and disease characteristics were collected through electronic medical records. 
Only pre-radiation therapy contrast-enhanced CT scans were collected for this study 
in addition to the simulation CT since these were routinely performed and available 
for all seven cases. Additional imaging such as ultrasound, positron emission 
tomography, and magnetic resonance images were not provided as part of this study. 
Disease characteristics, along with each patient’s available pre-simulation CT 
contrast-enhanced CT scans, are detailed below.  
Case 1 
Squamous cell carcinoma of the left base of tongue with a left nodal mass 
patient. The patient was staged as having T2 N1 disease and was dispositioned to 
receive definitive chemoradiotherapy. Contrast-enhanced CT was acquired < 2 weeks 
from simulation CT.  
46 
 
Case 2 
Squamous cell carcinoma of the left base of tongue and post-induction residual 
nodes patient. The patient was staged as having T2 N2b disease and was disposed 
to receive definitive chemoradiotherapy. Pre- and post-induction contrast-enhanced 
CT scans were made available. Pre-induction CT was performed three months prior 
to simulation CT, but the post-induction CT was collected three days prior to 
simulation.  
Case 3 
 Squamous cell carcinoma of the right glossopharyngeal sulcus with right nodal 
involvement. The patient was staged T1 N2b and was disposed to receive definitive 
radiotherapy. Contrast-enhanced CT was performed < 3 weeks from the date of 
simulation.  
Case 4 
 Squamous cell carcinoma of the right tonsil with right retropharyngeal node 
involvement patient. The patient was staged T2 N1 and was disposed to receive 
definitive radiotherapy. Contrast-enhanced CT was performed < 2 weeks from the 
date of simulation.  
Case 5 
 Squamous cell carcinoma of the right tonsil with right nodal involvement patient. 
The patient was staged T3 N2b and was disposed to receive definitive 
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chemoradiotherapy. Contrast-enhanced CT was performed < 3 weeks from the date 
of simulation.  
Case 6 
 Squamous cell carcinoma of the right tonsil with right nodal involvement patient. 
The patient was staged T1 N1 and was disposed to receive definitive radiotherapy. 
Contrast-enhanced CT and simulation CT were performed on the same day. 
Case 7 
 Squamous cell carcinoma of the right tonsil with post-induction residual 
contralateral nodal disease patient. The patient was staged T1 N2c and was disposed 
to receive chemoradiotherapy. Pre-induction contrast-enhanced CT was performed 
three months prior to simulation, but the post-induction scan was performed < 2 weeks 
than the simulation CT.  
Experiment Setup 
Seven radiation oncologists agreed to participate in this investigation. We 
designed a blinded study, where the radiation oncologists did not know whether they 
were contouring patients they had previously seen in the clinic. The physicians were 
provided the simulation CT scans with cranially registered contrast-enhanced CT 
images in the Pinnacle treatment planning system (Phillips Medical Systems, 
Amsterdam, Netherlands) and the clinical information for each case as described 
under the “Patients and Data Collection” sub-section. With this information, the 
physicians were asked to contour GTVs and high-risk CTVs for each individual case.  
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Contour Evaluation 
The contours delineated through this study were compared on a per patient 
basis as shown in Figure 6. This figure illustrates how inter- and intra-observer 
variability was quantified for Physician 1’s patient. Using the contours used for 
treatment and new contours from Physician 1 we can measure intra-observer 
variability. Then by using all contours (Physicians 1 through 7) evaluated the inter-
observer variability for each case.  
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Figure 6. Inter- and intra-observer variability evaluation 
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Volumetric Comparison 
For intra-observer variability, we defined the contour used for treatment as our 
ground-truth for each patient. Overlap metrics used for comparison included the Dice 
similarity coefficient (DSC), false negative Dice (FND), and false positive Dice (FPD); 
whereas distance metrics measured will include the mean surface distance (MSD), 
the 95th Percentile Hausdorff distance (95HD), and the Hausdorff distance (HD). 
These metrics are defined as follows, 
𝐷𝑆𝐶 =
2∗|𝐴∩𝐵|
|𝐴|+|𝐵|
                         (4.1) 
𝐹𝑁𝐷 =
2∗|𝐴′∩𝐵|
|𝐴|+|𝐵|
                        (4.2) 
𝐹𝑃𝐷 =
2∗|𝐴∩𝐵′|
|𝐴|+|𝐵|
                        (4.3) 
𝑀𝑆𝐷 =
1
2
⁡(𝑑?̅?,𝐵 +𝑑̅𝐵,𝐴)               (4.4) 
95𝐻𝐷 = ⁡𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒(𝑑𝐴,𝐵 ∪ 𝑑𝐵,𝐴, 95
𝑡ℎ)     (4.5) 
𝐻𝐷 = ⁡𝑚𝑎𝑥(𝑑𝐴,𝐵 ∪𝑑𝐵,𝐴)       (4.6) 
where |A| and |B| are the number of voxels from contoured volumes A and B, 
respectively, |A∩B| denotes the number of voxels included in the intersection between 
volumes A and B, A’ and B’ are the complements of A and B, respectively, 𝑑𝐴,𝐵  is a 
vector containing all minimum Euclidian surface distances from the surface point from 
volume A to B and 𝑑?̅?,𝐵 is the average value in the vector 𝑑. The DSC ranges in values 
from 0 (no overlap) to 1 (perfect overlap). The FND and FPD provide a measure of 
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under- and over-treatment, respectively. Their values range from 0 (no under- or over-
treatment) to 2 (complete under- or over-treatment).  
For inter-observer variability, conducted a series of analyses for each patient 
using the contours delineated as part of this study. First, we will perform a pair-wise 
comparison between the contours (i.e. Physician 1 vs Physician 2, Physician 1 vs 
Physician 3, …, Physician 6 vs Physician 7) using overlap (DSC) and distance (MSD, 
95HD, and HD) metrics. Then, we calculate the conformity index (CI) and generalized 
conformity index (CIgen) [54] for each patient. CI is defined as follows, 
𝐶𝐼 =
𝑉𝑜𝑙𝑢𝑚𝑒⁡𝑜𝑓⁡𝐼𝑛𝑡𝑒𝑟𝑠𝑒𝑐𝑡𝑖𝑜𝑛
𝑉𝑜𝑙𝑢𝑚𝑒⁡𝑜𝑓⁡𝑈𝑛𝑖𝑜𝑛
=
𝑉1⁡∩⁡𝑉2⁡∩⁡…⁡∩⁡𝑉𝑛
𝑉1⁡∪⁡𝑉2⁡∪⁡…⁡∪⁡𝑉𝑛
                     (4.7) 
and can be illustrated in Figure 7. Values for CI range from 0 to 1, where a value of 0 
means the delineations are fully disjointed and a value of 1 is observed when the 
delineations are the same. A limitation of the CI is that it is highly dependent on the 
number of delineated volumes, with CI typically decreasing with increasing number of 
delineated volumes. The volume of intersection, which is overlapped by all 
delineations, tends to become smaller while the volume of union, the union between 
the delineations, becomes larger for each delineation added. Kouwenhoven et al [54] 
address this limitation by introducing the generalized conformity index (CIgen). Just like 
CI, this version equals to 0 if all volumes are disjointed, and equals 1 if the volumes 
are equal and perfectly overlapped. In addition, it has no bias with respect to the 
number of volumes delineated and equals to the generalized conformity index equals 
to the Jaccard coefficient [50] when only two delineated volumes are compared. For 
the purposes of this study, we introduced a Dice version of the generalized conformity 
index (CIDSC) and define this metric as follows 
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𝐶𝐼𝐷𝑆𝐶 =
∑ 2∗⁡|𝐴𝑖∩𝐴𝑗|𝑝𝑎𝑖𝑟𝑠⁡𝑖,𝑗
∑ ⁡|𝐴𝑖|+|𝐴𝑗|𝑝𝑎𝑖𝑟𝑠⁡𝑖,𝑗
         (4.7) 
The generalized conformity index can be calculated from our Dice version of this index 
through Eq. 4.8. 
𝐶𝐼𝑔𝑒𝑛 =
𝐶𝐼𝐷𝑆𝐶
2−𝐶𝐼𝐷𝑆𝐶
           (4.8) 
 Lastly, estimated a consensus volume using a modified version [99] of the 
simultaneous truth and performance level estimation (STAPLE) algorithm [94]. The 
STAPLE algorithm calculates the maximum likelihood estimates of the true positive 
and false negative of individual segmentations and uses these values to produce a 
volume that estimates the best agreement between the individual segmentations. A 
limitation to the STAPLE algorithm is that it does not take into consideration intensity 
information of the image to be segmented, it only relies on individual segmentations. 
The methodology by Yang et al [99] addresses this limitation by creating a tissue 
appearance model and integrating it into the STAPLE fusion process. The resulting 
consensus volumes for each patient will be considered our ground-truth for this 
analysis and we will compare each physician’s delineations using overlap (DSC, FND, 
and FPD) and distance (MSD, 95HD, and HD) metrics. 
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Figure 7. Illustration of Conformity Index calculation between two regions of 
interest  
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Results 
 Five out of seven radiation oncologists participating in this study completed 
contours on all seven cases. Only contours from these five physicians were used for 
this analysis. Volumes (in cm3) for the physician delineations, STAPLE, and contour 
used for each cases’ radiotherapy are summarized in Table 6. The average volumes 
of GTV for cases 1 through 7 were 17.3 cm3, 38.2 cm3, 11.3 cm3, 14.7 cm3, 21.2 cm3, 
8.8 cm3,  and 16.1 cm3; whereas the average high-risk CTV average volumes for these 
cases were 99.9 cm3, 184.9 cm3, 85.2 cm3, 75.7 cm3, 104.9 cm3, 78.1 cm3, and 111.7 
cm3 for cases 1 through 7, respectively. The mean difference between these average 
volumes and the original volume used for treatment was 4.1 (±11.6) cm3 and 6.9 
(±35.6) cm3 for GTV and high-risk CTV volumes, respectively. The median coefficient 
of variation (standard deviation / mean * 100%) of volume between all 7 cases were 
31.8% (range: 5.7-83.2%) and 16.9% (range: 10.0-26.9%) for GTV and high-risk CTV, 
respectively.  
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Table 6. Volume (cm3) comparison between physician delineated high-risk CTVs and GTVs in contouring study 
RO 
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 
CTV GTV CTV GTV CTV GTV CTV GTV CTV GTV CTV GTV CTV GTV 
1 107.3 15.9 260.2 34.2 114.7 17.6 93.8 18.2 128.0 26.1 93.9 9.1 110.7 17.2 
2 93.0 19.4 183.9 58.8 79.3 15.7 70.6 13.2 101.6 23.0 67.6 9.2 147.7 30.9 
3 113.6 21.5 141.7 27.7 74.2 6.3 72.2 14.4 101.5 21.5 78.6 9.2 123.3 9.6 
4 94.7 12.3 175.5 31.9 101.2 9.1 80.1 12.9 98.6 17.0 87.9 8.1 96.7 9.3 
5 90.9 17.3 163.0 38.6 56.5 7.6 62.0 14.9 94.9 18.2 62.5 8.5 80.2 13.6 
               
Average 99.9 17.3 184.9 38.2 85.2 11.3 75.7 14.7 104.9 21.2 78.1 8.8 111.7 16.1 
Std. Dev. 10.0 3.5 45.0 12.2 22.9 5.1 12.0 2.1 13.2 3.7 13.2 0.5 25.7 8.9 
Vmax/Vmin 1.2 1.8 1.8 2.1 2.0 2.8 1.5 1.4 1.3 1.5 1.5 1.1 1.8 3.3 
               
STAPLE 93.2 15.3 168.1 30.8 72.6 8.4 63.8 13.4 95.3 17.7 71.9 6.8 103.8 12.5 
RT Contour 131.8 18.2 171.9 34.7 69.3 29.8 102.2 16.1 153.9 41.4 101.4 11.8 58.2 4.0 
RO: Radiation Oncologist; RT Contour: high-risk CTV used for treatment
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Intra-observer Variability 
 Volumetric comparisons between each physician’s delineation and the high-
risk clinical target volume they previously contoured and used for treatment are 
detailed in Table 7 and Table 8.  The median values for DSC, FND, FPD, MSD, 95HD, 
and HD were 0.727, 0.375, 0.183, 2.0 mm, 8.3 mm, and 10.8 mm, respectively, for 
GTV delineations. For high-risk CTV, median DSC, FND, FPD, MSD, 95HD, and HD 
values were 0.768, 0.369, 0.109, 4.0 mm, 11.7 mm, and 18.9 mm, respectively. Four 
out of five physician high-risk CTV delineations were smaller than the contours used 
for treatment. Median differences in volumes (RT – study contour) for CTV and GTV 
were -30.2 cm3 (range: -38.8 – +52.5 cm3) and -3.3 cm3 (range: -7.0 – +13.2 cm3), 
respectively. One physician’s contours for both CTV and GTV had zero overlap with 
the previously contoured volumes used for treatment. For this particular 
case/physician, MSD and HD values were 62.2 mm and 85.6 mm, respectively, for 
GTV and 59.6 mm and 92.4 mm, respectively, for high-risk CTV.  
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Table 7. Intra-observer volume comparison for high-risk CTV and GTV delineations 
RO 
Contoured Volumes (cm3) 
Study Contour RT Contour 
CTV GTV CTV GTV 
1 110.7 17.2 58.2 4.0 
2 93.0 19.4 131.8 18.2 
3 141.7 27.7 171.9 34.7 
4 80.1 12.9 102.2 16.1 
5 62.5 8.5 101.4 11.8 
 
 
 
Table 8. Intra-observer variability for high-risk CTV and GTV delineations 
RO 
CTV GTV 
DSC FND FPD MSD 95HD HD DSC FND FPD MSD 95HD HD 
1 0.000 0.689 1.311 59.6 81.6 92.4 0.000 0.375 1.625 62.2 82.0 85.6 
2 0.803 0.369 0.025 3.2 8.3 16.6 0.727 0.241 0.305 2.1 5.7 9.5 
3 0.783 0.313 0.120 4.2 16.5 30.0 0.704 0.409 0.183 2.5 8.3 10.8 
4 0.768 0.355 0.109 3.7 9.7 12.5 0.769 0.344 0.119 1.7 5.2 8.6 
5 0.745 0.492 0.018 4.0 11.7 18.9 0.734 0.427 0.106 1.9 9.0 12.9 
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Inter-observer Variability 
 A visual comparison between each radiation oncologists’ CTV delineations can 
be seen in Figures Figure 8 - Figure 14. The respective GTV delineations for these 
cases can be found in the Appendix (Figures Figure 52 - Figure 58) 
Pair-wise Comparison 
 A total of 10 volume pair comparisons were made for each case. The calculated 
DSC, MSD, 95HD, and HD value distributions are shown in Figure 15 and Figure 16. 
Since the metric’s values calculated for Case 7 varied largely in comparison to the 
other cases, Figure 16 offers a closer look to the distributions of Cases 1 through 6. 
When considering all cases and GTV contours the average values were 0.618 ± 
0.206, 4.3 mm ± 6.4 mm, 12.7 mm ± 15.3 mm, and 20.4 mm ± 17.5 mm for DSC, 
MSD, 95HD, and HD, respectively, and the median values were 0.698 (range: 0.001 
– 0.833), 2.5 mm (range: 1.2 mm – 34.1 mm), 7.5 mm (range: 3.2 mm – 71.9 mm), 
and 14.6 mm (range: 5.7 mm – 85.8 mm) for DSC, MSD, 95HD, and HD, respectively. 
For high-risk CTVs the average values were 0.715 ± 0.144, 5.2 mm ± 5.2 mm, 15.9 
mm ± 14.2 mm, and 24.0 mm ± 16.7 mm for DSC, MSD, 95HD, and HD, respectively, 
and the median values were 0.752 (range: 0.123 – 0.888), 3.9 mm (range: 1.5 mm – 
32.2 mm), 12.1 mm (range: 5.0 mm – 71.5 mm), and 20.8 mm (range: 7.9 mm – 88.7 
mm).   
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Figure 8. High-risk CTV delineations between physicians for Case 1 
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Figure 9. High-risk CTV delineations between physicians for Case 2 
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Figure 10. High-risk CTV delineations between physicians for Case 3 
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Figure 11. High-risk CTV delineations between physicians for Case 4 
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Figure 12. High-risk CTV delineations between physicians for Case 5 
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Figure 13. High-risk CTV delineations between physicians for Case 6 
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Figure 14. High-risk CTV delineations between physicians for Case 7  
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Figure 15. Distribution of overlap metric values calculated in inter-observer 
volume pair comparison 
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Figure 16. Distribution of overlap metric values calculated in inter-observer 
volume pair comparison for Cases 1 through 6 
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Conformity Index 
 The conformity index (overlap over union) values for cases 1 through 7 were 
0.41, 0.37, 0.24, 0.37, 0.41, 0.36, and 0.02 for CTV and 0.34, 0.21, 0.06, 0.35, 0.35, 
0.31, 0.00 for GTV. Generalized and DSC conformity index values for all seven cases 
are reported in Table 9. The median CIgen values were 0.61 (range: 0.29 – 0.65) and 
0.57 (range: 0.16 – 0.61) for CTV and GTV, respectively. The median CIDSC values 
were 0.76 (range: 0.45 – 0.79) and 0.72 (range: 0.28 – 0.76) for CTV and GTV, 
respectively.  
 
Table 9. Conformity Index values measured from inter-observer contours 
Case 
CTV GTV 
CIgen CIDSC CIgen CIDSC 
1 0.65 0.79 0.60 0.75 
2 0.62 0.76 0.47 0.64 
3 0.50 0.67 0.25 0.40 
4 0.61 0.76 0.61 0.76 
5 0.64 0.78 0.59 0.75 
6 0.61 0.76 0.57 0.72 
7 0.29 0.45 0.16 0.28 
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STAPLE Analysis 
 A detailed comparison between the STAPLE volumes and physician contours 
are shown in Table 10. When considering all cases the average DSC values was 
0.817 ± 0.114 and 0.733 ± 0.173, the average FND values were 0.139 ± 0.123 and 
0.185 ± 0.181, the average FPD values were 0.228 ± 0.163 and 0.348 ± 0.251, the 
average MSD values were 3.1 mm ± 3.3 mm and 2.7 mm ± 5.2 mm, the average 95HD 
values were 11.0 mm ± 11.5 mm and 8.6 mm ± 11.7 mm, and the average HD values 
were 17.9 mm ± 13.5 mm and 15.1 mm ± 14.3 mm for CTV and GTV, respectively. A 
statistical summary of the STAPLE comparison results are provided in Table 11.  
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Table 10. Volumetric comparison between physician’s contours and STAPLE volume.  
 
CTV GTV CTV GTV CTV GTV CTV GTV CTV GTV CTV GTV CTV GTV CTV GTV CTV GTV
1 0.862 0.858 0.744 0.718 0.702 0.392 0.751 0.767 0.781 0.759 0.772 0.697 0.404 0.027 0.716 0.603 0.146 0.293
2 0.906 0.804 0.892 0.662 0.83 0.571 0.854 0.823 0.894 0.817 0.856 0.775 0.494 0.53 0.818 0.712 0.146 0.124
3 0.861 0.81 0.844 0.835 0.895 0.724 0.876 0.875 0.832 0.794 0.877 0.781 0.812 0.616 0.857 0.777 0.029 0.085
4 0.795 0.802 0.91 0.88 0.757 0.735 0.81 0.826 0.905 0.87 0.867 0.845 0.909 0.652 0.85 0.801 0.063 0.082
5 0.908 0.844 0.894 0.714 0.762 0.444 0.931 0.886 0.903 0.877 0.863 0.817 0.648 0.832 0.844 0.773 0.102 0.156
Mean 0.866 0.824 0.857 0.762 0.789 0.573 0.845 0.835 0.863 0.823 0.847 0.783 0.653 0.531 0.817 0.733
Std Dev 0.046 0.026 0.068 0.092 0.075 0.157 0.068 0.048 0.055 0.05 0.043 0.056 0.211 0.303 0.114 0.173
1 0.068 0.123 0.042 0.229 0.073 0.255 0.058 0.079 0.068 0.048 0.096 0.156 0.564 0.815 0.138 0.244 0.188 0.263
2 0.095 0.077 0.063 0.026 0.125 0.124 0.095 0.184 0.095 0.053 0.175 0.074 0.332 0.046 0.14 0.083 0.092 0.054
3 0.04 0.021 0.242 0.22 0.094 0.419 0.062 0.086 0.04 0.11 0.079 0.063 0.102 0.515 0.094 0.205 0.069 0.191
4 0.197 0.309 0.069 0.103 0.078 0.223 0.077 0.192 0.197 0.149 0.033 0.066 0.126 0.493 0.111 0.219 0.065 0.145
5 0.105 0.096 0.121 0.174 0.362 0.604 0.084 0.058 0.105 0.108 0.207 0.066 0.48 0.124 0.209 0.176 0.154 0.193
Mean 0.101 0.125 0.107 0.15 0.147 0.325 0.075 0.12 0.101 0.093 0.118 0.085 0.321 0.398 0.139 0.185
Std Dev 0.059 0.109 0.081 0.086 0.122 0.189 0.015 0.063 0.059 0.043 0.071 0.04 0.206 0.315 0.123 0.181
1 0.209 0.161 0.471 0.334 0.523 0.962 0.44 0.387 0.366 0.434 0.361 0.451 0.628 1.131 0.428 0.551 0.134 0.355
2 0.093 0.315 0.153 0.65 0.214 0.734 0.196 0.169 0.138 0.313 0.113 0.376 0.681 0.895 0.227 0.493 0.205 0.267
3 0.237 0.358 0.071 0.111 0.116 0.133 0.186 0.164 0.199 0.303 0.168 0.375 0.273 0.254 0.179 0.242 0.069 0.108
4 0.213 0.088 0.112 0.136 0.408 0.306 0.303 0.156 0.112 0.11 0.233 0.245 0.056 0.204 0.205 0.178 0.123 0.078
5 0.08 0.217 0.09 0.398 0.113 0.509 0.055 0.17 0.095 0.138 0.067 0.299 0.224 0.212 0.103 0.278 0.056 0.134
Mean 0.166 0.228 0.179 0.326 0.275 0.529 0.236 0.209 0.182 0.26 0.189 0.349 0.372 0.539 0.228 0.348
Std Dev 0.074 0.11 0.166 0.219 0.183 0.33 0.144 0.1 0.11 0.134 0.115 0.079 0.27 0.441 0.163 0.251
FN
D
FP
D
Case 5 Case 6 Case 7 Mean Std. Dev.
D
SC
RO
Case 1 Case 2 Case 3 Case 4
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1 2.1 0.9 5.1 2.3 4.3 4.4 4.3 2.5 3.7 1.9 3.5 1.7 19.9 31.8 6.1 6.5 6.1 11.2
2 1.3 1.5 1.7 3.1 2.4 2.5 2.6 2.2 1.5 1.2 1.9 1.2 7.6 5.9 2.7 2.5 2.2 1.6
3 2.3 1.4 2.5 1.3 1.5 1.9 1.8 0.9 2.5 2.2 1.6 1.2 2.3 2.4 2.1 1.6 0.4 0.6
4 3.6 1.5 1.6 1 4 1.5 3.1 1.3 1.4 0.8 2 0.8 1 2.3 2.4 1.3 1.2 0.5
5 1.3 1 1.8 2.3 3.4 3.8 1 0.9 1.5 0.8 1.8 1 5.7 1.5 2.3 1.6 1.7 1.1
Mean 2.1 1.3 2.5 2 3.1 2.8 2.6 1.6 2.1 1.4 2.2 1.2 7.3 8.8 3.1 2.7
Std Dev 0.9 0.3 1.5 0.9 1.1 1.3 1.3 0.7 1 0.6 0.8 0.3 7.5 13 3.3 5.2
1 5.9 2.8 14.5 7.5 13.7 10.7 16.9 7.5 11.8 6.1 12.4 5.2 66.9 68.9 20.3 15.5 20.8 23.7
2 3.9 5 4.9 7.8 7.8 8.8 17.9 12.7 4.2 3.9 6 5.2 24.4 31.3 9.9 10.7 8.1 9.6
3 7.5 4.9 6.7 3.3 5.7 12 7.1 2.7 9.9 13 4.6 4.6 7.5 9.9 7 7.2 1.6 4.3
4 15 5.5 5 3.2 13.3 5 10.7 4 5 2.9 6 3 4.9 7 8.6 4.4 4.4 1.5
5 4.1 4 5 7.6 10.4 12 2.8 2.7 5.1 2.9 7.3 3.7 31.3 3.9 9.4 5.3 10 3.4
Mean 7.3 4.4 7.2 5.9 10.2 9.7 11.1 5.9 7.2 5.8 7.3 4.4 27 24.2 11 8.6
Std Dev 4.6 1.1 4.1 2.4 3.4 3 6.5 4.3 3.4 4.2 3 1 24.9 27.2 11.5 11.7
1 17.6 4.7 25.5 16 22.6 18 25.8 28.4 16.3 15.7 18.5 10.3 80.8 79.7 29.6 24.7 22.9 25.3
2 9.3 9.1 8 13 16 13.9 26.7 31.4 7.7 8.2 10.6 8.8 36.1 40.5 16.3 17.9 11 12.8
3 10.8 12.4 11.2 10 13 15.3 12.2 5.6 21.6 23.7 12.1 8.9 13.4 14 13.5 12.8 3.7 5.8
4 18.6 8.6 12.1 6.4 21.5 8.3 17.6 6.4 9.3 5 10.6 3.8 13.5 15.1 14.7 7.7 4.5 3.7
5 10.1 7.6 10 13.5 16.3 15.1 5.1 5.7 9.2 5.1 13.7 6.6 42.5 35.3 15.3 12.7 12.5 10.7
Mean 13.3 8.5 13.4 11.8 17.9 14.1 17.5 15.5 12.8 11.5 13.1 7.7 37.2 36.9 17.9 15.1
Std Dev 4.4 2.7 6.9 3.7 4 3.6 9.2 13.2 6 8.1 3.3 2.5 27.6 26.7 13.5 14.3
M
SD
95
H
D
H
D
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Table 11. Statistical summary of STAPLE and physician contour comparison 
 
 DSC FND FPD MSD 95HD HD 
C
T
V
 
Average 0.817 0.139 0.228 3.1 11.0 17.9 
Std. Dev. 0.114 0.123 0.163 3.3 11.5 13.5 
Median 0.856 0.095 0.196 2.3 7.3 13.5 
Minimum 0.404 0.033 0.055 1.0 2.8 5.1 
Maximum 0.931 0.564 0.681 19.9 66.9 80.8 
G
T
V
 
Average 0.733 0.185 0.348 2.7 8.6 15.1 
Std. Dev. 0.173 0.181 0.251 5.2 11.7 14.3 
Median 0.794 0.123 0.303 1.5 5.2 10.3 
Minimum 0.027 0.021 0.088 0.8 2.7 3.8 
Maximum 0.886 0.815 1.131 31.8 68.9 79.7 
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Discussion 
 In the era of high-precision radiation therapy, accurate and consistent tumor 
and target delineation is of outmost importance. Many have suggested that the 
inherent variability observed when contouring these volumes is the largest source of 
uncertainty in radiation therapy [6, 44, 84]. In this study, we investigated the inter- and 
intra-observer variability found within a group of sub-specialized head and neck 
radiation oncologists when delineating tumor and high-risk clinical target volumes at 
a single institution.  
 For intra-observer variability, we found the median DSC, MSD, and HD values 
to be 0.727, 2.0 mm, and 10.8 mm respectively, for GTV and 0.768, 4.0 mm, and 18.9 
mm, respectively, for high-risk CTV. In general, volumes contoured in this study were 
smaller in size than those designed and contoured during treatment. One physician’s 
contours, both CTV and GTV, from this study had zero overlap with what he previously 
contoured and used for treatment. However, although this is an extreme example, 
large variability was noticed amongst all participant’s contours for this particular case 
suggesting that additional information such as physical examination details or 
additional imaging (PET/CT and/or MRI) could have aided in developing a more 
consistent and accurate treatment design.  
 To evaluate inter-observer variability we conducted a pair-wise comparison, 
calculated conformity indexes, and compared the contours to a STAPLE volume for 
each case. The pair-wise analysis resulted in average DSC, MSD, and HD values of 
0.618, 4.3 mm, and 20.4 mm respectively, for GTV and 0.715, 5.2 mm, and 24.0 mm, 
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respectively, for high-risk CTVs contours. The DSC based conformity index had 
average values of 0.614 and 0.710 for GTV and CTV, respectively. Lastly, the 
comparison of the physician contours to the STAPLE volumes resulted in mean DSC, 
MSD, and HD values of 0.733, 2.7 mm, and 15.1 mm, respectively, for GTV contours  
and 0.817, 3.1 mm, and 17.9 mm, respectively, for high-risk CTV.  
 A median DSC value of 0.768 was calculated for high-risk CTV intra-observer 
variability whereas this value was 0.749 on inter-observer pair-wise comparison. The 
differences in variability between both inter- and intra-observer measurements was 
not statistically significant (p = 0.45, Wilcoxon rank-sum test) for high-risk CTVs nor 
for GTV delineations (p = 0.47, Wilcoxon rank-sum test).  
Overlap and distance metrics values saw an improvement (higher overlap and 
shorter distances) when comparing the physician contours to the STAPLE volume in 
comparison to values seen in the pair-wise volume comparison. This is expected as 
the STAPLE volume is a consensus delineation derived from the contours in this study 
with the goal of maximizing true positive and false negatives for each individual 
segmentation. While a STAPLE volume may represent the most likely “true” 
segmentation, comparing physicians’ contours to this volume may lead to an 
underestimate of the true inter-observer variability reported in contouring studies.  
When evaluating variability on a per case basis, we noticed physicians’ 
delineation variability was similar for cases 1, 2, 3, 4, 5, and 6. The largest variability 
in delineations was observed for Case 7, were median DSC, MSD, and HD values for 
high-risk CTV were 0.507 (range: 0.145 – 0.752), 8.1 mm (range: 2.9 mm – 32.2 mm), 
and 45.1 mm (range: 17.6 mm – 83.4 mm), respectively, as calculated on pair-wise 
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volume comparison. This seemed a particularly difficult case to delineate for all 
physicians. Based on electronic medical records, diagnosis of a left-sided neck mass 
was confirmed on PET/CT prior to induction. This mass was greatly reduced in size 
post-induction and prior to delivery of radiotherapy. Notes on this patient’s physical 
examination during HNPDC showed that both primary and nodal disease had overall 
responded well to chemotherapy showing no evidence of residual disease. The lack 
of physical examination information provided in this study could have played a role on 
the large variability observed for this case. This is supported by our findings from 
Chapter 3 were group physical examination resulted in new clinical findings in 14% of 
patients. Figure 16 showed slightly larger Hausdorff distances when comparing GTVs 
between physicians for cases 4 and 5. This increase in disagreement between contour 
surfaces is contributed by the inclusion of suspicious nodal disease by two and one 
physician/s for cases 4 and 5, respectively. In case 4, both physicians included 
suspicious masses in the lower right neck; whereas in case 5, one of the physicians 
included a suspicious mass on the right level V nodal region. These masses were all 
less than 1 cm3 in size. For case 4, the two nodal masses contoured were covered by 
the low-risk CTV on the plan used for treatment. However, the level V nodal mass, 
which was contoured by a single observer,  
Very few studies have investigated GTV and CTV variability in delineations for 
head and neck cancers [2, 12, 46, 91]. Hong et al [46] provided 20 head and neck 
radiation oncology experts with the same patient’s CT image and GTV contours and 
asked them to delineate target volumes. In their study, they found large heterogeneity 
in target design and treatment practices. For those physicians using two dose levels, 
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they found that high-risk CTV volumes had a standard deviation of 43 cm3 and the 
coefficient of variation was 52.4%. In our study, the median coefficient of variation 
between all cases was 16.9% (range: 10.0-26.9%).  
While evaluating the impact of imaging modality on GTV delineations, 
Thiagarajan et al [91] reported mean CI values ranging from 0.54 to 0.62 for primary 
disease delineations, whereas the mean value of CIgen for GTV (primary and nodal 
disease) was 0.42 in our study. A key difference between their study and ours is that 
they investigated delineation differences based on image modalities, whereas ours 
solely focuses on delineation variability based on CT and contrast-enhanced CT 
imaging. As in their study, we found that GTV volumes used for treatment and 
contoured based on information from several imaging modalities (simulation CT + 
contrast-enhanced CT and/or PET/CT and/or MRI) where slightly larger (22.3 cm3 vs 
18.2 cm3) but not significantly (p = 0.39, paired t-test).  
More recently, Blinde et al [12] reported, in abstract form, large variability in 
GTV and high-risk CTV delineations as seen on four oropharyngeal cancer patients. 
In their study, they provided international experts in head and neck radiation oncology 
with T1- pre- and post-contrast, and T2-weighted MRI scans along with patient history 
and a physical examination in order to delineate GTV and high-risk CTV. Based on 
contours from 24 radiation oncologists, they found ratios of maximum/minimum 
volumes to be as high as 11.6 for GTV (mean = 5.6) and 7.7 (mean = 6.2) for high-
risk CTV. These ratios were significantly larger (p < 0.0001, unpaired t-test) than the 
ones observed in our study for both GTV (mean = 2.0, range: 1.1 – 3.3) and high-risk 
CTV (mean = 1.6, range: 1.2 – 2.0) delineations.  
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The variability in head and neck cancer tumor and target volumes is a well-
known issue in the radiation oncology community [6]. International experts and leaders 
in head and neck radiation oncology published two guidelines last year alone to 
address this problem and to provide guidance towards delineation standardization 
amongst practitioners  [36, 57]. These studies provide a comparison between basic 
geometric expansion volumes [43] and more traditional anatomical-based 
delineations built on knowledge of patterns of failure and a detailed understanding on 
pathways of disease spread. While using basic geometric expansions has been 
shown to greatly reduce variability  in clinical target volume delineations [20, 43], these 
are dependent on the quality of GTV delineations which we show here to be subject 
of considerable variability. Larger margins could be implemented to account for the 
uncertainty in GTV delineations, but these could lead to potentially delivering 
unnecessary higher doses to surrounding tissues. While radiation oncologists 
continue their efforts to standardize head and neck clinical target volume delineation 
through recommendations and suggested guidelines, one solution to standardize the 
delineation of these volumes is automation. Automatically delineating these volumes 
would result in better quality data across multi-institutional studies. Auto-delineation 
models could be developed through large patient databases and then further improved 
after clinical implementation by assessing patient outcome and toxicities data.  
There are a few limitations to this study. First, we only investigate inter-observer 
variability for physicians at a single institution and therefore the variability reported in 
this study may underestimate variability reported amongst observers from multiple 
clinics. The clinical information provided to the participants in this study was limited 
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for each case and may not represent real clinical scenarios; this choice was made to 
provide similar information for all cases as patient information and breadth in 
description of disease available in the electronic medical records system varied 
between cases. Patient imaging provided in this study only included each cases’ 
simulation CT and pre-RT contrast-enhanced CT scans; these scans were available 
for all cases but a few of the cases had PET/CT and/or MRI scans which were used 
for target design at the time of treatment.  
Conclusion 
 Inter- and intra- observer variability in tumor and target delineation remains a 
major source of uncertainty in radiation therapy of the head and neck. Quantification 
of this variability for oropharyngeal GTV and high-risk CTV delineation at our institution 
showed a reduced variability in comparison to values reported in the literature. We 
recommend peer-review of GTV and CTV delineations on a per patient basis to 
minimize any possibility of missed and undertreated disease.   
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Chapter 5: Auto-Delineating High-Risk Clinical 
Target Volumes 
This chapter is based on the following publication:  
Cardenas, CE, McCarrol, RE, Court, LE, Elgohari, BA, Elhalawani, H, Fuller, CD, Kamal, MJ, 
Meheissen, MAM, Mohamed, ASR, Rao, Arvind, Williams, B, Wong, A, Yang, J, and Aristophanous, 
M. "Deep Learning Algorithm for Auto-Delineation of High-Risk Oropharyngeal Clinical Target Volumes 
with Built-in Dice Similarity Coefficient Parameter Optimization Function." International Journal of 
Radiation Oncology* Biology* Physics (2018) 101:468–478. © 2018 Elsevier Inc.  
No permission is required for reuse of this material, which was published under the Creative Commons 
CC-BY-NC-ND license.  
Introduction  
Manual delineation of clinical target volumes (CTVs) remains a time-consuming 
task in radiation oncology. CTVs are tissue volumes that contain the demonstrable 
gross tumor volume (GTV) and provide coverage for any suspected microscopic 
disease and pathways of tumor spread such as regional lymph nodes [49]. Because 
the radiation dose is prescribed to these volumes and adequate coverage is required 
to achieve cure, accurate CTV delineation is essential in radiation therapy. Although 
established guidelines are available to delineate site-specific CTVs, these volumes 
are still subject to high intra- and inter-observer variability for most treatment sites [31, 
46, 60–62]. This variability in delineation and the heterogeneity in clinical practice have 
hindered our ability to systematically assess the quality of the radiation therapy plans 
and are considered major sources of uncertainty [44]. In Chapter 3 we showed how 
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peer-review of clinical target volume delineations leads to major changes in 
delineations in 35% of head and neck IMRT cases. In Chapter 4, we quantified the 
inter-observer variability in the delineation of high-risk CTVs for the physician in our 
clinic.  
When treating head and neck cancer, radiation therapy prevails as the principal 
nonsurgical treatment option. For this site in particular, the complexity of radiation 
treatment planning and the time required to delineate the target and normal tissue 
volumes are significantly increased [75] owing to the large number of organs at risk 
located near head and neck tumors. To add to this complexity, head and neck 
treatment plans typically require several CTVs, which are used to deliver different 
radiation dose levels, depending on the risk of recurrence for that region (i.e. high-, 
intermediate-, and low-risk volumes). In particular, accurate delineation of the high-
risk CTV is imperative, and failure to provide adequate coverage has the potential to 
reduce tumor control and increase the risk of locoregional recurrence [29, 58]. 
Although an abundance of work auto-delineating normal structures using atlas-based 
registration techniques is available [41, 86, 100], little work has been performed to 
auto-delineate head and neck CTVs, especially to auto-delineate high-risk target 
volumes. Machine learning and deep learning normal tissue auto-segmentation 
approaches have increased in popularity during the past few years. Some 
improvements in normal tissue segmentation have been observed using these novel 
techniques; however, a need remains to investigate these approaches for auto-
delineation of CTVs.  
81 
 
To the best of our knowledge, no registration-based approaches are available 
to auto-delineate high-risk CTVs. This is not surprising owing to the lack of significant 
features on computed tomography (CT) images (limited by coverage of possible 
microscopic disease) and the high variability in GTV geometric shape, location, and 
subsite involvement. Although definition of the high-risk CTV is guided by the anatomic 
structures, the high-risk CTV is neither a distinct structure, such as the GTV, nor a 
specific anatomic structure, such as elective nodal chains. These limitations have 
hindered the development of auto-delineation algorithms for these volumes. 
Our previous work [18] has shown that distance metrics can provide sufficient 
information to automate the delineation of high-risk CTVs and that deep auto-
encoders [15, 16] provide a venue for good generalization even when few patients are 
used for training. This is primarily because these models were trained on a voxel by 
voxel basis providing hundreds of thousands of inputs per patient for training. In 
addition, a preliminary study [15] from our group showed that clustering patients per 
site and nodal status may lead to an improvement in prediction performance on a 
small cohort of oropharyngeal patients.  
Automating the CTV delineation process for head and neck tumors would offer 
many clinical advantages. First, it has the potential to reduce the variability in target 
design and clinical practice among radiation oncologists. This reduction in variability 
would provide better data for multi-institutional studies in which clinical practices can 
vary greatly [46]. Second, it would aid in reducing the physician contouring time. This 
would allow physicians to spend more time with patients to provide better quality of 
care.  
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In the present study, we propose a novel method to auto-delineate high-risk 
CTVs that overcomes several of the current limitations. Our approach requires only a 
limited amount of training data and performed well compared with manual contours. 
More specifically,  
 We propose a deep learning approach in which the model is trained on 
anatomic structure distance map information to produce patient-specific high-
risk CTVs.  
 We have addressed, to the best of our knowledge for the first time, a non-
uniform margin approach to the auto-delineation of high-risk CTVs for head and 
neck patients.  
 We introduce a novel threshold selection function to convert probability maps 
into binary volumes.  
 Finally, we present an evaluation of our method and show that our predicted 
volumes are in close agreement with manually drawn contours.  
Methods and Materials 
Patient and Image Characteristics 
A total of 52 oropharyngeal cancer patients (11 base of tongue node-negative, 
15 base of tongue node-positive, 15 tonsil node-negative, and 11 tonsil node-positive) 
who had undergone curative-intent intensity modulated radiation therapy for head and 
neck squamous cell carcinoma from January 2006 to August 2010 at The University 
of Texas MD Anderson Cancer Center were selected from an institutional review 
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board approved protocol. All patients had available simulation CT scans with 
previously manually contoured GTVs (primary and nodal, as applicable) and high-risk 
CTVs used for treatment planning. Each CT image included the head and neck region 
and had matrix sizes of 512 × 512 × number of slices (median 152, range: 47-348). 
The voxel size was 0.976 mm × 0.976 mm × 2.5 to 3.0 mm. The contours delineated 
on these images were used in the present study.  
Stacked Auto-Encoders 
We chose to use stacked auto-encoders owing to their ability to speed up 
training and provide improvement in predictions by initializing weights through 
unsupervised learning [9]. During unsupervised learning, only the input data are 
provided, and the auto-encoders learn a general representation of the data set. 
Hidden layer neurons were activated using the logistic function. After this 
unsupervised learning step, we trained the output layer through supervised learning 
and used cross-validation to fine-tune the network architecture. During the supervised 
learning step, our algorithm fine-tuned the architecture by updating the network’s 
weights to match the training set’s inputs to the training set’s known output. Our auto -
encoders are composed of 2 hidden layers, followed by a soft-max layer for binary 
classification. An illustration of the network’s architecture is provided in Figure 17. 
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Figure 17. Auto-encoder architecture used in high-risk CTV auto-delineation 
Final neural network architecture. The input layer has 36 nodes which provides distance vector information for 12 
anatomical structures (GTV and normal structures) for a single voxel. The distance vector includes the following three 
metrics for each anatomical structure: radial distance, phi angle (provides information in the cranio-caudal direction), and 
theta angle (provides information in the superior-inferior and medial-lateral directions). These metrics are calculated from 
the input voxel to the closest voxel of the anatomical structure prior to training the models. The second and third layers 
are composed of auto-encoders with 50 and 25 neurons, respectively. The auto-encoder weights are initialized through 
unsupervised learning. These layers are then followed by a softmax layer which uses the 25 features from the third layer 
to classify each voxel (part of CTV, or not part of the CTV) in a supervised fashion using labels from the training dataset. 
The output layer contains the probabilities for each predicted class for each voxel.
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To provide an improvement in generalization, we implemented L2-norm and 
sparsity (Kullback-Leibler divergence) regularization [77] into the mean squared error 
cost function (Eq. 5.1) used during unsupervised training; the cross-entropy cost 
function (Eq. 5.2) was used during supervised training and fine-tuning: 
𝐸 =⁡
1
𝑁
∑ ∑ (𝑥𝑘𝑛− 𝑥𝑘𝑛)
2𝐾
𝑘=1
𝑁
𝑛=1 + ⁡𝜆 ∗ Ω𝑤𝑒𝑖𝑔ℎ𝑡𝑠+ 𝛽 ∗ Ω𝑠𝑝𝑎𝑟𝑠𝑖𝑡𝑦   (5.1) 
⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡𝐸 =⁡
1
𝑁
∑ ∑ 𝑡𝑛𝑘 𝑙𝑛 𝑦𝑛𝑘 + (1 − 𝑡𝑛𝑘) 𝑙𝑛(1 − 𝑦𝑛𝑘)
𝐾
𝑘=1
𝑁
𝑛=1    (5.2) 
where λ is the coefficient for the L2-norm regularization term, β is the coefficient for 
the sparsity regularization term, tnk is the nkth entry of the target matrix and ynk is the 
nkth output from the auto-encoder when the input vector is xn. Finally, scaled 
conjugate gradient optimization [68] was selected for training owing to the greater 
convergence speed and classification performance [78, 85]. 
Model Features and Outcome 
The patients’ GTV (primary and nodal for node-positive patients), high-risk 
CTV, and anatomic structures (mandible, skull, vertebral body, pharyngeal and 
nasopharyngeal air cavities, left and right parotid glands, maxillary arch, hyoid, thyroid 
cartilage, and skin) were manually contoured in the Pinnacle treatment planning 
system (Phillips Medical Systems, Amsterdam, Netherlands). The high-risk CTVs and 
GTVs had been previously contoured for the purpose of planning the patients’ 
radiation therapy and underwent rigorous peer-review by a group of sub-specialized 
head and neck radiation oncologists [17]; the selected anatomic structures were 
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contoured specifically for the present study. All the volumes were converted to 3-
dimensional (3D) binary masks using MATLAB R2016b (MathWorks, Natick, MA). 
Three dimensional distance maps were calculated from the GTV and 
anatomical structure’s binary masks as follows: for each voxel, v(x,y,z), in the CT 
image space, minimum Euclidian distance vectors (r, θ, φ) were calculated for each 
structure (GTVs and anatomical structures) so that for each v(x,y,z) we would have 
12 distance vectors, V(r, θ, φ), 13 if node-positive, and 36 (or 39) distance input 
features. Distance vectors are illustrated in Figure 18. Signed distances were used to 
differentiate voxels that were located inside the contoured volume. In addition to these 
features, we extracted each voxel’s corresponding class (0 or 1) based on the high -
risk CTV mask providing the following relationship (Eq. 5.3): 
𝐶𝑇𝑉(𝑥, 𝑦, 𝑧)⁡~⁡𝑣𝐺𝑇𝑉(𝑥, 𝑦, 𝑧) + 𝑣𝑀𝑎𝑛𝑑𝑖𝑏𝑙𝑒(𝑥,𝑦, 𝑧) +⁡⋯ +⁡𝑣𝑆𝑘𝑖𝑛(𝑥,𝑦, 𝑧)      (5.3) 
To reduce the computational time, we only included voxels within 5 cm of the 
GTV for training and predicting for new patients. This was a conservative value 
because all high-risk CTVs used in the present study were within 3.5 cm of the GTV. 
Once the models were trained and used to predict on a test patient, the output from 
the test patient was a patient-specific probability map of the high-risk CTV. Our 
preliminary work [16] showed that training models by grouping patients per site and 
nodal status improved the overall prediction performance; thus, this approach was 
implemented in the present study. 
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Figure 18. Illustration of distance vectors to anatomical structures used in the 
auto-delineation of high-risk CTVs 
The left panel (a) shows a subset of the minimum Euclidian distance vectors 
calculated from the voxel in question, v(x,y,z), to the surrounding normal tissues and 
GTV. The voxel v(x,y,z) is shown as the black square at the foot of the 4 vectors and 
VM is the vector to the mandible, VGTV is the vector to the tumor, VRP is the vector to 
the right parotids, and VVB is the vector to the vertebral body contours. A closer look 
at the inputs for the model are shown on the right panel (b). On this figure, we illustrate 
how r, θ, φ are calculated for VRP(r, θ, φ): “r” is the magnitude of the distance vector, 
“θ” is the angle in the x-y plane, and “φ” is the z-plane angle (z to x-y plane).   
a) 
b) 
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Post-Processing and Probability Threshold Selection 
Once the probability map for a patient was created, we used a 3D Gaussian 
filter (σ = 1) to obtain a smooth probability map. Although most machine learning 
algorithms use a threshold of 0.5 to convert probabilities into binary classes, we chose 
to optimize this probability threshold selection by including a Dice similarity coefficient 
(DSC) [27] probability threshold selection function during cross-validation in model 
training. This provided a more useful metric than the area under the curve and 
classification error owing to the imbalance in classes. In addition, we evaluated the 
performance of the DSC loss function compared with that of distance metrics such as 
the mean surface distance (MSD) and the 95th percentile Hausdorff distance (95HD) 
between the predicted and ground-truth volumes. These metrics were evaluated by 
converting the probability maps into binary volumes by increasing the probabilities 
from 0 to 1 in 0.005 steps. Three-dimensional and 2-dimensional closing and opening 
algorithms were used on the binary images for additional post-processing before 
evaluation. To prevent overfitting our models set, we evaluated the models’ predictive 
accuracy, based on DSC, for different training epochs. An epoch is a complete pass 
through a given data set, meaning that at the end of each epoch, all patient data in 
the trained model were seen at least once by the neural network. 
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Evaluation 
Three-dimensional volume metrics were used to assess the performance of the 
predicted volumes. In addition to calculating the DSC, MSD, and 95HD between the 
predicted volumes and the manually contoured high-risk CTVs, we calculated the 
difference between the volumes, false-negative Dice (FND), false-positive Dice (FPD) 
[3], and the normalized volumetric difference (VD). The FND and FPD can be used as 
surrogates for potential near misses and overtreatment, respectively. 
𝐷𝑆𝐶 =
2∗𝑇𝑃
2∗𝑇𝑃+𝐹𝑁+𝐹𝑃
                    (5.4) 
𝑀𝑆𝐷 =
1
2
⁡(𝑑̅𝐷𝑁𝑁,𝐺 + 𝑑̅𝐺,𝐷𝑁𝑁)              (5.5) 
95𝐻𝐷 = ⁡𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒(𝑑𝐷𝑁𝑁,𝐺 ∪𝑑𝐺,𝐷𝑁𝑁, 95
𝑡ℎ)     (5.6) 
𝐹𝑁𝐷 =
2∗𝐹𝑁
2∗𝑇𝑃+𝐹𝑁+𝐹𝑃
                     (5.7) 
𝐹𝑃𝐷 =
2∗𝐹𝑃
2∗𝑇𝑃+𝐹𝑁+𝐹𝑃
                     (5.8) 
                                         𝑉𝐷 =
𝑉𝐷𝑁𝑁−𝑉𝐺
𝑉𝐺
                               (5.9) 
where TP, FN, and FP stand for true positive, false negative, and false positive, 
respectively; DNN and G stand for the auto-delineated and ground-truth (manual) 
contours; and dDNN,G  is a vector containing all minimum Euclidian distances from each 
surface voxel on volume DNN to volume G. In addition, we compared the CTVs 
generated using uniform margin expansions to our ground-truth CTVs using these 
same metrics. A uniform expansion of 0.5 cm from the GTV was selected, because it 
was systematically used by the Danish Head and Neck Cancer group [43]. Finally, we 
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evaluated the differences in planning target volumes (PTVs) when adding a 0.3-cm 
margin to the ground-truth (PTV), DNN, and uniform margin CTVs. 
Cross-Validation 
During model training, we used nested leave-one-out cross-validation 
(LOOCV) for parameter-tuning using a grid search approach. The parameters 
optimized during the grid search were the number of layers, number of nodes per 
layer, L2 weight regularization value at each layer, sparsity regularization value at 
each layer, and sparsity proportion at each layer. In our nested LOOCV method 
(Figure 19), all voxels from the test patient were excluded from training and were not 
used to predict a volume until the parameters had been optimized through an internal 
cross-validation loop. In this internal LOOCV loop, models were trained, leaving out 
all voxels for the cross-validation patient. Every time a model was trained in the 
internal LOOCV loop, the model was used to predict the high-risk CTV of the cross-
validation patient, and their prediction performance was used to determine the optimal 
parameter selection. 
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Figure 19. Block diagram for leave-one-out cross-validation scheme 
In the inner loop, model parameters were selected by maximizing the score function 
using Dice similarity coefficient (DSC) curves for all patients in the inner loop. The 
probability threshold value identified for the corresponding model parameters was 
used after training the final model to convert the predicted probability map into a binary 
structure on a test patient (outer loop). This final volume was then evaluated using 
overlap and distance metrics to compare it to the physician manually delineated high-
risk clinical target volumes. (max: maximum; std: standard deviation) 
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Results 
Using an Intel Xeon central processing unit (2.8 GHz 10 cores) and a Tesla 
K40 graphic processing unit, training required on average 2.51 ± 0.85 hours per 
patient, and the predicted high-risk CTVs were created within a mean time of 2.75 ± 
0.62 seconds. Although the predictions were almost instantaneous, calculating the 
distance maps for each patient before predicting the new volumes required on 
average 9.0 ± 3.3 minutes. The volume statistics for the manually contoured GTVs 
and high-risk CTVs, DNN CTV, uniform CTV, and their respective PTVs are listed in 
Table 12, and their respective distributions are shown in Figure 20. The mean volume 
difference between the DNN and ground-truth CTV was 1.0 ± 29.5 cm3 (range: 73.3 
to 63.9). The corresponding difference between the uniform and ground-truth CTV 
was 47.7 ± 30.5 cm3 (range: 2.3-126.6). All CTVs generated with uniform margins 
were smaller than the ground-truth CTVs, and 50% of DNN-predicted volumes were 
smaller than their corresponding ground-truth volumes. When comparing volume 
overlap between the ground-truth PTV and PTV DNN, we found a mean DSC of 0.81 
± 0.05 (range: 0.67-0.90). The DSC values between the ground-truth PTV and PTV-
uniform margin were significantly reduced (P < .0001, Wilcoxon rank-sum test), with 
a mean of 0.73 ± 0.10 (range: 0.35-0.87).  
93 
 
 
 
 
 
  
Table 12. Volume (in cm3) statistics for manually contoured GTVs and high-
risk CTVs (CTV1), predicted CTV1s (CTV1-DNN), uniform expansion CTV1 
(CTV1- Uniform), and their corresponding planning target volumes (PTV1) 
 Min Median Max Mean Standard Deviation 
GTV 1.0 22.4 103.9 26.8 20.7 
CTV1 14.3 101.2 255.2 102.9 58.7 
CTV1-DNN 16.1 88.6 273.8 101.1 55.6 
CTV1-Uniform 5.3 56.7 195.9 62.4 39.2 
PTV1 24.2 147.0 389.5 151.1 80.5 
PTV1-DNN 29.4 127.1 423.3 145.3 77.7 
PTV1-Uniform 11.3 87.3 267.4 93.9 53.4 
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Figure 20. Volume distributions of the gross tumor volume (GTV), ground-truth 
CTV (CTV1), DNN predicted CTV (CTV-DNN), and the uniform margin expansion 
CTV (CTV-Uni) volumes 
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When comparing the DSC threshold selection function to the distance metric 
performance (Figure 21), both functions produced similar results for the training, 
cross-validation, and test sets when choosing the maximum DSC and minimum MSD 
and 95HD scores for probability threshold selection. Because calculation of the DSC 
requires minimum computational resources, we opted to use this metric for probability 
threshold selection moving forward. 
Evaluation of the epochs used for training showed an initial increase in 
performance that was followed by a decrease in performance on the cross-validation 
and test sets when using 500 epochs. This decrease in performance was not observed 
in the training set, hinting that the models began overfitting approximately between 
250 and 500 epochs (Figure 22).  
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Figure 21. Comparison of DSC and distance metrics for probability threshold 
selection for training, cross-validation and test sets.  
Mean DSC (plus standard error for each probability) is shown on blue, mean 95HD and MSD 
are in red and yellow, respectively. Note: DSC is displayed as DSC x 10 for improved visual 
comparison. 
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Figure 22. Epoch analysis results for training, cross-validation and test sets.  
Epochs used were 15 (blue), 50 (orange), 150 (yellow), 250 (purple), and 500 (green).  Error 
bars provide standard error from the mean DSC value at each probability threshold.  
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A comprehensive evaluation between the DNN auto-delineated volumes and 
physician manual contours is provided Table 13 and Figure 23. The predicted volumes 
for 4 patients are illustrated in Figure 24. The predicted delineations showed good 
agreement between these volumes and the physician manual contours. For the 52 
patients, the median DSC was 0.814 (range 0.622-0.904), median MSD was 2.75 mm 
(range 1.57-5.47), and median 95HD was 7.49 mm (range 4.74-17.85). Overall, the 
auto-delineated volumes were slightly larger on average (mean normalized volume 
difference of 0.034 ± 0.265), with a median FPD of 0.199 (range: 0.004-0.652) and 
median FND of 0.151 (range: 0.010-0.623). Evaluation of the ground-truth volumes 
showed large variability in the GTV-to-CTV expansions in the cranio-caudal direction, 
with a mean expansion of 10.7 ± 5.1 mm (range: 3.0-26.6) in the cranial direction and 
9.7 ± 6.2 mm (range: 0.0-30.0) in the caudal direction. The variability measured in the 
cranio-caudal expansion of the ground-truth CTVs affected the accuracy of the DNN 
predicted volumes in these directions showing high FND (under-treatment) and FPD 
(over-treatment) values for some patients. 
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Table 13. Volumetric comparison between predicted and physician high-risk CTV contours 
Patient Site DSC FPD FND MSD 95HD VD VolGTV (cm3) VolG (cm3) VolDNN (cm3) Threshold 
1 To_N0 0.622 0.652 0.104 3.6 10.0 0.755 1.4 14.3 25.0 0.420 
2 To_N0 0.848 0.123 0.180 2.0 4.9 -0.055 20.4 58.4 55.2 0.510 
3 To_N0 0.692 0.112 0.504 4.1 11.8 -0.328 20.2 101.1 68.0 0.440 
4 To_N0 0.865 0.141 0.129 2.1 6.1 0.013 29.0 80.0 81.0 0.450 
5 To_N0 0.831 0.110 0.228 2.6 9.1 -0.111 43.4 127.2 113.0 0.590 
6 To_N0 0.749 0.492 0.010 2.9 7.3 0.635 9.7 33.7 55.2 0.410 
7 To_N0 0.814 0.241 0.130 2.4 5.0 0.118 12.0 42.6 47.6 0.435 
8 To_N0 0.747 0.137 0.369 2.5 5.5 -0.208 6.2 27.9 22.1 0.405 
9 To_N0 0.752 0.443 0.053 3.8 10.0 0.484 17.3 52.2 77.5 0.450 
10 To_N0 0.853 0.176 0.118 1.7 5.0 0.060 5.5 37.1 39.3 0.465 
11 To_N0 0.835 0.172 0.157 2.5 7.0 0.015 24.8 101.5 103.0 0.395 
12 To_N0 0.701 0.068 0.531 5.5 17.9 -0.376 13.5 116.3 72.6 0.455 
13 To_N0 0.887 0.074 0.151 1.6 4.8 -0.073 22.3 86.1 79.8 0.410 
14 To_N0 0.838 0.183 0.141 1.9 4.8 0.043 2.7 32.5 33.9 0.475 
15 To_N0 0.786 0.147 0.280 2.7 7.5 -0.125 6.6 48.5 42.5 0.475 
16 To_N+ 0.784 0.213 0.219 3.3 10.1 -0.006 11.9 80.6 80.1 0.405 
17 To_N+ 0.803 0.112 0.282 3.6 11.0 -0.157 37.1 174.5 147.1 0.360 
18 To_N+ 0.799 0.144 0.259 4.1 10.0 -0.108 53.8 245.4 218.9 0.395 
19 To_N+ 0.826 0.210 0.139 3.0 7.8 0.073 78.5 255.2 273.8 0.335 
20 To_N+ 0.814 0.104 0.269 2.6 6.5 -0.152 15.6 101.2 85.8 0.455 
21 To_N+ 0.850 0.145 0.154 2.2 6.2 -0.010 33.4 127.8 126.5 0.345 
22 To_N+ 0.769 0.204 0.258 3.0 7.5 -0.052 11.5 78.5 74.4 0.455 
23 To_N+ 0.837 0.226 0.101 2.0 5.5 0.133 24.1 113.5 128.7 0.390 
24 To_N+ 0.803 0.370 0.025 3.1 8.2 0.417 36.7 136.9 194.0 0.420 
25 To_N+ 0.790 0.056 0.364 4.0 11.3 -0.267 103.9 244.9 179.5 0.345 
26 To_N+ 0.904 0.129 0.064 1.6 4.8 0.068 37.5 101.4 108.2 0.530 
27 BOT_N0 0.742 0.465 0.050 2.8 7.6 0.523 12.1 37.4 57.0 0.455 
28 BOT_N0 0.664 0.549 0.123 3.9 8.8 0.540 10.3 35.7 55.0 0.725 
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29 BOT_N0 0.834 0.192 0.140 2.2 5.7 0.054 22.1 61.5 64.8 0.560 
30 BOT_N0 0.843 0.213 0.101 1.9 5.0 0.119 18.0 54.6 61.0 0.620 
31 BOT_N0 0.812 0.047 0.330 3.2 9.8 -0.248 37.1 120.9 90.9 0.555 
32 BOT_N0 0.689 0.019 0.604 5.2 14.4 -0.452 21.3 89.5 49.0 0.400 
33 BOT_N0 0.771 0.308 0.150 4.4 13.0 0.171 29.1 106.1 124.3 0.500 
34 BOT_N0 0.764 0.020 0.452 4.0 9.0 -0.356 53.1 143.4 92.4 0.465 
35 BOT_N0 0.740 0.378 0.142 4.0 9.1 0.269 10.7 68.1 86.4 0.620 
36 BOT_N0 0.687 0.004 0.623 3.4 7.0 -0.472 1.0 30.5 16.1 0.550 
37 BOT_N0 0.756 0.375 0.113 3.2 7.6 0.301 6.6 27.0 35.2 0.445 
38 BOT_N+ 0.838 0.212 0.112 1.9 4.7 0.106 6.5 59.9 66.2 0.445 
39 BOT_N+ 0.887 0.057 0.169 1.7 4.8 -0.106 32.7 144.8 129.4 0.520 
40 BOT_N+ 0.803 0.338 0.056 3.1 7.5 0.328 33.3 110.7 147.0 0.390 
41 BOT_N+ 0.886 0.106 0.122 1.9 5.0 -0.015 22.4 131.1 129.1 0.535 
42 BOT_N+ 0.851 0.055 0.242 2.7 7.7 -0.171 43.7 208.5 172.9 0.485 
43 BOT_N+ 0.836 0.143 0.184 2.9 9.5 -0.040 33.5 147.4 141.6 0.505 
44 BOT_N+ 0.866 0.179 0.090 2.5 6.4 0.093 65.6 192.5 210.4 0.500 
45 BOT_N+ 0.827 0.115 0.231 2.5 7.5 -0.110 19.0 102.3 91.1 0.475 
46 BOT_N+ 0.850 0.200 0.100 2.7 7.5 0.105 30.2 143.5 158.7 0.425 
47 BOT_N+ 0.799 0.141 0.262 2.9 7.3 -0.114 22.4 108.9 96.5 0.430 
48 BOT_N+ 0.852 0.264 0.033 2.1 5.8 0.261 27.5 99.0 124.8 0.495 
49 BOT_N+ 0.781 0.193 0.244 3.1 6.6 -0.050 8.7 78.7 74.8 0.495 
50 BOT_N+ 0.876 0.136 0.112 2.2 5.8 0.024 66.4 181.3 185.7 0.360 
51 BOT_N+ 0.828 0.149 0.195 3.0 8.0 -0.045 56.2 151.8 144.9 0.415 
52 BOT_N+ 0.826 0.289 0.059 2.7 6.4 0.260 25.7 94.3 118.8 0.380 
 
BOT_N0,N+ = base of tongue node negative, positive; To_N0,N+ = tonsil node negative, positive; DSC = Dice Similarity 
Coefficient; FND = False Negative Dice; FPD = False Positive Dice; MSD = Mean Surface Distance (mm); 95HD = 95th 
percentile Hausdorff Distance (mm); VD = normalized volume difference; VolGTV = GTV volume (cm3); VolG = Ground-truth 
volume (cm3); VolDNN = DNN predicted volume (cm3); Threshold = Selected threshold value through DSC function.  
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Figure 23. Volumetric comparison between the auto-delineated and manually 
contoured high-risk CTVs. 
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Figure 24. Comparison between predicted and physician ground-truth high-risk 
CTVs for four oropharyngeal cancer patients 
The predicted volume is shown in blue and the ground-truth is contoured in red. The 
primary and nodal gross tumor volume is also included (green). From left to right, we 
illustrate a case from each site and nodal status (base of tongue node-negative, tonsil 
node-negative, base of tongue node-positive, and tonsil node-positive). 
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The inter-disease site and nodal group comparison is presented in Figure 25. 
The predicted volumes from patients with nodal disease showed slightly greater 
overlap agreement, in terms of DSC, to the ground truth than did those without nodal 
disease (median DSC 0.83 vs 0.77). However, this difference was not statistically 
significant (P = 0.25, Wilcoxon rank-sum test). In addition, the DSC values for the 
nodal volumes showed less variability (Table 14). 
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Table 14. Volumetric comparison between predicted and ground-truth high-
risk CTVs per tumor site and nodal involvement 
  
DSC FPD FND 
MSD 
(mm) 
95 HD 
(mm)   
T
o
_
N
0
 
Minimum 0.622 0.068 0.010 1.6 4.8 
Median 0.814 0.147 0.151 2.5 7.0 
Maximum 0.887 0.652 0.531 5.5 17.9 
Mean 0.788 0.218 0.206 2.8 7.8 
Standard Deviation 0.076 0.172 0.153 1.1 3.6 
T
o
_
N
+
 
Minimum 0.769 0.056 0.025 1.6 4.8 
Median 0.803 0.145 0.219 3.0 7.8 
Maximum 0.904 0.370 0.364 4.1 11.3 
Mean 0.816 0.174 0.194 3.0 8.1 
Standard Deviation 0.037 0.084 0.105 0.8 2.2 
B
O
T
_
N
0
 Minimum 0.664 0.004 0.050 1.9 5.0 
Median 0.756 0.213 0.142 3.4 8.8 
Maximum 0.843 0.549 0.623 5.2 14.4 
Mean 0.755 0.234 0.257 3.5 8.8 
Standard Deviation 0.059 0.195 0.210 1.0 2.8 
B
O
T
_
N
+
 
Minimum 0.781 0.055 0.033 1.7 4.7 
Median 0.838 0.149 0.122 2.7 6.6 
Maximum 0.887 0.338 0.262 3.1 9.5 
Mean 0.840 0.172 0.147 2.5 6.7 
Standard Deviation 0.031 0.080 0.076 0.5 1.3 
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Figure 25. Volumetric comparison between predicted and manual volumes per 
disease site and nodal status. 
The top panel illustrates the overlap metrics (DSC, FND, and FPD) between the four 
disease site and nodal status groups (BOT_N+: base of tongue node-positive, 
BOT_N0: base of tongue node-negative, To_N+: tonsil node-positive, To_N0: tonsil 
node-negative). The bottom panel provides a comparison between the four disease 
site and nodal status groups based on the distance metrics. 
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Discussion 
 The use of deep learning in medical image segmentation has become more 
popular over the past few years. Most efforts have focused on auto-segmenting 
normal tissues, with very little work performed to automate the delineation of CTVs. In 
our approach, we used distance maps from normal structures and GTVs to learn the 
physician patterns in auto-delineating high-risk CTVs. This approach was chosen 
owing to the lack of visible anatomic edges on CT imaging and the high variability in 
GTV location and size. In addition, because our algorithm uses the binary contours to 
compute the inputs for our model, the normal tissue and GTV contours created using 
any modality (i.e. magnetic resonance imaging) could be used to generate automated 
high-risk CTVs. Furthermore, this approach could be used to train physician- or 
institution-specific models to automate this process and retaining the patterns used 
for the desired clinical practice. This remains to be evaluated as it was outside the 
scope of the present study. 
 Our deep learning approach was able to auto-delineate high-risk CTVs with 
DSC values (mean DSC 0.81) comparable to those observed for normal tissue auto-
segmentation techniques [66]. McCarroll et al showed that after clinically 
implementing a normal tissue auto-segmentation tool, the average DSC between the 
auto-contours and physician-edited volumes was 0.78 for 8 head and neck normal 
structures. The mean DSC value of the auto-delineated high-risk CTVs is higher than 
the mean DSC value found in the pair-wise analysis in Chapter 4 (mean DSC = 0.72).     
Overall, our DSC values ranged from 0.62 to 0.90, and the median MSD was 2.75 
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mm. These results are comparable to those reported by inter- and intra-observational 
studies for manual delineation of these volumes [2, 12]. When using uniform margin 
expansions, we found that all auto-generated CTVs were smaller in volume than the 
ground-truth volumes and that mean difference in volumes between the DNN auto-
delineated and ground-truth CTVs was 1.0 ± 29.5 cm3. The variability in the cranio-
caudal extent of the GTV-to-CTV margin expansion made it difficult to assess the 
occurrence of under- and overtreatment. On physician review of all cases with FND 
and FPD values > 0.450, the cranio-caudal extent of the DNN-predicted volumes was 
considered acceptable. The dosimetric effects of using auto-delineated CTVs is 
difficult to assess without clinical outcomes data. Owing to the high overlap between 
the predicted and ground-truth volumes, we would expect minimal changes to the 
normal tissue doses. In a preliminary study [16], 5 radiation oncologists visually 
inspected a subset of the DNN-predicted volumes as a part of a blinded study. They 
found that 85% of the auto-delineated and 93% of the ground-truth volumes would be 
acceptable for clinical use with only minor changes. Very little work has been 
performed to auto-delineate high-dose CTVs. Belshi et al [8] proposed automating 
these volumes using a 3D uniform margin expansion from manually contoured GTVs 
for conformal radiation therapy. However, the introduction of intensity modulated 
radiation therapy allowed for more complex, conformal, and patient-specific radiation 
plans, which required more accurate target definition to ensure the tumor is not 
undertreated and to limit the dose to the surrounding normal tissues. Chao et al [19] 
showed that using a 1-cm uniform margin expansion from the GTV reduced observer 
variability when auto-delineating high-risk CTVs for 2 head and neck patients. 
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However, their study did not provide an overlap comparison of these volumes to the 
ground-truth volume (volume used for treatment); thus, the ability of a 1-cm uniform 
margin to reproduce the physicians’ goal was unclear. Hong et al [46] conducted a 
survey to investigate differences in CTV delineation among experienced head and 
neck radiation oncologists and found significant heterogeneity between physician 
contours and clinical practice. They found that high-risk CTVs had a large standard 
deviation (43 cm3). In our analysis, we found that the mean volume difference between 
the predicted and ground-truth volumes was 1.0 cm3, just a small fraction of the 
variability found in the study by Hong et al [46], showing that volume variability can be 
reduced through auto-delineation. Finally, their study showed that although published 
guidelines are available to standardize head and neck target volume delineation, 
significant variations between experienced physician contours still exist and 
standardization of this process is urgently needed. A more recent study by Blinde et 
al [12] showed in abstract form that they observed a large variability when delineating 
high-risk CTVs in a group of >20 radiation oncologists. In their preliminary results, they 
observed volume differences of up to a factor of 8. The lack of standardization in CTV 
delineation can be problematic for many reasons. The heterogeneity in target design 
and clinical practice increases the variation in clinical information. Reducing this 
through standardized target volumes could help produce better quality clinical data. 
Our results are promising because our approach can be implemented in multiple 
institutions to improve standardization of radiation therapy, which could, in turn, 
reduce uncertainties in radiation therapy clinical trials.  
109 
 
 An inherent product of the auto-delineation of CTVs is the reduction of 
physician contouring time. This benefit is increased when planning treatment of head 
and neck tumors because data have suggested that target delineation in this region 
is comparatively difficult to contour and results in greater inter-observer variability than 
other anatomic sites [75]. Hong et al [46] reported that the head and neck CTV 
average contouring time was 102.5 minutes (range: 60-210 minutes). Although it is 
unknown how much time was required to delineate the high-risk CTV alone, it is clear 
that any reduction in contouring time could benefit the treatment planning workflow. 
The model we have presented produces high-risk CTVs with a mean time requirement 
of 10 minutes, with almost 99% of computational time devoted to preparing the inputs 
before volume prediction. This computationally expensive process could be improved 
by optimizing the currently used algorithm to compute the inputs using graphic 
processing units in which voxel-based distance measurements could be calculated in 
a parallel fashion. 
 It has been shown that the quality of the radiation therapy plan greatly depends 
on delineation accuracy and physician experience [13, 80, 96]. Our institution’s head 
and neck service treats ~400 patients annually, and every patient treated undergoes 
our head and neck planning and development clinic in which the attending physician’s 
CTV contours are peer-reviewed by the head and neck group [17]. It is our belief that 
this peer-review process aids in the reduction of inter-observer variability and provides 
high-quality contours for deep learning approaches. Thus, the use of automatically 
delineated CTVs could help physicians bridge this gap in quality assurance when peer 
review is not available. A CTV auto-delineation tool could be used to provide 
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physicians with contours before the peer-review sessions at which the radiation 
oncologists would assess the contours’ coverage and make any edits, if necessary, 
before approval of the target volumes. 
 Our approach had a few limitations. First, it relied on manual delineation of 
normal structures and the GTV for which some inter-observer variability has been 
reported. Furthermore, image quality and dental artifacts could affect the accuracy of 
these segmentations; however, because the manual segmentations used in the 
present study were reviewed by > 2 physicians, we believe this peer-review process 
will provide better quality normal tissue and target volume segmentations. The time-
consuming task of manually delineating the structures used in the present study could 
be overcome by implementing auto-segmentation of these volumes by way of atlas-
based segmentation and positron emission tomography-based segmentation of 
normal structures and the GTV, respectively. This could aid in the reduction of inter -
observer variability. Second, our patient set had high variability in disease 
presentation. This variability was reduced by training auto-delineation models using 
patient data according to disease site and nodal status. However, even for patients 
within each disease site and nodal status group, secondary sites of disease (e.g. tonsil 
tumor invading the soft palate) could translate into poor predictive performance. Using 
a larger number of patients and clustering these according to disease extent could 
improve pattern recognition in physician delineation patterns; however, this remains 
to be investigated. Finally, all volumes used for training our models were collected 
from a single institution, and these might not represent the clinical practice at other 
institutions. 
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Conclusions 
By implementing a DSC-based threshold selection function, our DNN auto-
delineation algorithm accurately identified physician patterns to predict clinically 
acceptable high-risk CTV contours. Our models allowed for the prediction of new 
volumes within a few minutes and have the potential to greatly reduce physician 
contouring time. Most of the predicted high-risk CTVs were in close agreement with 
the physician manual contours and could be implemented clinically with only minor or 
no changes. 
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Chapter 6: Auto-Delineating Low-Risk Clinical 
Target Volumes 
Introduction 
Clinical target volumes (CTVs) are essential volumes of interest used in 
radiation therapy treatment planning. These volumes provide coverage to the 
observable gross tumor volume (GTV) as well as any suspected microscopic disease 
and pathways of tumor spread such as regional lymph nodes[49]. The task of 
delineating head-and-neck CTVs is unique in that radiation oncologists manually 
contour several target volumes throughout the head-and-neck region to prescribe 
volume-dependent doses based on the risk of disease recurrence. Several reports 
show that this process can be time consuming and subject to high inter- and intra-
observer variability [46, 75]. There are two main sources for this inter-observer 
variability: interpretation of the disease which influences what is treated and the 
treatment design which influences how volumes are delineated. The inherent 
variability in CTV delineation is quite problematic since patient outcomes depend 
heavily on accurate segmentation of target volumes. In addition, this variability hinders 
the ability to methodologically assess the quality of radiation therapy treatment plans 
and is considered a large source of uncertainty [44]. Therefore, there is a need for an 
accurate and consistent tool to automatically segment these volumes.  
 The majority of published works researching the auto-segmentation of clinical 
target volumes in the head-and-neck have been focused on auto-segmenting low-risk 
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lymph node regions using atlas-based approaches[42, 88, 97]. Atlas-based auto-
segmentation techniques are limited due to large inter-subject anatomical variations 
which typically don’t generalize well because of the small number of subjects included 
in the contouring atlas. Taking into consideration these anatomical variations in the 
head-and-neck region, Han et al proposed the use of shape information to improve 
the registration between test and atlas subjects. Similarly, Yang et al used a two-step 
registration approach (rigid, then deformable) to auto-segment low-risk CTVs for tonsil 
cancer patients. Both of these studies reported large variability in overlap between the 
predicted segmentation and the physician manually-contoured ground-truth volumes.  
In contrast to atlas-based registration techniques, deep learning allows for the 
use of larger image datasets to be used for training. It is believed that the inclusion of 
more subjects allows for better model generalization and these approaches have 
quickly become state-of-the-art. In Chapter 5, we developed a deep learning 
architecture to auto-delineate high-risk CTVs for oropharyngeal patients and have 
since shown the benefits of using an auto-delineation tool in comparison to multi-
observer manual delineations [16]. However, we still lack a way to auto-segment 
clinical target volumes as a whole volume.  
 The aim of this study is to provide a tool to auto-segment clinically acceptable 
CTVs for oropharyngeal cancer patients. In Chapter 3 we showed that the clinical 
decision of determining what to cover and to what extent on per clinical target volume 
basis varies widely from patient to patient [17]; therefore, we developed our models to 
predict a single CTV which is representative of the union of all CTVs (high-risk, 
intermediate-risk, low-risk) used for treatment in our clinic. The proposed methodology 
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and subsequent results are promising, and could have great impact in reducing inter- 
and intra-observer variability when designing head-and-neck radiotherapy plans.   
Methods  
Patient Dataset 
We retrospectively evaluated over 2000 head-and-neck patients treated with 
volumetric arc radiation therapy at our institution between February 2013 and October 
2017 under an Institutional Review Board approved protocol. Patients were further 
selected who met the following criteria:  
 The primary tumor had to be located in the oropharynx (tonsil, base of tongue, 
etc.). 
 Patients had to be treated with curative intent and were receiving head-and-
neck radiotherapy for the first time (no re-treatments).  
 Radiotherapy simulation CT and final treatment plan had to be available. 
 Treatment plan must include contours for primary disease (GTVp), as well as 
a minimum of two clinical target volume levels. 
Three-hundred and twelve patients met this criteria. Since over 90% of patients 
received bilateral coverage in their radiotherapy treatment, meaning that both the left 
and right side of the head-and-neck region were intentionally targeted during 
treatment, we excluded the few patients with ipsilateral treatment designs. This left us 
with 285 patients for this study. These patients were treated by a large group (8+) of 
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head-and-neck sub-specialized radiation oncologists; each patient’s treatment plan 
and target volumes were peer-reviewed prior to start of treatment [17].  
Data Preparation 
Simulation CT image and radiation therapy structures DICOM files were 
exported for each patient. The images and physician contoured structures were 
visually inspected and the CTV levels were combined into a single structure (CTVall). 
This was particularly important since the number of CTV levels used varied between 
cases (median: 4, range: 2-6) and the coverage provided by the intermediate- and 
low-risk CTVs varied largely. In addition, we combined all physician contours 
identifying gross disease (primary and nodal) into a single structure (GTVall). Lastly, 
we used a thresholding tool in RayStation v6 (RaySearch Laboratories, Stockholm, 
Sweden) to define the patient’s body contour (External).  
The CT images, CTVall, GTVall, and External contours were converted into 3D 
matrices in Python (version 3.6.3) using the pydicom module. We then linearly 
transformed the intensity of our CT images using our clinic’s head-and-neck CT 
window [-350, 350 Hounsfield Units] to have values from 0 to 1 (i.e. -350 = 0 and 350 
= 1). The image and contour matrices were resampled to have a slice thickness of 3.0 
mm, and pixel spacing of 1.0 mm, and set a matrix size of # of slices × 512 × 512. 
Since the cranio-caudal extent of the simulation CT scan varied widely between cases, 
we manually identified two anatomical markers (Figure 26). Cranially, we identified the 
most caudal slice where the sphenoid bone is fused to the basilar part of the occipital 
bone. Caudally, we identified the most cranial slice where the sternum was observed.  
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Figure 26. Illustration of anatomical markers used to crop images in order to normalize the field of view in the auto-
delineation of low-risk CTVs. 
The left panel shows an axial CT slice illustrating the fusion of sphenoid bone and basilar part of the occipital bone (green 
box) used to determine the cranial slice (SCr). The two middle panels show coronal and sagittal views, respectively, with the 
cranial (green) and caudal (red) extents shown. Anything above and below the green and red lines, respectively, is cropped 
out and not used as inputs into the model. The right most panel shows an axial CT slice illustrating the most cranial extent 
of the sternum (red box) which was used to identify the caudal slice (SCd). 
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After visually identifying the cranial and caudal slices for each patient, the CT 
image and contour matrices were cropped to only include slices between these 
anatomical markers plus a 10 mm margin on both cranial and caudal directions. These 
markers were chosen because all patients’ low-risk CTV contours were contained in 
between these slices. After reducing the image space in the slice direction, we sought 
to remove rows and columns in our matrices that did not contain the patient’s body. 
We found that using a region of interest of size 340 x 400 centered about the center-
of-mass of the external contour provided appropriate coverage for all patients. This 
allowed for a reduction of pixels in the axial space of approximate 48%. Lastly, we 
resized all images and contour matrices from number of slices (SCr – SCd) × 340 × 400 
to 60 × 140 × 200. Finally we split our dataset into training (210 patients) and test (75 
patients) cohorts. 
Two-channel U-Net Architecture  
Ҫiҫek et all introduced the 3D variant of the U-Net architecture which offers 
many attractive features for biomedical imaging[23]. This architecture is trained end-
to-end from scratch and performs well even when limited training data is available. 
More importantly, it allows for context information from adjacent slices in an image to 
pass through the network to provide more consistent predictions on a slice-per-slice 
basis. Clinical target volume delineation is highly dependent on patient anatomy and 
tumor presentation, therefore we propose to implement a two-channel architecture for 
our segmentation task. The first channel feeds the CT image’s 3D matrix, whereas the 
second channel feeds the GTVall contour 3D matrix to provide tumor location 
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information to the network. The use of two channels make our input 60 × 140 × 200 × 
2 in size.  
Hyper-parameter Search 
Along with the standard 3D U-Net, our architecture has a down-convolutional 
and an up-convolutional path, utilizes batch normalization before each ReLU, doubles 
the number of features before each max pooling layer, and uses shortcut connections 
of equal resolution to provide high-resolution features to the up-convolutional path, but 
we choose to identify the remaining optimal parameters for our segmentation task. 
Parameter selection was determined using a grid-search approach and parameters 
investigated included the number of resolution steps, number of root features, 
convolution kernel size, dropout ratio, max pooling kernel size and stride size, and 
weighted cross-entropy values for the segmentation class.  
To search for the optimal parameters, we used 3-fold cross-validation within 
our training dataset. Predicted segmentations on the cross-validation sets were then 
scored by using a metric (Equation 6.1) based on the Dice similarity coefficient (DSC) 
(Equation 6.2), which provides a measure of the overlap between the predicted 
segmentation and ground-truth, and the False Negative Dice (FND) (Equation 6.3), 
which provides a measure of under-treatment in our segmentation task. These metrics 
are defined as: 
 𝑆𝑐𝑜𝑟𝑒(𝑦, ?̂?) ⁡ = ⁡𝐷𝑆𝐶(𝑦𝑖 , ?̂?𝑖)⁡– ⁡𝑤⁡ × ⁡𝐹𝑁𝐷(𝑦𝑖 , ?̂?𝑖)  (6.1) 
 𝐷𝑆𝐶(𝑦𝑖 , ?̂?𝑖) =
2×(?̂?𝑖∩𝑦𝑖)
|𝑦𝑖 |+|?̂?𝑖 |
   (6.2) 
 𝐹𝑁𝐷(𝑦𝑖 , ?̂?𝑖) =
2×(?̅̂?𝑖∩𝑦𝑖)
|𝑦𝑖|+|?̂?𝑖|
  (6.3) 
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where 𝑦𝑖 ∩ ?̂?𝑖 is the number of pixels where both 𝑦𝑖 , ?̂?𝑖 are equal to 1 and |𝑦𝑖|, |?̂?𝑖| is 
sum of positive pixels for each vector. For the FND, ?̂̅?𝑖 ∩ 𝑦𝑖 is the number of pixels 
were the background (?̂̅?𝑖) prediction vector and the ground-truth are equal to 1. The 
DSC has values from 0 to 1, where a value of 1 means that there is perfect overlap 
between the two volumes. The FND has values from 0 to 2, where a value of 0 means 
that the predicted volume fully overlapped the ground-truth. We chose to include FND 
in determining the best model parameters since most radiation oncologists would 
often prefer to over-contour (over-treat) than to miss any microscopic disease. A 
weight factor, 𝑤, with a value of 1.5 for this task, was used to penalize models with 
large under-segmented regions. The model parameters with the highest mean Score 
value in the cross-validation sets was chosen to train our final model. Based on this 
optimal architecture, we trained these parameters using a cost value of 1, 2, and 5 
resulting in three volumes, CTVTight, CTVModerate, and CTVWide, respectively.  
Training 
Rotational, shear, and translational shift transformations were applied during 
training. Our training batch size was 1 patient’s down-sampled CT scan and data 
augmentation was performed on-the-fly on each iteration. We used the weighted 
cross-entropy loss to compare the network output with the ground-truth. Our initial 
learning rate was 5×10-3 and was decayed using a linear step every other epoch. The 
architecture was developed and trained using TensorFlow on an NVIDIA Volta GPU. 
Parameter optimization models were trained for 1400 iterations (10 epochs) and took 
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approximately 4 days. The final model was trained for 50 epochs and took 
approximately 8 hours to train. 
Results 
After manually determining the cranial and caudal extent of the image, 
preparing the image set and predicting on a new patients was completed in under a 
minute for all test cases. Box plots with the cross-validation results (DSC, FND, and 
Score) observed during hyper-parameter selection can be found Figure 27. The 
optimal architecture based on our overlap Score (Equation 6.1) is shown in Figure 28. 
The test patient set’s volumes, differences in volume, True Positive Fraction, Dice 
Similarity Coefficient, False Negative Dice, False Positive Dice, Mean Surface 
Distance, and Hausdorff Distance value distributions are shown in Figures Figure 29 
- Figure 36 for the tight, moderate and wide auto-delineated CTVs. A summary of 
these distributions is provided in Tables Table 15 - Table 17. 
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Figure 27. Hyper-parameter performance assessment on low-risk clinical target volume cross-validation set 
Boxplots showing metric distributions of cross-validation cases during hyper-parameter selection. Parameters investigated 
included number of resolutions steps (2 or 3), number of root features (12, 24, or 48), convolutional kernel size (3x3x3 or 
5x5x5), drop-out ratio (0.5 or 0.75), max-pooling kernel size (2x2x2 or 3x3x3), max-pooling stride size (2 or 3), and class 
weights (1, 2, or 5) for the segmentation class. Only a subset of the models are shown in this figure.   
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Figure 28. Illustration of the final network architecture and input channels for low-risk auto-delineation. 
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Figure 29. Distribution of volumes (cc) for the ground-truth, tight, moderate and 
wide low-risk CTVs 
 
Figure 30. Distribution of differences in volumes (cc) between the auto-
delineated (tight, moderate and wide) and ground-truth low-risk CTVs 
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Figure 31. Distribution of True Positive Fraction values between the auto-
delineated (tight, moderate and wide) and ground-truth low-risk CTVs 
 
Figure 32. Distribution of Dice Similarity Coefficient values between the auto-
delineated (tight, moderate and wide) and ground-truth low-risk CTVs 
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Figure 33. Distribution of False Negative Dice values between the auto-
delineated (tight, moderate and wide) and ground-truth low-risk CTVs 
 
Figure 34. Distribution of False Positive Dice values between the auto-
delineated (tight, moderate and wide) and ground-truth low-risk CTVs 
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Figure 35. Distribution of Mean Surface Distance values between the auto-
delineated (tight, moderate and wide) and ground-truth low-risk CTVs 
 
Figure 36. Distribution of Hausdorff Distance values between the auto-
delineated (tight, moderate and wide) and ground-truth low-risk CTVs 
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Table 15. Summary of volumetric comparison between test set auto-
delineations (CTVtight) and the physician contoured ground-truth volumes 
 Truth Tight 
 Volume Volume ΔV TPF DSC FND FPD MSD HD 
Minimum 355.9 333.4 -499.1 0.548 0.683 0.022 0.041 2.2 15.1 
25th Percentile 543.0 606.3 -47.7 0.813 0.797 0.109 0.130 2.9 20.4 
Median 683.1 708.6 30.0 0.843 0.817 0.154 0.201 3.2 24.4 
75th Percentile 821.1 857.2 101.0 0.885 0.838 0.187 0.259 3.5 29.8 
Maximum 1490.4 1305.8 333.0 0.972 0.875 0.563 0.512 7.3 75.8 
Average 719.9 738.8 18.9 0.839 0.815 0.163 0.207 3.3 26.6 
Std. Deviation 241.2 190.2 134.4 0.073 0.036 0.091 0.095 0.8 9.2 
** Volumes in cm3, MSD and HD in mm 
ΔV: Volume difference (V tight – Vtruth), TPF: True Positive Fraction, DSC: Dice Similarity Coefficient , FND: False 
Negative Dice, FPD: False Positive Dice, MSD: Mean Surface Distance, HD: Hausdorff Distance 
 
Table 16. Summary of volumetric comparison between test set auto-
delineations (CTVmoderate) and the physician contoured ground-truth volumes 
 Truth Moderate 
  Volume Volume ΔV TPF DSC FND FPD MSD HD 
Minimum 355.9 354.4 -507.0 0.556 0.692 0.028 0.033 2.1 14.3 
25th Percentile 543.0 624.3 -19.9 0.822 0.799 0.097 0.153 2.8 19.7 
Median 683.1 739.0 33.3 0.860 0.817 0.137 0.210 3.2 24.0 
75th Percentile 821.1 890.6 119.1 0.895 0.842 0.178 0.282 3.5 30.5 
Maximum 1490.4 1346.3 300.0 0.966 0.883 0.552 0.510 7.3 76.7 
Average 719.9 761.5 41.6 0.852 0.816 0.148 0.220 3.3 26.6 
Std. Deviation 241.2 199.6 130.5 0.068 0.037 0.084 0.096 0.8 10.0 
** Volumes in cm3, MSD and HD in mm 
ΔV: Volume difference (Vmoderate – Vtruth), TPF: True Positive Fraction, DSC: Dice Similarity Coefficient , FND: 
False Negative Dice, FPD: False Positive Dice, MSD: Mean Surface Distance, HD: Hausdorff Distance 
 
Table 17. Summary of volumetric comparison between test set auto-
delineations (CTVtight) and the physician contoured ground-truth volumes 
 Truth Wide 
  Volume Volume ΔV TPF DSC FND FPD MSD HD 
Minimum 355.9 532.8 -281.5 0.663 0.611 0.003 0.084 2.8 15.7 
25th Percentile 543.0 841.9 211.5 0.931 0.744 0.027 0.311 3.6 21.7 
Median 683.1 948.9 276.5 0.954 0.781 0.040 0.391 4.2 25.9 
75th Percentile 821.1 1148.7 364.9 0.966 0.809 0.059 0.466 4.6 31.6 
Maximum 1490.4 1627.0 538.7 0.996 0.866 0.371 0.768 6.5 71.4 
Average 719.9 995.9 276.0 0.940 0.775 0.053 0.397 4.2 28.1 
Std. Deviation 241.2 223.5 134.2 0.051 0.051 0.056 0.126 0.8 9.5 
** Volumes in cm3, MSD and HD in mm 
ΔV: Volume difference (Vwide – Vtruth), TPF: True Positive Fraction, DSC: Dice Similarity Coefficient , FND: False 
Negative Dice, FPD: False Positive Dice, MSD: Mean Surface Distance, HD: Hausdorff Distance 
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The test set predictions showed good overlap agreement with the ground-truth 
volumes; the average true positive fractions were 0.839, 0.852, and 0.940 for the tight, 
moderate, and wide auto-delineations, respectively. In terms of DSC, the percent of 
cases having DSC > 0.75 were 96%, 96%, and 69% for the tight, moderate, and wide 
auto-delineations, respectively. When considering MSD, the percent of cases having 
MSD <= 3.0 mm were 37%, 36%, and 1% for the tight, moderate, and wide auto-
delineations, respectively. These percentage of patients meeting MSD <= 5.0 mm 
were 97%, 97%, and 80% for tight, moderate, and wide auto-delineations, 
respectively.  
On a case-by-case visual inspection of the predicted clinical target volumes, 
we noticed that there was greater disagreement between the neural network’s 
prediction and the ground-truth in the lower nodal region. This was expected as it is 
typical in clinical practice for physicians to treat these low-risk regions more differently 
than regions with observable (GTV) disease (Chapter 3). 
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Figure 37. Comparison between auto-delineated and physician contoured low-
risk CTVs. 
Axial (top left), sagittal (top right), and coronal (bottom left) views of a test patient’s CT 
image along with the auto-segmented CTV (light-blue) and physician ground-truth 
(yellow). The GTV contour is included (green). Volumetric overlap between the 
segmentations can be appreciated in the far right panel. 
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Discussion 
This is the first study to show that is possible to automate oropharyngeal clinical 
target volume delineation using a convolutional neural network. The two-channel 3D 
U-Net network was able to identify physician contouring patterns (Figure 37) and we 
found that the predicted segmentations had high overlap agreement with the physician 
contoured volumes. More importantly, we implemented a DSC/FND score during 
cross-validation to identify parameters that provided segmentations with the least 
missed volumes. This is important in radiation therapy since undertreating microscopic 
disease can lead to loco-regional recurrences.  
While the CTVwide volumes were able to produce the highest overlap (true 
positive fraction) between the auto-delineated and ground-truth targets, their volumes 
were generally much larger than the ground-truth and in some cases not appropriate 
for clinical use. Besides the true positive fraction and false negative Dice metrics, 
CTVtight and CTVmoderate volumes resulted in better volumetric agreement than the 
CTVwide volumes. Almost 100% of CTVtight and CTVmoderate volumes had mean surface 
distances to the ground-truth targets which were less than or equal to 5 mm.   
In a blinded survey of a small subset of these patients, we asked 2 head and 
neck expert radiation oncologists to rate the most appropriate delineation amongst the 
ground-truth and auto-delineated volumes. One physician preferred the CTVtight a 
majority of the time while the second physician preferred mostly the CTVmoderate 
volumes over the ground-truth. It remains unclear which volume is most appropriate 
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for clinical use and that this may be dependent of physician preference. The CTVwide 
volumes were ranked as “worst” in all presented cases.  
The importance of accurate CTV delineation has been a topic widely discussed 
in the head-and-neck radiation oncology community [6]. While many contouring guide-
lines exist, it remains unknown how many physicians follow these recommendations. 
Hong et al showed large heterogeneity in CTV contouring and clinical practice 
amongst head-and-neck experts when they were asked to contour an identical 
oropharyngeal case [46]. This inter-observer variability has been suggested to be the 
largest source of uncertainty in radiotherapy treatment planning. In their study, the 
ratio between the maximum and minimum volumes manually delineated on a single 
oropharyngeal case was 18.3, whereas the median ratio in maximum and minimum 
volumes (measured for each patient) in our study was 1.15 (range: 1.00 – 1.65), 1.15 
(range: 1.00 – 1.64), and 1.45 (range: 1.05 – 2.22) for the tight, moderate, and wide 
auto-delineated volumes, respectively. Similar maximum-minimum ratios (range: 1.72 
– 3.41) were reported by Peng et al [79] on manual delineations from 10 radiation 
oncologists on a single nasopharynx case.  
Several publications have shown that physician expertise and patient load are 
highly correlated with patient outcomes[13, 96], meaning that more experienced 
physicians who see a larger number of cancer cases per year tend to provide patients 
with better treatment outcomes. The ground-truth segmentations used in this study 
come from a large group of sub-specialized head-and-neck radiation oncologists and 
undergo thorough peer-review prior to treatment (Chapter 3). This QA process in our 
clinical workflow aids in reducing physician errors and possible tumor misses. 
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Furthermore, our approach could be used to QA other contouring approaches, such 
as atlas-based segmentation techniques or manual delineations, and could be used 
as a suggested starting point to help reducing variability between radiation oncologist 
clinical target volume delineations.  
Conclusion 
Using clinical target volumes previously segmented and used in our clinic to 
deliver patient treatments, the proposed two-channel 3D U-Net architecture is able to 
segment the union of clinical target volumes with high overlap (DSC > 0.75 on 96% of 
cases for tight and moderate auto-delineation models and 97% of cases having MSD 
<= 5.0 mm). A comprehensive dosimetric evaluation will be conducted in Chapter 7 to 
quantify dosimetric differences between CTVtight and CTVmoderate with respect to plans 
created based on the physician ground-truth targets.  
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Chapter 7: Dosimetric Evaluation of Radiation 
Therapy Plans Optimized on Auto-Delineated Low-
Risk Clinical Target Volumes 
Introduction 
 In medical imaging segmentation, volume overlap metrics (such as the Dice 
similarity coefficient [27] and Jaccard index [50]) and distance metrics (such as the 
mean surface distance and Hausdorff distance) are considered the standard to assess 
an algorithm’s prediction performance in comparison to physician segmentations or to 
compare variability in delineations amongst different observers [51, 90]. While these 
are very useful to assess differences between segmentations, they fail to convey how 
differences in delineations could affect the dose that the patient would actually receive.  
 As more advanced algorithms are developed to automatically segment normal 
tissues and target volumes approaching human-like performance, determining how 
these auto-segmentations influence or bring about dosimetric changes is of outmost 
importance for their use in automated treatment planning. McCarroll et al [65, 67] 
showed that when optimizing head and neck plans based on auto-segmented normal 
tissues which were used for treatment after minor edits (Hausdorff distance < 1 cm) 
only resulted in a 2.4% difference to clinically relevant dose-volume histogram (DVH) 
metrics in comparison to plans optimized using the unedited auto-segmentations. 
Similar results were found by Mitchell et al [72] when comparing heart and lung doses 
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from manually and automated contours on breast radiotherapy plans. In another 
study, Delaney et al [26] showed that “rough” contours of the salivary glands were 
sufficient to achieve clinically acceptable treatment plans and suggested that highly 
accurate normal tissue delineations may not be necessary to achieve good quality 
treatment plans for some cases.  
Contouring edits on delineated target volumes have been shown to result in 
significant changes in normal tissue and target volume doses [64, 73, 79, 92]. 
Mohamed et al [73] showed large reductions in the probability of developing dysphagia 
≥ grade 2, feeding tube persistence at 6-month post-treatment and hypothyroidism at 
1-year post-treatment when assessing the feasibility and dosimetric benefits of using 
adaptive target volumes in head and neck IMRT. While investigating the dosimetric 
consequences of using atlas-based auto-segmented head and neck node levels as 
low-risk clinical target volumes, Voet et al [92] showed that plans based on these auto-
segmented volumes resulted on an average V95 (percent of volume receiving 95% of 
the prescribed dose) reduction of 7.2% ± 5.4% when compared to the physician-edited 
planning target volume (PTV) plans. Their study concluded that even small physician 
edits to atlas-based low-risk clinical target volumes (CTVs) could result in large 
underdosing of target volumes. Similarly, Peng et al [79] showed how inter-observer 
target delineation variability affected target coverage on a single nasopharyngeal 
cancer IMRT case. When comparing target delineations between 10 physicians, they 
noticed PTV underdosage as large as 56.1% (PTV volume receiving 100% of 
prescribed dose / PTV volume) when comparing individual physician delineations and 
STAPLE PTVs.  
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In this chapter we evaluate target coverage and doses to normal tissues of 25 
head and neck cancer patients when using auto-delineated low-risk CTV predictions 
from Chapter 6. Quantifying dosimetric differences between plans optimized on auto-
delineated targets and physician targets will aid in determining if the auto-delineations 
are suitable and acceptable for clinical use. 
Methods and Materials 
Patient Dataset 
 Twenty-five oropharyngeal cancer patients previously treated between 2014 
and 2017 were used for this study under an institutional review board approved 
protocol. These 25 cases were a subset of the 75 patients in the test set used to 
assess our predicted delineations in Chapter 6. Patient disease characteristics and 
tumor/target volumes are shown in Table 18. All patients’ treatment design provided 
bilateral neck coverage to reduce the risk of disease spread. This was determined for 
each patient at the time of treatment. 
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Table 18. Patient disease characteristics and tumor/target volumes for patients in dosimetric study. 
Case ID 
Primary 
Disease 
Disease 
Stage 
Age at 
Diagnosis 
# of Target 
Volumes 
Primary Tumor 
Volume (cm3)  
Nodal Tumor 
Volume (cm3) 
Union of CTVs 
Volume (cm3) 
1 CEC_0033 Base of Tongue T4N2c 73 4 68.2 96.2 1003.1 
2 CEC_0035 Base of Tongue T4N2c 41 3 33.4 28.5 717.0 
3 CEC_0043 Base of Tongue T4N0 61 3 37.6 n/a 714.4 
4 CEC_0053 Base of Tongue T3N2b 45 3 10.7 26.8 634.0 
5 CEC_0094 Tonsil T4bN2c 58 4 110.6 59.6 1010.0 
6 CEC_0126 Tonsil T1N2b 72 4 9.7 34.5 604.9 
7 CEC_0136 Base of Tongue T2N2c 59 4 6.8 41.5 738.8 
8 CEC_0142 Base of Tongue T1N2b 53 4 5.0 85.2 634.6 
9 CEC_0146 Base of Tongue T2N2b 58 3 10.7 14.7 1026.4 
10 CEC_0154 Base of Tongue T2N2b 51 4 13.0 25.1 463.4 
11 CEC_0156 Base of Tongue T1N2b 39 4 7.8 23.3 622.0 
12 CEC_0160 Base of Tongue T3N0 60 4 16.2 n/a 547.2 
13 CEC_0165 Tonsil T2N2c 68 4 18.0 36.7 620.3 
14 CEC_0182 Tonsil T2N2c 50 4 18.4 21.6 714.2 
15 CEC_0185 Base of Tongue T1N2b 57 2 8.2 15.1 355.7 
16 CEC_0194 Base of Tongue T2N1 81 4 8.3 1.2 414.0 
17 CEC_0209 Base of Tongue T1Nx 64 3 15.7 n/a 851.2 
18 CEC_0214 Tonsil T3N2b 59 4 70.0 7.8 670.5 
19 CEC_0225 Base of Tongue T3N2b 70 3 25.3 39.1 733.4 
20 CEC_0247 Tonsil T2N2b 40 3 20.0 33.6 1008.5 
21 CEC_0252 Base of Tongue T1N2b 71 3 12.8 19.5 689.6 
22 CEC_0265 Base of Tongue T4N0 70 2 33.5 n/a 469.0 
23 CEC_0287 Tonsil T2N2a 55 4 15.2 13.9 427.2 
24 CEC_0293 Tonsil T3N2b 52 4 42.0 27.2 627.3 
25 CEC_0312 Base of Tongue T3N2b 64 4 5.9 10.9 403.6 
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Delineation of CTVs, PTVs, and OARs  
 Three sets of CTVs and PTVs were defined for each patient. CTVs (high-, 
intermediate-, and low-risk volumes) previously delineated during patient treatment 
were combined into a single CTV structure for this in silico study and defined as our 
ground-truth volume (CTVtruth). These volumes were delineated by a group of sub-
specialized head and neck radiation oncologists using either Pinnacle (Philips 
Healthcare, Andover, MA), Eclipse (Varian Medical Systems, Palo Alto, CA), or 
Raystation (RaySearch Medical Laboratories AB, Stockholm, Sweden) treatment 
planning systems. Then, two deep learning auto-delineation models were used to 
predict our union of CTVs for each patient. The selection of the models were based 
on physician preference after visual evaluation of several top performing models 
developed in Chapter 6. The first predicted volume (CTVtight) which provided tighter 
margins whereas the second volume (CTVmoderate) provided, in general, additional 
coverage.  
 Planning target volumes were defined by providing a 5 mm uniform margin 
expansion from the CTVs and were pulled from the patient surface contour by a 
uniform 3 mm margin. Using this approach for each CTV resulted in the PTVtruth, 
PTVtight, and PTVmoderate volumes. Three treatment plans were created for each patient 
using these PTVs as their respective individual targets.  
 Organs at risk (OARs) were auto-segmented using an in-house atlas-based 
deformable image registration auto-segmentation tool [93, 97, 99] which has been in 
clinical use at our institution and used in plans of 500+ head and neck cancer patients 
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[66]. These OARs were visually inspected and accepted without making any manual 
edits. This decision was based on the results from McCarroll et al [65, 67] which 
showed that minor edits to auto-segmented volumes resulted in insignificant 
dosimetric differences in normal structure doses when using the physician edited and 
un-edited contours.   
VMAT Planning 
 To create volumetric modulated arc therapy (VMAT) plans, we used the 
Radiation Planning Assistant (RPA) [24], which is a fully-automated treatment 
planning tool developed in-house that uses Eclipse Treatment Planning System’s 
(Varian Associates, Palo Alto, CA) application programing interface (API) to optimize 
and output high-quality head and neck VMAT plans.  The RPA automates processes 
such as treatment couch removal, definition of treatment isocenter, initial setup of 
beam parameters, and auto-segmentation of OARs and creation of planning 
structures required for treatment planning. Then the RPA takes advantage of Eclipse’s 
RapidPlan knowledge-based treatment planning module which uses previously 
treated plans to create dose-volume histogram (DVH) estimation models to set 
patient-specific normal tissue constraints for new patients. The RPA uses a modified 
version of the “Washington University Head & Neck” DVH estimation model provided 
within RapidPlan where additional planning structures are included. Priority weights 
for target, planning structures, and normal tissues used during plan optimization were 
determined prior to this study. These were adjusted iteratively to produce clinically 
acceptable plans based on our institution’s plan quality standards.  
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 Four 360-degree treatment arcs were used for all patients. The first two arcs 
had collimator angles set at 10 and 350 degrees, respectively, and the remaining two 
arcs had their collimator set to 90 degrees. Jaws were set for all arcs such that the 
PTV plus a 5 mm margin was inside the field of view for the full arc rotation.  X jaw 
size was limited to a maximum value of 18 cm. If this size was exceeded on arcs with 
collimators at 10 and 350 degrees then the jaw was set to be symmetric with a size of 
18 cm. Since all cases exceeded this x jaw limit on the 90 degree arcs, these arc fields 
were split so that both fields would allow for sufficient coverage for the PTV plus 5 mm 
margin and to stay within the 18 cm jaw size limit.  
 Plans were optimized to provide coverage to a single target (either PTVtruth, 
PTVtight, or PTVmoderate) per plan. A dose prescription of 66 Gy was selected for this in 
silico experiment to reproduce clinically challenging treatment scenarios, in 
particularly when trying to achieve normal tissue constrains. In order to ensure 
appropriate target coverage, the final plans were normalized so that the 95% of the 
PTV volume received at least 98% (64.68 Gy) of the prescribed dose.   
Volumetric Comparison 
When more than three CTVs were delineated on the original treatment plan 
these volumes were defined as follows: 1) high-risk CTV (CTV1) is defined as the 
union of all target volumes receiving a prescribed dose greater or equal to 64 Gy, 2) 
intermediate-risk CTV (CTV2) is defined as the union of all target volumes receiving a 
prescribed dose greater or equal to 59 Gy but less than 64 Gy, and 3) low-risk CTV 
(CTV3) is defined as the union of all target volumes receiving a prescribed dose less 
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than 59 Gy. Risk-dependent PTV volumes (PTV1 for high-risk PTV, PTV2 for 
intermediate-risk PTV, and PTV3 for low-risk PTV) were created as described in the 
subsection “Delineation of CTVs, PTVs, and OARs.” All risk-dependent CTVs and 
PTVs were mutually exclusive meaning that voxels for each volume could only be 
members of either high-, intermediate-, or low-risk volumes, with priority given to 
higher risk volumes.  
For each auto-delineated CTV (CTVtight and CTVmoderate), we calculated the true 
positive fraction (TPF) (Equation 7.1) for the high-, intermediate-, and low-risk CTVs 
defined for each patient at the time of treatment. The TPF provides a measure of how 
much the auto-delineated volumes overlaps and a TPF score of 1 means the auto-
delineated volume (𝑉𝑏) fully overlaps the volume in question (𝑉𝑎) and a score of 0 
would equal to zero overlap between the volumes. The TPF was also calculated for 
both PTVtight and PTVmoderate with the corresponding physician defined PTVs. 
   𝑇𝑃𝐹(𝑎, 𝑏) =
𝑉𝑎 ⁡∩⁡𝑉𝑏
𝑉𝑎
                (7.1) 
Lastly, we calculated the Dice Similarity Coefficient (DSC)[28] (Equation 7.2), 
mean surface distance (MSD) (Equation 7.3), and Hausdorff distance (HD) (Equation 
7.4) between the predicted CTVs/PTVs and the union of the physician delineated 
CTVs/PTVs. These are defined as follows,  
    𝐷𝑆𝐶 =
2∗𝑇𝑃
2∗𝑇𝑃+𝐹𝑁+𝐹𝑃
                   (7.2) 
         𝑀𝑆𝐷 =
1
2
⁡(𝑑̅𝑎,𝑏 +𝑑̅𝑏,𝑎)               (7.3) 
 ⁡⁡⁡⁡⁡⁡⁡⁡𝐻𝐷 = ⁡𝑚𝑎𝑥(𝑑𝑎,𝑏 ∪ 𝑑𝑎,𝑏)        (7.4) 
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where TP, FN, and FP stand for true positive, false negative, and false positive, 
respectively; b and a stand for the auto-delineated and ground-truth (physician) 
contours; and da,b  is a vector containing all minimum Euclidian distances from each 
surface voxel on volume a to volume b. 
Dosimetric Analysis 
 The normal tissue doses evaluated in this study include those for the parotids, 
brainstem, and spinal cord. Mean doses, as well as maximum doses as defined by 
RTOG 1016 (contralateral parotid mean dose < 26 Gy, brainstem max dose < 52 Gy, 
and spinal cord max dose < 50 Gy), were used to compare these between auto-
delineated and physician target plans. We then evaluated doses to the original targets 
(CTVs and PTVs) by extracting the mean dose (𝐷) and minimum doses to 95% (𝐷95), 
98% (𝐷98) and 100% (𝐷100) of each respective volume. Similarly, we calculated the 
target volume percentage receiving 90% (𝑉90), 95% (𝑉95), 98% (𝑉98), 99% (𝑉99), 
and 100% (𝑉100) of the prescription dose. The differences in metrics between the 
auto-delineated and physician target plans were evaluated for each volume.  
Results 
 Based on their respective targets (PTVtruth, PTVtight, and PTVmoderate), all RPA 
plans met dose prescription specifications for targets and most normal tissues. Figure 
38 illustrates the average doses (between all patients) for target and normal tissues 
for each respective target plan. Figure 39-Figure 41 illustrate mean doses (between 
all patients) and their respective 95% confidence intervals at each dose point for the 
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three plans. Individual plans’ dose-volume histograms for all 25 patients can be found 
in the Appendix (Figures Figure 59 - Figure 63). Examples of three cases’ dose 
distributions with the physician ground-truth PTV volume segmentations are shown in 
Figures Figure 42 - Figure 44.  
The brainstem and spinal cord were spared below their allowable maximum 
doses in all RPA plans. The average maximum doses for the brainstem were 45.3 Gy 
(range: 36.7 – 49.1 Gy), 45.6 Gy (range: 42.7 – 47.2 Gy), and 46.0 Gy (range: 44.2 – 
48.1 Gy) for the physician, tight, and moderate target plans, respectively. The average 
maximum doses for the spinal cord were 41.1 Gy (range: 39.3 – 43.7 Gy), 40.9 Gy 
(range: 39.5 – 42.2 Gy), and 41.1 Gy (range: 40.0 – 42.1 Gy) for the physician, tight, 
and moderate target plans, respectively.  
Meeting dose constraints for the ipsilateral and contralateral parotids was not 
achievable in some cases due to the close proximity between tumor volumes and 
these normal tissues. The average mean doses for the ipsilateral parotid were 42.1 
Gy (range: 23.9 – 61.8 Gy), 40.5 Gy (range: 25.1 – 59.3 Gy), and 40.7 Gy (range: 26.3 
– 60.8 Gy) for the physician, tight, and moderate target plans, respectively. The 
average mean doses for the contralateral parotid were 27.1 Gy (range: 16.4 – 46.9 
Gy), 26.4 Gy (range: 18.0 – 41.9 Gy), and 27.3 Gy (range: 19.3 – 42.3 Gy) for the 
physician, tight, and moderate target plans, respectively. On average plans with auto-
delineated targets resulted in a dose reduction of 1.6 Gy and 1.4 Gy for the tight and 
moderate target plans, respectively, when compared to the physician plans.  
 Average dose-volume histogram metrics calculated per CTVs and PTVs are 
shown in Table 19 and Table 20, respectively. Across all volumes, larger differences 
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were observed for stricter metrics (V100, D100, D99, and D98) than more 
conservative metrics (V98, V95, D95, and D90). Overall, there were smaller 
differences for CTV DVH metrics between auto-delineated and physician target plans 
than for PTV DHV metrics. This was expected as providing an additional margin to the 
auto-delineated CTVs would provide coverage for any missed volume (physician 
CTV). Figure 42Figure 44 show the best, median, and worst patient plans based on 
D100.  
 When considering individual risk targets, the difference between auto-
delineated and physician target plans for high-risk CTV and PTV were on average -
1.9 Gy and -3.7 Gy, respectively, across all dose metrics and -0.5% and -1.3%, 
respectively, across all percent of volume receiving minimum dose metrics. These 
average differences were larger for intermediate- and low-risk CTV (-7.0 Gy / -3.4% 
and -10.0 Gy / -4.3%, respectively) and PTVs (-9.4 Gy / -6.6% and -14.9 Gy / -8.7%, 
respectively). These numbers were primarily driven by the larger differences observed 
for V100, D100, D99, and D98 and were smaller for all V98, V95, D95, and D90. The 
percent of patient plans passing RTOG 1016 clinical trial criterion for target volumes 
and normal tissue are shown in Table 21.   
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Figure 38. Dose-Volume Histogram showing mean doses for the physician 
(truth), tight, and moderate target plans 
 
Figure 39. Dose-Volume Histogram showing the mean dose and 95% confidence 
interval for the physician target plans 
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Figure 40. Dose-Volume Histogram showing the mean dose and 95% confidence 
interval for the auto-delineated (tight) target plans 
 
Figure 41. Dose-Volume Histogram showing the mean dose and 95% confidence 
interval for the auto-delineated (moderate) target plans  
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Table 19. Clinical target volume average dose-volume histogram metrics and range for the physician (truth) and 
auto-delineated (tight and moderate) target plans  
  
CTV-1 CTV-2 CTV-3 CTV-all 
V
1
0
0
 Truth 99.4% (95.5 - 100%) 99.1% (97.2 - 100%) 99.1% (97.3 - 99.9%) 99.1% (98.1 - 99.8%) 
Tight 98.7% (94.8 - 100%) 94.6% (60.1 - 100%) 92.9% (84.1 - 99.7%) 95.3% (88.1 - 99.7%) 
Moderate 99.0% (94.3 - 100%) 95.3% (70.4 - 100%) 94.2% (83.1 - 99.4%) 96.1% (91.1 - 99.5%) 
V
9
8
 Truth 99.9% (99.0 - 100%) 99.8% (98.5 - 100%) 99.9% (99.6 - 100%) 99.8% (99.4 - 100%) 
Tight 99.3% (95.9 - 100%) 96.1% (64.9 - 100%) 95.1% (87.5 - 99.9%) 96.8% (90.7 - 99.9%) 
Moderate 99.4% (95.2 - 100%) 96.6% (73.7 - 100%) 96.2% (86.5 - 99.7%) 97.4% (93.5 - 99.9%) 
V
9
5
 Truth 100.0% (99.8 - 100%) 100.0% (99.1 - 100%) 100.0% (99.8 - 100%) 100.0% (99.7 - 100%) 
Tight 99.5% (96.5 - 100%) 97.1% (69.3 - 100%) 96.5% (90.0 - 100%) 97.7% (92.4 - 100%) 
Moderate 99.6% (95.9 - 100%) 97.4% (77.0 - 100%) 97.4% (90.5 - 99.8%) 98.2% (95.4 - 99.9%) 
D
1
0
0
 Truth 63.5 Gy (58.3 - 65.8) 62.0 Gy (51.3 - 65.0) 62.1 Gy (54.3 - 64.5) 60.9 Gy (51.4 - 63.7) 
Tight 57.2 Gy (29.6 - 65.1) 44.0 Gy (12.4 - 64.3) 32.5 Gy (12.5 - 56.5) 31.0 Gy (12.1 - 56.3) 
Moderate 56.5 Gy (32.3 - 65.7) 44.9 Gy (11.4 - 65.8) 34.3 Gy (12.1 - 54.7) 33.1 Gy (11.3 - 54.8) 
D
9
9
 Truth 66.5 Gy (64.7 - 67.2) 66.0 Gy (63.2 - 66.7) 66.1 Gy (65.4 - 66.8) 66.1 Gy (65.7 - 66.8) 
Tight 64.6 Gy (46.7 - 67.3) 57.9 Gy (27.2 - 67.2) 53.6 Gy (38.6 - 66.8) 56.8 Gy (36.9 - 66.8) 
Moderate 65.0 Gy (49.9 - 67.2) 57.7 Gy (23.2 - 67.0) 55.8 Gy (40.9 - 66.4) 58.5 Gy (39.1 - 66.6) 
D
9
8
 Truth 66.8 Gy (65.4 - 67.5) 66.5 Gy (65.3 - 67.2) 66.4 Gy (65.9 - 67.0) 66.5 Gy (66.0 - 67.1) 
Tight 65.7 Gy (53.8 - 67.5) 61.0 Gy (34.2 - 67.4) 58.5 Gy (43.8 - 67.1) 61.1 Gy (44.4 - 67.1) 
Moderate 66.1 Gy (55.3 - 67.4) 60.7 Gy (32.1 - 67.3) 60.5 Gy (49.2 - 66.9) 62.4 Gy (51.4 - 66.9) 
D
9
5
 Truth 67.3 Gy (66.1 - 67.9) 67.1 Gy (66.3 - 67.8) 66.9 Gy (66.3 - 67.4) 67.0 Gy (66.5 - 67.5) 
Tight 67.1 Gy (65.9 - 67.9) 64.8 Gy (40.6 - 67.7) 64.0 Gy (54.2 - 67.4) 65.5 Gy (57.2 - 67.5) 
Moderate 67.2 Gy (65.0 - 67.7) 64.8 Gy (41.4 - 67.7) 65.1 Gy (58.1 - 67.3) 66.1 Gy (63.2 - 67.3) 
D
9
0
 Truth 67.6 Gy (66.7 - 68.3) 67.5 Gy (66.6 - 68.3) 67.2 Gy (66.6 - 67.9) 67.4 Gy (66.9 - 67.9) 
Tight 67.5 Gy (66.8 - 68.2) 66.4 Gy (47.8 - 68.1) 66.3 Gy (62.7 - 67.8) 67.0 Gy (65.2 - 67.9) 
Moderate 67.6 Gy (67.0 - 68.2) 66.5 Gy (48.9 - 68.0) 66.6 Gy (63.0 - 67.6) 67.1 Gy (66.3 - 67.7) 
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Table 20. Planning target volume average dose-volume histogram metrics and range for the physician (truth) and 
auto-delineated (tight and moderate) target plans.  
  
PTV-1 PTV-2 PTV-3 PTV-all 
V
1
0
0
 Truth 97.5% (91.9 - 99.5%) 89.1% (73.1 - 97.9%) 87.3% (74.5 - 95.1%) 90.5% (88.5 - 91.8%) 
Tight 95.9% (85.4 - 99.3%) 81.6% (38.2 - 99.3%) 78.1% (63.7 - 94.1%) 84.2% (72.8 - 95.5%) 
Moderate 96.4% (88.3 - 99.2%) 83.8% (46.6 - 99.0%) 80.4% (60.3 - 92.5%) 86.1% (74.6 - 94.6%) 
V
9
8
 Truth 98.9% (96.0 - 99.9%) 93.8% (82.8 - 99.3%) 93.2% (83.4 - 98.5%) 94.9% (94.9 - 95.0%) 
Tight 97.4% (89.0 - 99.8%) 85.9% (42.4 - 99.8%) 82.9% (70.9 - 96.4%) 88.1% (77.9 - 97.2%) 
Moderate 97.7% (91.2 - 99.8%) 87.9% (52.2 - 99.7%) 85.2% (67.5 - 95.0%) 89.8% (79.7 - 96.6%) 
V
9
5
 Truth 99.6% (98.2 - 100%) 97.0% (91.6 - 99.9%) 97.1% (91.3 - 99.8%) 97.8% (97.3 - 98.3%) 
Tight 98.3% (91.8 - 100%) 89.7% (47.5 - 100%) 87.2% (77.1 - 98.1%) 91.3% (82.3 - 98.4%) 
Moderate 98.5% (93.0 - 100%) 91.3% (57.9 - 100%) 89.4% (75.1 - 97.1%) 92.8% (84.1 - 98.0%) 
D
1
0
0
 Truth 56.0 Gy (47.7 - 61.2) 47.5 Gy (20.6 - 58.8) 46.7 Gy (38.2 - 57.1) 45.2 Gy (37.3 - 49.9) 
Tight 45.1 Gy (21.7 - 61.4) 30.6 Gy (9.5 - 59.6) 21.2 Gy (9.2 - 36.0) 19.4 Gy (9.3 - 36.3) 
Moderate 46.0 Gy (16.2 - 61.3) 32.8 Gy (9.1 - 61.6) 22.6 Gy (8.5 - 36.3) 20.9 Gy (8.5 - 36.3) 
D
9
9
 Truth 64.7 Gy (61.1 - 66.7) 60.0 Gy (45.6 - 65.1) 60.6 Gy (58.3 - 64.2) 60.9 Gy (59.3 - 61.8) 
Tight 60.6 Gy (43.8 - 66.4) 46.8 Gy (19.7 - 66.4) 39.4 Gy (24.7 - 60.3) 42.9 Gy (24.1 - 61.0) 
Moderate 60.8 Gy (41.4 - 66.1) 48.2 Gy (16.3 - 66.0) 41.7 Gy (20.8 - 57.0) 45.4 Gy (29.2 - 59.6) 
D
9
8
 Truth 65.8 Gy (63.0 - 67.1) 61.8 Gy (51.6 - 65.9) 62.0 Gy (59.4 - 65.0) 62.5 Gy (61.7 - 63.0) 
Tight 62.9 Gy (49.0 - 67.0) 51.1 Gy (30.3 - 67.0) 44.6 Gy (30.0 - 62.8) 49.3 Gy (31.8 - 63.5) 
Moderate 63.2 Gy (46.5 - 67.0) 52.2 Gy (27.2 - 66.6) 47.3 Gy (30.7 - 61.0) 51.9 Gy (37.4 - 62.8) 
D
9
5
 Truth 66.8 Gy (65.2 - 67.6) 64.2 Gy (60.2 - 67.0) 64.0 Gy (61.3 - 66.0) 64.7 Gy (64.6 - 64.7) 
Tight 65.7 Gy (59.1 - 67.6) 58.2 Gy (34.4 - 67.6) 53.6 Gy (40.6 - 65.6) 57.6 Gy (43.9 - 66.2) 
Moderate 65.9 Gy (56.9 - 67.6) 59.0 Gy (33.9 - 67.2) 56.1 Gy (44.7 - 64.7) 59.5 Gy (47.7 - 65.8) 
D
9
0
 Truth 67.4 Gy (66.4 - 68.0) 65.8 Gy (63.2 - 67.4) 65.5 Gy (63.1 - 66.7) 66.1 Gy (65.8 - 66.5) 
Tight 67.1 Gy (64.1 - 68.0) 62.3 Gy (38.0 - 67.9) 60.2 Gy (51.0 - 67.1) 63.0 Gy (55.5 - 67.4) 
Moderate 67.3 Gy (65.3 - 67.9) 63.1 Gy (40.1 - 67.6) 61.9 Gy (53.3 - 66.6) 64.2 Gy (57.5 - 67.0) 
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Figure 42. Case with best dosimetric agreement, in terms of D100, between 
physician and auto-delineated target plans 
The physician treated volume (PTV) is delineated in red. Each column illustrates axial, 
sagittal, and coronal views of the physician, tight, and moderate target plans.  
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Figure 43. Case with median dosimetric agreement, in terms of D100, between 
physician and auto-delineated target plans 
The physician treated volume (PTV) is delineated in red. Each column illustrates axial, 
sagittal, and coronal views of the physician, tight, and moderate target plans.  
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Figure 44. Case with worst dosimetric agreement, in terms of D100, between 
physician and auto-delineated target plans 
The physician treated volume (PTV) is delineated in red. Each column illustrates axial, 
sagittal, and coronal views of the physician, tight, and moderate target plans. 
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Table 21. Percent of target volumes passing treatment planning evaluation 
criteria defined by RTOG 1016 for auto-delineated and physician target plans 
    Plans  
Targets   Truth Tight Moderate 
 CTV-1     
  D95%[Gy] (>= 64.68 Gy) 100% 100% 100% 
  V95%[%] (>= 90%) 100% 100% 100% 
  D99%[Gy] (>= 60 Gy) 100% 88% 88% 
 CTV-2     
  D95%[Gy] (>= 64.68 Gy) 100% 92% 88% 
  V95%[%] (>= 90%) 100% 96% 96% 
  D99%[Gy] (>= 60 Gy) 100% 56% 60% 
 CTV-3     
  D95%[Gy] (>= 64.68 Gy) 100% 68% 84% 
  V95%[%] (>= 90%) 100% 100% 100% 
  D99%[Gy] (>= 60 Gy) 100% 32% 40% 
 CTV-all     
  D95%[Gy] (>= 64.68 Gy) 100% 92% 100% 
  V95%[%] (>= 90%) 100% 100% 100% 
  D99%[Gy] (>= 60 Gy) 100% 36% 52% 
 PTV-1     
  D95%[Gy] (>= 64.68 Gy) 100% 84% 92% 
  V95%[%] (>= 90%) 100% 100% 100% 
  D99%[Gy] (>= 60 Gy) 100% 68% 76% 
 PTV-2     
  D95%[Gy] (>= 64.68 Gy) 84% 36% 28% 
  V95%[%] (>= 90%) 100% 64% 72% 
  D99%[Gy] (>= 60 Gy) 64% 12% 16% 
 PTV-3     
  D95%[Gy] (>= 64.68 Gy) 92% 12% 12% 
  V95%[%] (>= 90%) 100% 40% 48% 
  D99%[Gy] (>= 60 Gy) 76% 4% 0% 
 PTV-all     
  D95%[Gy] (>= 64.68 Gy) 100% 24% 32% 
  V95%[%] (>= 90%) 100% 60% 72% 
  D99%[Gy] (>= 60 Gy) 100% 4% 0% 
OARs      
 Brain Stem  Max Dose (<= 52.00 Gy) 100% 100% 100% 
 Spinal Cord  Max Dose (<= 50.00 Gy) 100% 100% 100% 
 Parotid (I) Mean Dose (<= 26.00 Gy) 4% 8% 0% 
 Parotid (C) Mean Dose (<= 26.00 Gy) 68% 52% 48% 
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 In terms of overlap, the high-risk CTVs had the highest overlap with mean TPF 
values of 0.97 (95% CI: 0.95 – 0.99) and 0.97 (95% CI: 0.96 – 0.99) for CTVtight and 
CTVmoderate, respectively. The intermediate-risk CTVs had mean TPF values of 0.82 
(95% CI: 0.76 – 0.87) and 0.84 (95% CI: 0.79 – 0.89) for CTVtight and CTVmoderate, 
respectively. The low-risk CTVs had mean TPF values of 0.80 (95% CI: 0.77 – 0.84) 
and 0.83 (95% CI: 0.80 – 0.86) for CTVtight and CTVmoderate, respectively. The physician 
CTVall volumes had mean TPF values of 0.86 (95% CI: 0.84 – 0.89) and 0.88 (95% 
CI: 0.86 – 0.90) for CTVtight and CTVmoderate, respectively. Similar trends in overlap were 
observed for the PTV delineations. The high-risk PTVs had the highest overlap with 
mean TPF values of 0.98 (95% CI: 0.96 – 0.99) and 0.98 (95% CI: 0.97 – 0.99) for 
PTVtight and PTVmoderate, respectively. The intermediate-risk PTVs had mean TPF 
values of 0.84 (95% CI: 0.79 – 0.89) and 0.85 (95% CI: 0.81 – 0.90) for PTVtight and 
PTVmoderate, respectively. The low-risk PTVs had mean TPF values of 0.83 (95% CI: 
0.80 – 0.86) and 0.85 (95% CI: 0.82 – 0.88) for PTVtight and PTVmoderate, respectively. 
Lastly, the physician PTVall volumes had mean TPF values of 0.88 (95% CI: 0.86 – 
0.90) and 0.89 (95% CI: 0.88 – 0.91) for CTVtight and CTVmoderate, respectively. Overlap 
distributions per target are shown in Figure 45.  
 We found strong correlations between TPF and some dose-volume histogram 
metrics in our study. Predominantly, correlations were stronger for PTV overlap than 
they were for CTV overlap. Correlations were moderate to weak for high-risk 
CTVs/PTVs were higher overlap was observed between the auto-delineated and 
physician target volumes which inherently resulted in smaller dosimetric differences 
between plans. The strongest linear correlations were noticed between the differences 
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in percent volume receiving 95% of the prescribed dose and TPF which are show in 
Figures Figure 46 and Figure 47. R2 values were as high as 0.97 (for PTV3) in the tight 
plans for ΔV95[%]. Similar R2 values were noticed for PTVall on both plans between 
TPF and ΔV95[%].  
 Comparable, but slightly lower, R2 values were noticed between the minimum 
dose to 95% of the target volume and TPF showing strong correlations for some 
targets. These relationships are shown in Figures Figure 48 and Figure 49 for CTVs 
and PTVs, respectively.  Moderate to strong correlations were measured between the 
minimum dose to 98% of the target volume and TPF showing strong correlations for 
some targets (Figures Figure 50 and Figure 51).  
 When considering the DSC, MSD, and HD between physician and auto-
delineated CTV/PTVall volumes we found a lack of linear relationship between these 
metrics and differences in DVH metrics. The highest R2 value between all metrics for 
both CTV/PTVall was 0.09. These differences can be appreciated in the Appendix 
Figures Figure 64 - Figure 69.  
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Figure 45. Distribution of overlap between the physician-delineated target volumes and the auto-delineated CTVs 
(CTVall) and their corresponding PTVs (PTVall) 
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Figure 46. Correlation between true positive fraction and difference in percent 
volume receiving 95% of the prescribed dose for CTVs in tight and moderate 
plans 
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Figure 47. Correlation between true positive fraction and difference in percent 
volume receiving 95% of the prescribed dose for PTVs in tight and moderate 
plans 
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Figure 48. Correlation between true positive fraction and difference in minimum 
dose (Gy) to 95% of the volume for CTVs in tight and moderate plans 
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Figure 49. Correlation between true positive fraction and difference in minimum 
dose (Gy) to 95% of the volume for PTVs in tight and moderate plans 
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Figure 50. Correlation between true positive fraction and difference in minimum 
dose (Gy) to 98% of the volume for CTVs in tight and moderate plans 
160 
 
 
Figure 51. Correlation between true positive fraction and difference in minimum 
dose (Gy) to 95% of the volume for PTVs in tight and moderate plans 
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Discussion 
 In this chapter we created radiation therapy treatment plans using three 
different targets: a physician defined CTV (CTVtruth) and two auto-delineated CTVs 
(CTVtight and CTVmoderate). These CTV volumes represented the union of all CTVs 
(CTV1 U CTV2 U CTV3) defining the overall treatment volume. We used the RPA [24], 
a fully-automated treatment planning tool that uses RapidPlan and Eclipse for dose 
calculation, to create plans with normalized doses such that 95% of the PTV volume 
would receive 98% of the prescribed dose (66 Gy). The OARs used in the optimization 
were auto-segmented using an atlas-based algorithm [93, 97, 99] within the RPA.  
 Our results showed that doses to normal structures were similar between 
physician and auto-delineated target plans. All plans (physician and auto-delineated) 
resulted in spinal cord and brainstem maximum doses below the desired specified 
thresholds. Since all patient’s primary tumors were located in the oropharynx it was 
difficult to achieve mean parotid doses below 26 Gy for most ipsilateral and some 
contralateral parotids.  
 Overlap differences between the physician and auto-delineated targets 
sometimes resulted in small cold spots in the periphery of the physician delineated 
targets for plans created on the auto-delineated targets. Because of these cold spots, 
there were larger differences in stricter metrics (V100, D100, D99, and D98) than 
those which were more conservative (V98, V95, D95, and D90). Since we adopted a 
dose normalization approach to create comparable plans, it was expected for the 
stricter metrics (those measuring doses/volumes which were greater than what the 
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plans were normalized based on) to be more sensitive to small differences between 
the physician and auto-delineated volumes. Generally, these cold spots (or under-
treated regions) were found in the intermediate- and low-risk target volumes. This is 
consistent with findings from Chapter 3 where we observed larger differences in 
volumes after recommended changes made during peer-review of patients’ targets. 
Since the auto-delineated volumes were modeled after a large patient set, the auto-
delineated volumes used in this study were subject to the inherent inter-observer 
variability as measured in Chapter 4. The majority of high-risk CTVs were covered by 
the auto-delineated volumes by at least 90% of their volume, however one case’s 
high-risk CTV was only covered to approximately 80% and 85% in the tight and 
moderate auto-delineated CTVs, respectively. This particular case’s base of tongue 
tumor (T4 N0) extended caudally and involved the right vallecula, epiglottis, and 
aryepiglottic fold, with some concerns for early extension into the right per-epiglottic 
space found during patient physical examination. The algorithm developed in Chapter 
6 and used to auto-delineated CTVs for this study lacks access to physical 
examination findings which has the potential to drive changes in delineations for some 
cases (Chapter 3). For this case, using a 5 mm PTV margin provided enough coverage 
to guarantee the high-risk CTV to have only a 2% difference in volume receiving 95% 
of the prescribed dose when compared to the physician target plans.  
One of the most interesting results in this chapter was the strong linear 
relationship observed between the true positive fraction of the physician’s volumes 
covered by the auto-delineated volumes and the dose-volume histogram metrics. This 
correlation could be used to estimate dosimetric differences between several 
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physicians or auto-delineated target volume plans for the same patient. This would 
provide a significant time savings since it would no longer be required to optimize 
plans on each individual target volume when wanting to compare plans between 
physicians allowing for a quick evaluation of physician-in-training delineated target 
volumes.  We noticed that the correlations were not as strong for high-risk CTVs but 
this could be explained by the fact that a large majority of these volumes saw smaller 
differences when comparing physician and auto-delineated plans. Mattiucci et al [64] 
investigated the relationship between differences in dose-volume histogram metrics 
and the DSC and mean HD for head and neck replanning. While the results in their 
study support a significant relationship between DSC and PTV’s ΔV95 between co-
registered and physician volumes, these metrics fail to convey information about 
differences in sizes between ground-truth and predicted volumes [90] (i.e. both 
predicted volumes which are smaller or larger could have the same DSC/HD values).  
Mattiucci et al report that all of their volumes were smaller that the physician ground-
truth volumes. Since these differences in volumes (some auto-delineations were 
larger and some were smaller than their respective ground-truths) were observed in 
our dataset we found no correlations between DSC and HD to dose-volume histogram 
metrics.  
A recent study by Peng et al [79] showed how inter-observer variability in target 
delineation in a single nasopharynx case affected dose-volume histogram metrics 
when plans are created on different physician target volumes. In their study, the 
authors chose to use a STAPLE of all physicians’ target volumes as their ground-truth 
and subsequently based their ground-truth plans on these volumes. Even when using 
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STAPLE volumes, which we showed in Chapter 4 that they tend to undermine 
differences between physicians, they found significant differences in dosimetric 
parameters between the STAPLE and physician target plans. The results presented 
in our study are consistent with those found by Peng et al. It is clear that even small 
differences in overlap between ground-truth and physician or auto-delineated volumes 
often translate in major differences in dosimetric parameters used to clinically assess 
plans. When visually comparing the dose distributions in our study (Figures Figure 42 
- Figure 44) with those shown in the Peng study (Figure 1, https://ars.els-
cdn.com/content/image/1-s2.0-S1368837518301672-gr1_lrg.jpg) we notice smaller 
distribution differences in our cases, even for the worst performing case (Figure 44).  
 Our study is subject to some limitations. We chose to use a single dose 
prescription to the whole treatment volume and we acknowledge this does not 
represent a true clinical scenario. The goal of this in silico study was to quantify 
differences in doses by using different treatment volumes (physician and auto-
delineated) and we chose to use a single dose to minimize the variability observed in 
defining different target volumes (high-, intermediate-, and low-risk CTVs). In addition, 
this study is limited to a comparison of delineations and plans from a single institution. 
The final physician volumes used for treatment used as our ground-truth are subject 
to peer-review evaluation reducing the likelihood of potential near-misses. Since the 
auto-delineated volumes were modeled after a large subset of patients treated by the 
same physicians, we expect this variability to be reduced in comparison to multi-
institutional variability where practices and treatment design vary largely.  
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 Lastly, the results presented in this study are encouraging. First, we have 
shown that by using auto-delineated target volumes we have been able to greatly 
reduce dose distribution variability as observed in the literature [79]. Secondly, we 
have demonstrated that overlap between delineations can be predictive in changes in 
dose-volume histogram metrics between plans. This relationship can be useful for 
training purposes (i.e. radiation oncology resident education) where trainees could 
quickly estimate differences in dosimetric parameters by comparing their delineations 
to expert contours without having to optimize treatment plans.  
Conclusion 
 Auto-delineated target plans resulted in dose distributions closely resembling 
those from physician target plans for a majority of cases. Differences in doses to 
normal tissues were negligible between physician and auto-delineated target plans, 
while larger dose differences were observed for intermediate and low-risk targets. 
Overlap between targets had a strong linear relationship with some dose-volume 
histogram metrics, indicating that these geometric metrics could be used to estimate 
dosimetric differences between different plans.   
166 
 
Chapter 8: Discussion 
 The main goal of this study was to develop population-based models to auto-
delineate clinical target volumes of oropharyngeal cancer patients. Once these models 
were developed, we evaluated and compared dose-volume histogram metrics from 
radiation therapy plans based on auto-delineated and physician targets. To 
accomplish this, we began in Aim 1 by assessing clinical target volume delineation 
variability between expert head and neck radiation oncologists at The University of 
Texas MD Anderson Cancer Center. Then in Aim 2 we developed a high-risk clinical 
target volume auto-delineation algorithm that provided better overlap and distance 
metric results than those measured in Aim 1. Lastly, in Aim 3 we compared out low-
risk clinical target volume auto-delineation algorithm to the measured variability and 
then we created treatment plans based on these auto-delineations and compared 
these to record dosimetric differences to the physician target plans.  
 In Aim 1 we assessed the clinical target volume delineation variability between 
expert head and neck radiation oncologists at The University of Texas MD Anderson 
Cancer Center. We started by identifying clinical factors that lead to clinical target 
volume changes during a peer-review session that is conducted before every patient 
begins treatment. We found that physician experience was the only clinical factor 
suggesting changes in delineation. This is consistent with findings in the literature 
suggesting that radiation oncologist experience is closely related to patient outcomes 
[13, 96]. In addition, we found that over 10% of patients had new findings as a result 
of group physical examination during the treatment quality assurance sessions. In a 
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separate study, we quantified the inter- and intra-observer variability in oropharyngeal 
gross tumor volume and high-risk clinical target volume delineations and found that 
the variability observed within the experts in our clinic is greatly reduced in compared 
to reports in the literature [12, 46]. Still, significant differences in delineations amongst 
physicians were observed for some cases. 
 In Aim 2 we developed a deep learning algorithm to auto-delineated high-risk 
clinical target volumes and used the results from Aim 1 to assess the performance of 
our algorithms. Our deep learning approach used an auto-encoder architecture that 
was trained using distance vectors from normal tissues to each individual voxels to 
estimate gross tumor volume to high-risk clinical target volume margins. The auto-
delineations from our algorithm resulted in patient-specific non-uniform margin 
expansions which on average outperformed the variability measured in Aim 1. In 
addition, our auto-delineation algorithm’s results had better agreement than what has 
been reported in the inter-observer delineation studies [12, 46, 91]. This was the first 
deep learning solution proposed to auto-delineate high-risk clinical target volumes. 
Recently, some centers have clinically implemented the use of uniform margin 
expansions from the gross tumor volume to the high-risk clinical target volume to 
reduce inter-observer variability in volume delineations [43]. Similarly, the clinical 
implementation of our population-based auto-delineation tool could offer similar 
benefits.  
 In Aim 3 we developed a deep learning algorithm to auto-delineated low-risk 
clinical target volumes and used the results from Aim 1 to assess the performance of 
our algorithms. Our deep learning approach used a two-channel 3D deep 
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convolutional neural network architecture called “3D U-Net” [23]. The first channel fed 
the architecture with the patient’s CT images providing some anatomical context to 
the network, whereas the second channel fed the network with the gross tumor volume 
segmentations to provide patient-specific tumor location and disease information to 
the network. Our algorithm’s volumes had DSC values that were higher than those 
reported in the literature [25, 97]. When evaluating dosimetric differences in plans 
based on auto-delineated and physician targets we saw differences that were 
consistent with studies that have investigated the effect of inter-observer variability in 
target delineation in dose distributions [79].   
 There are a few limitations that apply throughout the studies conducted in this 
thesis. First, we quantified inter-observer variability from physicians in our clinic alone 
and these results may not reflect the variability reported across institutions where 
clinical practices and treatment designs can be more heterogeneous. The purpose of 
quantifying this variability was to understand how this variability could affect the 
development of population-based models to predict target volume delineations. 
Another limitation is that the clinical target volume auto-delineation models were 
trained on patients treated at a single institution, therefore replicating clinical practice 
patterns found on patients treated at The University of Texas MD Anderson Cancer 
Center. While the auto-delineated volumes (both high- and low-risk clinical target 
volumes) may not be considered clinically acceptable at other institutions, the 
workflow and methodologies presented in this thesis could be replicated to train these 
architectures based on local patient data resulting on more accurate predictions based 
on local practice and treatment design patterns. A major limitation for both high- and 
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low-risk clinical target volume auto-delineation models is the requirement of gross 
tumor volume segmentations. As we showed in Chapter 4, these tumor volume 
segmentations are subject to inter- and intra-observer variability and inaccurate 
definition of these volumes introduces a systematic error which would then affect 
subsequent steps in the treatment planning process.  
Future Directions 
While we noticed dosimetric differences between auto-delineated and 
physician target plans (Chapter 7), these dose metric differences were within those 
reported on studies assessing inter-observer variability in target delineation and the 
resulting dose differences between different observer’s plans [79, 92]. To further 
validate the use of auto-delineated targets for treatment planning it would be useful to 
provide physicians the auto-delineated targets as a starting point for real patients 
treated in our clinic. This clinical implementation would allow us to measure any 
required edits made prior to clinical use. In addition, we could replicate the analysis 
performed in Chapter 7 to investigate differences between provided and edited auto-
delineated targets. A study by Chao et al [20] demonstrated that when physicians are 
provided with template target volumes these resulting physician-edited targets have 
reduced variability when compared to targets delineated from scratch. Our models 
from Chapters 5 and 6 have the ability to provide 2 dose-level treatment plans, but a 
third (intermediate) dose level could be defined by providing a uniform margin from 
the high-risk CTVs. This has approach has been adapted by the DAHANCA group 
resulting in significant reduction in intermediate-risk target volume delineations [43].  
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 Another interesting topic of research would be investigating the development 
of physician-specific auto-delineations models. In Chapters 3 and 4 we showed that it 
is difficult to determine a real ground-truth volume when physicians often disagree in 
how they delineate target volumes. Some physicians may prefer the use of tighter 
target volumes whereas others could prefer more conservative delineations, as we 
saw in Chapter 6. This is supported by Beadle and Anderson who suggested that “1 
person’s target volume is not everyone’s target volume” based on reports in the 
literature [6]. Developing physician-specific targets has the potential of improving 
comparisons between physicians and auto-delineated contours reducing some 
systematic errors introduced by training a model on patient set treated by a large 
number of physicians.   
 Future investigation in the development of auto-delineation of gross tumor 
volume models would address a major limitation found in both models developed in 
Chapters 5 and 6. Men et al used deep learning to auto-delineate nasopharyngeal 
gross tumor volumes on CT images with high agreement to the physician ground-truth 
delineations [69]. It would be interesting to investigate and compare the differences in 
auto-delineations from models developed on single modality images (i.e. simulation 
CT) versus those delineations from multi-modality images (i.e. PET/CT/MRI). Yang et 
al [98] showed that a multichannel auto-segmented gross tumor volume was closer in 
agreement to the physician ground-truth than those auto-delineated on PET images 
alone.  
 Developing deep learning algorithms to predict clinical target volumes of other 
tumor sites could aid in reducing delineation variability for these treatment sites. 
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Convolutional neural networks have been developed to auto-delineate 
nasopharyngeal and rectal cancer clinical target volumes [69, 70] but many more 
treatment sites could benefit from these deep learning algorithms. Creating a tool that 
automatically provides physicians with target volumes would be a significant 
contribution to our field. This would allow for the collection of better clinical data by 
removing one of the largest sources of uncertainty in radiation therapy. This would be 
particularly useful in clinical trials and multi-institutional studies where heterogeneity 
in clinical practices is largest amongst practitioners.  
Conclusions 
 In this study we developed deep learning algorithms to auto-delineate high- and 
low-risk clinical target volumes. We found that our algorithms performed well when 
compared to inter- and intra-observer variability measured in our clinic and to values 
reported in the literature. Radiation treatment plans based on the auto-delineated 
volumes provided enough coverage to the physician target volumes such all cases 
planned met D95 and V95 criteria when using moderate margin auto-delineations. 
Furthermore, we showed strong relationship between geometric and dose-volume 
histogram metrics which could be used to estimate dose differences between 
delineations. Our results demonstrate that good quality plans can be achieved by 
using auto-delineated target volumes.   
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Appendix 
 
Figure 52. GTV delineations between physicians for Case 1 (Chapter 4) 
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Figure 53. GTV delineations between physicians for Case 2 (Chapter 4) 
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Figure 54. GTV delineations between physicians for Case 3 (Chapter 4) 
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Figure 55. GTV delineations between physicians for Case 4 (Chapter 4) 
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Figure 56. GTV delineations between physicians for Case 5 (Chapter 4) 
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Figure 57. GTV delineations between physicians for Case 6 (Chapter 4) 
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Figure 58. GTV delineations between physicians for Case 7 (Chapter 4)  
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Figure 59. Dose Volume Histogram Comparison for Truth, Tight, and Moderate 
target plans for Cases CEC_0033 through CEC_0094 (Chapter 7) 
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Figure 60. Dose Volume Histogram Comparison for Truth, Tight, and Moderate 
target plans for Cases CEC_0126 through CEC_0154 (Chapter 7) 
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Figure 61. Dose Volume Histogram Comparison for Truth, Tight, and Moderate 
target plans for Cases CEC_0156 through CEC_0185 (Chapter 7) 
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Figure 62. Dose Volume Histogram Comparison for Truth, Tight, and Moderate 
target plans for Cases CEC_0194 through CEC_0247 (Chapter 7) 
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Figure 63. Dose Volume Histogram Comparison for Truth, Tight, and Moderate 
target plans for Cases CEC_0252 through CEC_0312 (Chapter 7)  
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Figure 64. Correlations between Dice Similarity Coefficient (DSC), mean surface 
distance (MSD), and Hausdorff distance (HD) and difference in percent volume 
receiving 95% of the prescribed dose for CTVall in tight and moderate plans 
185 
 
 
Figure 65. Correlations between Dice Similarity Coefficient (DSC), mean surface 
distance (MSD), and Hausdorff distance (HD) and difference in percent volume 
receiving 95% of the prescribed dose for PTVall in tight and moderate plans 
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Figure 66. Correlation between Dice Similarity Coefficient (DSC), mean surface 
distance (MSD), and Hausdorff distance (HD) and difference in minimum dose 
(Gy) to 98% of the volume for CTVall in tight and moderate plans 
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Figure 67. Correlation between Dice Similarity Coefficient (DSC), mean surface 
distance (MSD), and Hausdorff distance (HD) and difference in minimum dose 
(Gy) to 98% of the volume for PTVall in tight and moderate plans 
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Figure 68. Correlation between Dice Similarity Coefficient (DSC), mean surface 
distance (MSD), and Hausdorff distance (HD) and difference in minimum dose 
(Gy) to 95% of the volume for CTVall in tight and moderate plans 
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Figure 69. Correlation between Dice Similarity Coefficient (DSC), mean surface 
distance (MSD), and Hausdorff distance (HD) and difference in minimum dose 
(Gy) to 95% of the volume for PTVall in tight and moderate plans 
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